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CHAPTER 1 
 
NG-Acyl-argininamides as NPY Y1 Receptor Antagonists: 
Influence of Stucturally Diverse Acyl Substituents on Stability and 
Affinity  
 
 
 
1.1 Introduction 
 
G Protein-coupled receptors (GPCRs) represent a major class of biological targets in drug 
discovery. Focusing on neuropeptide Y (NPY) and histamine receptors as models of 
aminergic and peptidergic GPCRs, respectively, we are particularly interested in bioisosteric 
approaches to develop special receptor subtype-selective tools, e. g., bivalent ligands, 
prodrugs, radiolabeled and fluorescent compounds.1-6 Strongly basic groups such as 
guanidines (including Arg residues) are essential structural features of numerous GPCR 
ligands, but are unfavourable with respect to bioavailability and brain penetration. This is also 
true for many high affinity NPY and histamine receptor agonists and antagonists.7, 8 
Therefore, special effort was put into the search for bioisosteric replacements of strongly 
basic functional groups. Recently, we reported on the exploitation of guanidine - 
acylguanidine bioisosterism with respect to histamine H2, H3 and H4 receptor ligands5, 9-12 and 
arginine-type NPY Y1 receptor antagonists.1, 3, 4, 6, 7, 13, 14   
NPY is a highly conserved peptide which plays an important role as a neurotransmitter in the 
central and peripheral nervous system.15 In humans, four receptor subtypes, referred to as 
NPY Y1, Y2, Y4 and Y5 receptors, mediate the biological effects of NPY. For instance, in the 
periphery NPY Y1 receptor (Y1R) stimulation causes an increase in blood pressure. In the 
central nervous system (CNS) Y1R activation elicits anxiolytic and sedative effects and is 
involved in the stimulation of food intake.15 
Arginine derivatives such as the Y1R antagonist BIBP322616 (1a, Figure 1) have been proven 
as valuable pharmacological tools regardless of properties being far from drug-like. 
Interestingly, the reduction of the basicity of the Arg-derived Y1R antagonist 1a by 
introducing electron-withdrawing NG-substituents such as acyl groups turned out to be a 
promising general route to guanidine derivatives with increased potency, to fluorescent 
ligands and radioactive tracers.3-7, 14 Even bulky fluorophores attached to the guanidine via 
spacers of different size were tolerated; a moderate decrease in affinity did not compromise 
suitability of the compounds as pharmacological tools. However, depending on the chemical 
2 
 
nature of the linker cleavage of the acylguanidine group may occur as demonstrated for a 
model compound.17  
In continuation of our studies on the structure-activity relationships of argininamide-type Y1R 
antagonists we synthesized a series of NG-acylated analogues of 1a in order to explore the 
impact of structurally diverse substituents on stability and pharmacological activity in vitro 
(Y1R binding and antagonism). As the small library of Y1R antagonists was synthesized to 
cover a wide range of distribution coefficients (logD) the BIBP 3226 skeleton was substituted 
with hydrophobic alkyl chains or sugars and amines to alter the polarity of the parent 
compound (Figure 1). 
 
 
1.2 Results and Discussion 
 
1.2.1 Synthesis of the NG-acylated argininamides 
 
The NG-acylated argininamides were efficiently prepared according to the general synthetic 
route shown in Scheme 1. N-Boc-S-methylisothiourea (3) was acylated with the respective 
carboxylic acids yielding the isothiourea derived guanidinylation reagents 4b-4g, 4i, 4k-4q, 
4s-4u. Guanidinylation of D-ornithinamide 5 and subsequent removal of protecting groups 
gave the envisaged NG-acylated argininamides. Amine 5 is available from D-ornithine in six 
steps in 32% overall yield.4  
Synthetic strategies for the preparation of carboxylic acids 7, 8, 11, 14, 17, 20, 22, 27, 28, 30, 
and 36 are depicted in Schemes 2 – 4. Acids 7 and 8, containing a triazole entity, were 
prepared through a Cu(I)-catalysed “click-reaction” between 4-azidobutanoic acid and tBu-
protected propargyl alcohol or Boc-protected propargyl amine (Scheme 2). Carboxylic acid 
14 was prepared via guanidinylation of 6-aminohexanoic acid methyl ester with N,N’-diBoc-
S-methylisothiourea followed by ester hydrolysis (Scheme 2). For the synthesis of succinic 
acid derivative 17 ethylenediamine was one-fold guanidinylated with N,N’-diBoc-S-methyl-
isothiourea yielding amine 16, which was treated with succinic anhydride (Scheme 2). Acid 
precursors 20 and 22 were obtained through the treatment of amines 19 and 21 with succinic 
anhydride (Scheme 2). The suberic acid derivatives 27 and 28 were prepared through 
amidation of octandioic acid mono-benzyl ester with amines 24 and 21, respectively, followed 
by benzyl ester cleavage (Scheme 3). Octandioic acid derivative 30 was obtained via 
amidation of non-protected suberic acid with 3-aminopropanoic acid benzyl ester (Scheme 3). 
The synthesis of carboxylic acid 36 started from pyrene-1-carboxylic acid (31), which was 
amidated with mono-Boc-protected ethylenediamine (21
3 
 
Boc group was removed with hydrochloric acid yielding amine 33, which was coupled with 
3,6,9-trioxaundecandioic acid mono-benzyl ester (34) to give compound 35. Hydrogenolysis 
of 35 resulted in acid 36 (Scheme 4). 
 
 
 
Figure 1. Structures of NG-acylated derivatives of the Y1R antagonist BIBP 3226 (1a) ranked 
according to calculated logD values (ACD-labs software version 12, pH = 7.4); experimental 
logD values from HPLC measurements18 in parentheses.    
 
  
D-Gluconic acid derivative 1i was synthesized from penta-acetylated D-gluconic acid. 
Unfortunately, deprotection of the hydroxyl groups failed. The base-labile acylguanidine 
moiety prevents basic selective cleavage of the acetyl protecting groups. Enzymatic 
deprotection using a lipase preparation (Novozym 435) was also unsuccessful. To circumvent 
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such problems, sugar derivative 1n, containing a galactose entity, was prepared. The synthesis 
of the respective carboxylic acid 11 is shown in Scheme 2. Two acetal protecting groups were 
introduced in the first step and the remaining primary hydroxyl function was esterified with 
succinic anhydride. The acetal groups are compatible with the general synthetic strategy 
outlined in Scheme 1 and can be easily removed in the final deprotection step with 
TFA/DCM.  
BIBP 3226 derivatives 1j and 1r were prepared through 4-fluorobenzoylation and 
propionylation of amines 1s and 1u, respectively (Scheme 5). 
 
 
 
Scheme 1. General route for the synthesis of NG-acylated BIBP 3226 derivatives 1b-1g, 1i, 
1k-1q and 1s-1u. a) Boc2O, NaOH, tBuOH, 90%; b) DIPEA, EDC, HOBT, DCM, (1s: TBTU, 
DIPEA, DMF), 31 - 95%; c) HgCl2, NEt3, DMF, 39 - 78%; d) TFA/DCM 1:1, quantitative 
yield. 
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Scheme 2. Synthesis of carboxylic acids 7, 8, 11, 14, 17, 20 and 22. a) CuSO4 (5 mol%), Na-
ascorbate (10 mol%), MeOH, H2O, 67%-86%; b) acetone, iodine, 71%; c) succinic anhydride, 
DMAP, NEt3, 73%; d) HgCl2, NEt3, DMF, 84%; e) THF, NaOH, 71%; f) CHCl3, 16 h, 97%; 
g) THF, NEt3, 49%; h) CF3COOEt, DCM; i) Boc2O, DCM; j) K2CO3, MeOH, H2O, 47% 
overall; k) succinic anhydride, THF, NEt3, 77%; l) DCM, 99%. 
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Scheme 3. Synthesis of suberic acid derivatives 27, 28 and 30. a) DCM, EDC, HOBt, DIPEA, 
62%; b) Pd-C, H2, 90% - 94%; c) DCM, EDC, HOBt, DIPEA, 44%. 
 
 
 
 
Scheme 4. Synthesis of the pyrene-1-carboxamide derivative 36. a) DCM, EDC, HOBt, 
DIPEA, 52%; b) MeOH, HCl, 83%; c) DMF, EDC, HOBt, DIPEA, 59%; d) Pd-C, MeOH, 
quantitative.  
 
 
 
Scheme 5. Synthesis of the NG-acylated BIBP 3226 derivatives 1j and 1r. a) NEt3, DMF, 65% 
(1j), 21% (1r). 
 
 
1.2.2 Stability and Y1R antagonistic activity 
 
As the acylguanidine moiety of NG-acylated argininamide-type Y1R antagonists may be 
considered as the most probable cleavage site the stability of the presented BIBP 3226 (1a) 
derivatives was investigated with respect to the formation of 1a at physiological pH of 7.4. A 
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release of 1a under the conditions of the pharmacological assays has to be taken into account 
as 1a is a highly potent Y1R antagonist (Ki = 1.3 nM) and could pretend a higher potency of 
the investigated compounds. Therefore the stability of the NG-acylated argininamides was 
investigated at pH 7.4 on the time scale of the assays. Formation of 1a was not observed for 
the strongly hydrophobic compounds 1c, 1d and 1e, which are devoid of hetero atoms in their 
NG-acyl substituents. The hydrophobic ligands 1f and 1g, both containing an amide group in 
the acyl substituent, showed a very minor decomposition over 90 min (< 0.5%). Instability 
was more pronounced (decomposition up to 2.6% over 90 min) for the more polar compounds 
(1h, 1i, 1k – 1q) bearing amide, ester, triazole, sugar, amine, carboxylic or guanidine 
functions in the acyl residue.  
Exceptionally high instabilities were found for argininamides with succinyl attached to the 
guanidine (1j, 1r – 1u). Compounds 1r – 1u quantitatively decomposed to 1a over 90 min 
(Table 1). This process was exemplarily explored by RP-HPLC-MS using the hydrophobic 
compound 1j, which allows the detection of the acyl substituent upon cleavage. As becomes 
obvious from Figure 2 compound 1j is cleaved via an intramolecular attack of the succinic 
amide nitrogen at the carbonyl group attached to the guanidine resulting in the N-alkyl 
succinimide derivative 39. The lability of the acylguanidines bearing nucleophiles in position 
5 or 6 of the acyl side chain is in accordance with the recently reported reactivity of 5-
aminopentanoyl substituted guanidine.17  
All compounds proved to be stable at acidic pH (0.1 % aqueous trifluoroacetic acid, pH 2-3). 
Under these conditions the acylguanidine group is almost quantitatively protonated due to pKa 
values in the range of 7 – 8. Obviously, this changes the susceptibility against hydrolysis and 
prevents intramolecular attacks of nucleophiles at the carbonyl group, respectively. 
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Figure 2. Exploration of the decomposition mechanism of BIBP 3226 derivative 1j incubated 
in an aqueous buffer (pH 7.4) at 20 °C. LC-MS analysis was performed after an incubation 
period of 20 and 90 min. 1j is decomposed to BIBP 3226 (1a) and the succinimide derivative 
39 through an intramolecular attack of the succinic amide nitrogen at the guanidine linked 
carbonyl group. Chromatograms were acquired by single ion monitoring analysis. 
 
 
Except for the highly unstable compounds 1j and 1r – 1u the NG-acylated argininamides were 
characterised in terms of Y1R antagonism (Kb values) and Y1R affinity (Ki values) using a 
Fura-2 assay on human erythroleukemia (HEL) cells19 and a radioligand binding assay on SK-
N-MC human neuroblastoma cells,4 respectively. Kb and Ki values are summarized in Table 1. 
Except for 1h (Ki = 0.9 nM) all NG-acylated argininamides showed a reduced Y1R affinity 
compared to the parent compound 1a (Ki = 1.3 nM, Table 1). The decrease in affinity was 
most pronounced (up to three orders of magnitude) for the most hydrophobic compounds (1b 
– 1e, Table 1), which have limited solubility and might interact with the cell membrane.  
Direct attachment of pyrene-1-carboxylic acid to the guanidine-N (compound 1e) resulted in 
complete loss of Y1R affinity. By contrast, high Y1R affinity can be retained, if the pyrene 
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moiety is attached to the guanidine group through a linker (compounds 1d and 1f, Figure 1, 
Table 1).  
 
The Y1R affinity of the polar sugar and guanidine substituted compounds 1n and 1q is about 
35 times lower compared to the affinity of 1a. The argininamide 1a may be considered a 
mimic of the C-terminal dipeptide in NPY (...-Arg35-Tyr36-NH2). It may be speculated that the 
introduction of a second guanidine moiety (as provided by compound 1q) could enhance 
binding affinity through mimicking the second arginine residue (Arg33).20 However, the Ki 
value of compound 1q was only 51 nM – perhaps due to an inappropriate distance between 
the two guanidine groups.  
The hydroxy substituted Y1R antagonist 1l (Ki = 3.0 nM), proved to be as potent as 1a. It is 
conceivable that the hydroxy group mimics Thr32 or Tyr27 of the natural ligand NPY. Both 
amino acids are very important for the binding of NPY to the Y1R, as identified by alanine 
scan.21 The amine analogue of 1l, compound 1m, binds with similar affinity to the Y1R (Ki = 
6.7 nM). 
As partial decomposition of compounds 1i, 1k and 1o - 1q occurs (up to 2.6% over 90 min), 
the determined Ki values of these five compounds have to be considered with reservation, as 
the affinity of the cleavage product 1a (Ki = 1.3 nM) and the assay periods (from preparation 
of solutions to read out: 60 – 90 min) have to be taken into account.  
With respect to the prediction of the affinity of new compounds, three issues have to be taken 
into account: substitution with bulky groups directly at the BIBP 3226 backbone results in a 
complete loss of affinity, that can be compensated with a spacer of adequate length. 
Derivatives with a small aromatic or heteroaromatic substituent (1g, 1l, 1m) show slightly 
higher binding affinity compared to the more flexible derivatives (1g vs. 1k, 1o, 1p; 1m vs. 
1q). Relatively small hydrophobic substituents, as in 1h (Ki = 0.9 nM) and the radioligand 
[3H]-UR-MK114 (Ki = 1.3 nM),4 result in similar and even higer affinity compared to BIBP 
3226. Interactions of the acyl substituent with the Y1R are difficult to predict, because these 
residues are presumably oriented toward flexible extracellular loop regions7 and, depending 
on chemical nature and size of the acyl residue, an interaction with membrane lipids cannot be 
ruled out. 
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Table 1. LogD values, stability, Y1R antagonistic activity (Kb) and Y1R binding affinity (Ki) 
of BIBP 3226 derivatives 1b – 1u. 
 
no. logDa % decomposition (pH 
7.4, 20  °C) after 20 / 
90 min  
Y1R antagonism  
Kbb [nM] 
Y1R affinity  
Ki c [nM] 
1ad 0.7 (1.4) -- 1.5 ± 0.2 1.3 ± 0.2 
1b 12.5 n.d. 140 ± 10 1500 ± 120 
1c 9.4 0 / 0 170 ± 8 460 ± 19 
1d 7.6 (5.3) 0 / 0 n.d.e 270 ± 70  
1e 7.2 0 / 0 n.d.e inactive 
1f 6.0 (3.1) 0 / < 0.5 n.d.e 59 ± 16 
1g 4.6 (3.2) 0 / < 0.5 1.10 ± 0.04 40 ± 9 
1h 3.9 0 / 0.8 0.06 ± 0.01f 0.9 ± 0.1f 
1i 3.5 (2.9) 0.9 /2.6 83 ± 8 110 ± 38 
1j 3.5 30 /69 n.d.g n.d.g 
1k 2.9 0 /0.7 170 ± 18 260 ± 82 
1l 1.8 (1.4) 0.9 /2.1 0.40 ± 0.03 3.0 ± 0.5 
1m 1.7 0.6 / 1.7 14 ± 4 6.7 ± 0.1 
1n 0.9 (1.0) < 0.5 /1.3 510 ± 190 41 ± 5 
1o 0.7 < 0.5 /1.4 450 ± 52 73 ± 11 
1p -0.3 (1.3) < 0.5 /1.4 230 ± 64 130 ± 10 
1q -0.3 (1.4) < 0.5 /1.6 18 ± 8 51 ± 18 
1r -0.6 64 /100 n.d.g n.d.g 
1s -1.3 51 /100 n.d.g n.d.g 
1t -1.4 61 /100 n.d.g n.d.g 
1u -1.8 (1.3) 40 /100 n.d.g n.d.g 
a
 Calculated with ACD-labs software version 12, pH = 7.4; in brackets: experimental logD 
determined with HPLC measurements. b Kb values for inhibition of NPY (10 nM) induced 
calcium mobilization in HEL cells (Fura-2 assay); all mean values ± SEM from two or three 
(1k, 1n, 1o, 1p, 1u) independent experiments. c Ki values determined from the displacement 
of 1.5 nM [3H]-UR-MK1144 on SK-N-MC cells; all mean values ± SEM from two or three 
(1c, 1f, 1g, 1k, 1l, 1p) independent experiments. d BIBP 3226. e Due to their fluorescent 
properties pyrene ligands are not compatible with the Fura-2 assay. f Keller et al.1 g not 
determined due to the high instability. 
 
 
 
1.3 Conclusion 
 
The stability of the NG-acylated argininamides strongly depends on the nature of the acyl 
residue. It becomes obvious from the high instability of the succinyl derivatives (1j, 1r – 1u) 
that cleavage is favoured when the residues harbour nucleophilic functional groups capable of 
an intramolecular attack on the acyl carbonyl. This is also conceivable for argininamides 
decomposing to a minor extent and bearing NG-acyl residues containing amide, ester, triazole, 
sugar, amine, carboxylic or guanidine functions (1h, 1i, 1k – 1q). This has to be taken into 
account in pharmacological investigations, in particular, when cleavage products are highly 
bioactive as in the case of 1a (Ki = 1.3 nM). However, despite these limitations broad 
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structural variation of NG-acyl substituents was tolerated (affinities in the nM range). Most of 
the investigated compounds proved to be sufficiently stable at pH 7.4 to determine reliable in 
vitro pharmacological data. In conclusion, the NG-acylation of the stongly basic guanidine 
group in argininamides is a successful bioisosteric approach to more drug-like properties 
provided that the outlined stability considerations are taken care of. This is not restricted to 
the NPY field, as guanidine groups are crucial structural features of many different 
biologically active compounds including GPCR ligands  
 
 
1.4 Experimental 
 
1.4.1 General experimental conditions 
 
Unless otherwise noted, solvents (analytical grade) were purchased from commercial 
suppliers and used without further purification. Ethyl acetate (EA), petrol ether (PE, 60 – 70  
°C), methanol and dichloromethane were obtained in technical grade and distilled before 
application. Acetonitrile (MeCN) for HPLC was obtained from Merck (Darmstadt, Germany). 
Pentacosa-10,12-diynoic acid (Sigma-Aldrich Chemie GmbH, Munich, Germany), 4-(pyren-
1-yl)butanoic acid (Sigma-Aldrich Chemie GmbH, Munich, Germany), hexadecanoic acid 
(Riedel-de Haen, Seelze, Germany), suberic acid (Fluka, Sigma-Aldrich Chemie GmbH, 
Munich, Germany) and D-(+)-galactose (Merck, Darmstadt, Germany) were purchased. 
Preparative HPLC was performed with a system from Knauer (Berlin, Germany) consisting of 
two K-1800 pumps and a K-2001 detector. A Nucleodur 100-5 C18 (250 × 21 mm, 5 µm; 
Macherey-Nagel, Germany) and a Eurospher-100 C18 (250 × 32 mm, 5 µm; Knauer, 
Germany) served as RP-columns at flow rates of 20 and 38 mL/min, respectively. Mixtures of 
MeCN and diluted aqueous TFA (0.1 %) were used as mobile phase. 1H-NMR spectra were 
recorded at 300 MHz on a Bruker Avance 300 spectrometer or at 600 MHz on a Bruker 
Avance III 600 with cryogenic probehead (Bruker, Karlsruhe, Germany). 13C-NMR spectra 
were recorded at 75 MHz on a Bruker Avance 300 spectrometer. All chemical shifts values 
are reported in ppm. UV/VIS spectra were recorded with a Varian Cary BIO 50 UV/VIS/NIR 
spectrophotometer (Varian Inc., CA, USA). Mass spectra: Finnigan SSQ 710A (EI), Finnigan 
MAT 95 (CI), Finnigan MAT TSQ 7000 (Thermo FINNIGAN, USA) (ES/LC-MS). LC-
system for LC-MS: Agilent 1100 (Palo Alto, USA). LC-MS method I (LC-MS-I): Column: 
Phenomex Luna C18, 3.0 µm, 100 x 2 mm HST (Phenomenex, Aschaffenburg, Germany); 
flow: 0.30 mL/min; solvent A (water + 0.1% TFA), solvent B (MeCN); gradient: 0 min [A/B 
95/5], 1 min [A/B 95/5], 11 min [A/B 2/98], 18 min [A/B 2/98], 19 min [A/B 95/5], 24 min 
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[A/B 95/5]. LC-MS method II: Column: Phenomex Luna C18, 2.5 µm, 50 x 2 mm HST 
(Phenomenex, Aschaffenburg, Germany); flow: 0.40 mL/min; solvent A (water + 0.1% TFA), 
solvent B (MeCN); gradient: 0 min [A/B 95/5], 8 min [A/B 2/98], 11 min [A/B 2/98], 12 min 
[A/B 95/5], 15 min [A/B 95/5]. Analytical HPLC (HPLC): Compounds 1c-1i, 1k-1q, 1t, 1u: 
Phenomex Luna C18, 3.0 µm, 150 x 2 mm (Phenomenex, Aschaffenburg, Germany); flow: 
0.30 mL/min; solvent A (H2O + 0.0059%TFA), solvent B (MeCN); gradient: 0 min [A/B 
95/5], 30 min [A/B 2/98]; 1j, 1r, 1s: Eurospher-100 C18, 5 µm, 250 x 4.0 mm (Knauer, 
Berlin, Germany); flow: 0.80 mL/min; solvent A (water + 0.05% TFA), solvent B (MeCN); 
gradient: 0 min [A/B 85/15], 28 min [A/B 45/55], 33 min [A/B 5/95], 40 min [A/B 5/95]. 
Melting points were determined with a Lambda Photometrics Optimelt MPA100 apparatus 
(Lambda photometrics, Harpenden, UK), they are not corrected. Thin layer chromatography 
(TLC) was performed on alumina plates coated with silica gel (Merck silica gel 60 F245, 
thickness 0.2 mm). Column chromatography (CC) was performed with Merck Geduran SI 60 
silica gel as the stationary phase.  
The synthesis of 38, 1a and 1h was described elsewhere.1, 4 Compounds 3,2 5,4 6,22 penta-
acetyl gluconic acid,23 tBu-protected propargyl alcohol,24 tBu-protected propargyl amine,25 
10,26 11,27 14,28 16,29 19,30 21,31 23,32 31,33 374 were prepared according to literature pro-
cedures. 
 
 
1.4.2 Synthetic protocols and analytical data of 7, 8, 17, 20, 22, 25-28, 30 and 32-36 
 
4-[4-(tert-Butoxymethyl)-1H-1,2,3-triazol-1-yl]butanoic acid (7) 
4-Azidobutanoic acid (419 mg, 3.25 mmol) was mixed with Boc-protected propargyl alcohol 
(364 mg, 3.25 mmol) in 5 mL MeOH. Then ascorbic acid (65 mg, 0.33 mmol) dissolved in 1 
mL H2O and copper sulphate pentahydrate (8 mg, 0.03 mmol) dissolved in 1 mL H2O were 
added and the reaction mixture was heated to reflux overnight. Next day MeOH was 
evaporated completely and dichloromethane (30 mL) and sat. aqueous NaHSO4 solution (20 
mL) were added. The organic layer was collected and then diluted NaOH (40 mL, 1 mol/L) 
was added. The aqueous layer was collected and acidified with NaHSO4 solution until pH < 2. 
Dichloromethane (40 mL) was added and the acid was extracted. The organic phase was dried 
over MgSO4, the solvent was evaporated and a white solid was obtained (674 mg, 86%), m.p. 
81 °C. 1H NMR (300 MHz, CDCl3): 1.26 (s, 9H), 2.15 – 2.25 (m, 2H), 2.39 (t, J = 6.88, 2H), 
4.42 (t, J = 6.94, 2H), 4.58 (s, 2H), 7.55 (s, 1H), 10.31 (bs, 1H). 13C NMR (75 MHz, CDCl3): 
25.3, 27.5, 30.5, 49.3, 56.2, 74.1, 122.5, 146.8, 176.4. C11H19N3O3: MS (CI, NH3): m/z(%) 
242(100, MH+). 
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4-{4-[(tert-Butoxycarbonylamino)methyl]-1H-1,2,3-triazol-1-yl}butanoic acid (8) 
4-Azidobutanoic acid (0.89 g, 6.90 mmol) was mixed with Boc-protected propargylamine 
(1.07 g, 6.90 mmol) in MeOH (10 mL). NaOH (1 mol/L) was added until the pH value was 
between 6 and 8. Then ascorbic acid (65 mg, 0.33 mmol) dissolved in 1 mL H2O and copper 
sulphate pentahydrate (8 mg, 0.03 mmol) dissolved in 1 mL H2O were added and the reaction 
mixture was heated to reflux overnight. Next day MeOH was evaporated under reduced 
pressure and the residue was diluted with 80 mL EA and 80 mL of aqueous NaHSO4 solution 
(5%w). The organic layer was separated, dried over MgSO4 and the solvent was evaporated. 
The crude material was recrystallised from EA yielding a white crystalline solid (1.31 g, 
67%), m.p. 117 °C. 1H NMR (300 MHz, CD3OD): 1.43 (s, 9H), 2.10 – 2.20 (m, 2H), 2.25 – 
2.35 (m, 2H), 4.29 (s, 2H), 4.44 (t, J = 6.89, 2H), 7.82 (s, 1H). 13C NMR (75 MHz, CD3OD): 
26.7, 29.0, 31.5, 36.9, 50.6, 80.5, 124.2, 147.3, 158.3, 176.1. C12H20N4O4: MS (LC-MS-II): 
m/z(%) [tR = 5.1 min]: 285(35, MH+), 569(100).  
 
6-(tert-Butoxycarbonylamino)-2,2-dimethyl-4,11-dioxo-3-oxa-5,7,10-triaza-tetradec-5-
en-14-oic acid (17) 
Compound 16 (300 mg, 0.99 mmol) and succinic anhydride (119 mg, 1.19 mmol) were 
dissolved in a mixture of THF (10 mL) and NEt3 (150 mg, 1.49 mmol) and stirred overnight. 
Next day water was added (10 mL) and the mixture was stirred for one hour. THF was 
evaporated completely and the residue was diluted with water (20 mL). Aqueous NaHSO4 
solution (5%w, 10 mL) was added and the mixture was extracted with dichloromethane (2 x 
50 mL). The organic layer was dried over MgSO4 and the solvent was evaporated yielding a 
white solid (197 mg, 49%), m.p. 77-80 °C. 1H NMR (300 MHz, CDCl3): 1.47 (s, 9H), 1.49 (s, 
9H), 2.50 – 2.60 (m, 2H), 2.60 – 2.70 (m, 2H), 3.35 – 3.45 (m, 2H), 3.45 – 3.60 (m, 2H), 7.00 
– 8.40 (bs, 1H), 8.50 (bs, 1H), 8.67 (bs, 1H), 11.38 (bs, 1H). 13C NMR (75 MHz, CDCl3): 
28.0, 28.2, 30.3, 30.5, 40.3, 41.9, 79.9, 83.9, 153.0, 157.6, 162.5, 172.9, 175.1. C17H30N4O7: 
MS (LC-MS-I): m/z(%) [tR = 10.3 min]: 403(100, MH+), 805(10).  
 
4-{2-[(2-tert-Butoxycarbonylaminoethyl)(tert-butoxycarbonyl)amino]ethylamino} 
-4-oxobutanoic acid (20) 
Compound 19 (1.00 g, 3.30 mmol) was dissolved in 5 mL THF and a solution of succinic 
anhydride (0.33 g, 3.30 mmol) in 5 mL THF was added. Then NEt3 (0.50 g, 4.95 mmol) was 
added to the mixture. The mixture was stirred overnight at ambient temperature. Next day 
THF was removed completely and the crude product was dissolved in 20 mL 
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dichloromethane. It was washed with aqueous NaHSO4 sol. (5%w, 30 mL), dried over 
MgSO4 and the solvent was evaporated giving a white solid (1.03 g, 77%), m.p. 90 °C. 1H 
NMR (300 MHz, CDCl3): 1.40 (s, 9H), 1.43 (s, 9H), 2.48 (bs, 2H), 2.64 (bs, 2H), 3.10 - 3.40 
(m, 8H), 4.95 – 5.25 (m, 1H), 7.00 – 7.30 (m, 1H), 9.31 (bs, 1H). 13C NMR (75 MHz, 
CDCl3): 20.4, 29.7, 30.6, 39.3, 39.6, 47.0, 47.8, 79.6, 80.7, 156.6, 156.7, 172.8, 175.7. 
C18H33N3O7: MS (ES): m/z(%) 204(5), 245(45), 304(50), 348(25), 404(100, MH+), 426(5), 
808(7), 825(15). 
 
3-(2-tert-Butoxycarbonylaminoethyl)aminocarbonylpropanoic acid (22) 
Succinic anhydride (0.41 g, 4.06 mmol) and NEt3 (56 µL, 0.41 mmol) were added to a 
solution of amine 21 (0.65 g, 4.06 mmol) in dichloromethane (3 mL). The mixture was heated 
to 60 °C for 25 min (microwave synthesizer (Biotage Initiator 8)). After removal of the 
solvent under reduced pressure the product (insoluble in dichloromethane) was afforded as a 
white solid (1.05 g, 99%). 1H NMR (300 MHz, DMSO-d6): 1.37 (s, 9H), 2.25 – 2.32 (m, 
2H), 2.37 – 2.44 (m, 2H), 2.91 – 2.99 (m, 2H), 3.00 – 3.08 (m, 2H), 6.78 (t, J = 5.45, 1H), 
7.85 (t, J = 5.29, 1H), 12.08 (bs, 1H). 13C NMR (75 MHz, DMSO-d6): 28.1, 29.0, 29.9, 38.6, 
39.5, 77.5, 155.5, 171.0, 173.8. C11H20N2O5: (LC-MS-II): m/z(%) [tR = 4.63 min]: 261(40, 
MH+), 278(6, MNH4+), 521(35, 2MH+), 538(100, 2MNH4+). 
 
Benzyl 8-(3-methoxy-3-oxopropylamino)-8-oxooctanoate (25) 
Acid 23 (250 mg, 0.95 mmol), DIPEA (368 mg, 2.85 mmol), and HOBT ⋅ H2O (142 mg, 1.05 
mmol) were dissolved in ice-cold dichloromethane (20 mL) and EDC (147 mg, 0.95 mmol) 
was added under nitrogen atmosphere. After 15 minutes amine 24 (98 mg, 0.95 mmol) was 
added. The reaction mixture was stirred overnight. Next day the reaction mixture was washed 
with aqueous NaHSO4 sol. (5%w, 20 mL) and sat. aqueous NaHCO3 solution (20 mL). The 
solvent was dried over MgSO4, filtered and evaporated. The crude product was purified by 
column chromatography (PE/EA 3:1 -> EA Rf = 0.4 [EA]) yielding the product as a white 
solid (253 mg, 76%), m.p. 48 °C. 1H NMR (300 MHz, CDCl3): 1.31 (m, 4H), 1.60 (m, 4H), 
2.10 (m, 2H), 2.30 (t, J = 7.48, 2H), 2.50 (m, 2H), 3.50 (dd, J1 = 6.07, J2 = 11.99, 2H), 3.68 
(s, 3H), 5.10 (s, 2H), 6.00 – 6.10 (bs, 1H), 7.30 – 7.38 (m, 5H). 13C NMR (75 MHz, CDCl3): 
24.0, 25.4, 28.75, 28.80, 33.9, 34.2, 34.7, 36.6, 51.8, 66.1, 128.2, 128.6, 136.1, 173.0, 173.2, 
173.6. C19H27NO5: MS (CI, NH3): m/z(%) 350(100, MH+). 
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Benzyl 8-[2-(tert-butoxycarbonylamino)ethylamino]-8-oxooctanoate (26) 
Compound 23 (264 mg, 1.00 mmol) was dissolved in 10 mL of dichloromethane. HOBT ⋅ 
H2O (149 mg, 1.10 mmol) and DIPEA (387 mg, 3.00 mmol) were added under nitrogen 
atmosphere. The mixture was stirred and cooled in an ice bath. EDC (171 mg, 1.10 mmol) 
was added and after 15 min amine 21 (160 mg, 1.00 mmol) was added. The mixture was 
stirred overnight. Next day DCM was added (10 mL), the organic phase was washed once 
with aqueous NaHSO4 (5%w, 20 mL) and sat. aqueous NaHCO3 sol. (20 mL), was dried over 
MgSO4 and the organic layer was evaporated. The crude product was purified by column 
chromatography (PE/EA 1:1 -> EA Rf = 0.3 [EA]). A white, wax-like solid (251 mg, 62%), 
m.p. 60 °C was obtained. 1H NMR (300 MHz, CDCl3): 1.25 – 1.25 (m, 4H), 1.43 (s, 9H), 
1.55 – 1.70 (m, 4H), 2.10 – 2.17 (m, 2H), 2.30 – 2.37 (m, 2H), 3.20 – 3.30 (m, 2H), 3.30 – 
3.40 (m, 2H), 4.97 (bs, 1H), 5.10 (s, 2H), 6.20 (bs, 1H), 7.30 – 7.40 (m, 5H). 13C NMR (75 
MHz, CDCl3): 24.7, 25.4, 28.4, 28.7, 28.8, 34.1, 36.5, 40.3, 40.7, 66.1, 79.6, 128.2, 128.6, 
136.1, 157.0, 173.6, 173.8. C22H34N2O5: MS (ES): m/z(%) 407(100, MH+). 
 
8-(3-Methoxy-3-oxopropylamino)-8-oxooctanoic acid (27) 
Compound 25 (210 mg, 0.60 mmol) was dissolved in MeOH, placed into an autoclave and 
Pd/C (25 mg) was added after flushing the autoclave with N2. The reaction mixture was 
stirred overnight at room temperature and 12 bar hydrogen pressure. Pd/C was removed by 
filtration over celite, MeOH was evaporated and a white solid was obtained (146 mg, 94%), 
m.p. 73 °C. 1H NMR (300 MHz, CD3OD): 1.34 (m, 4H), 1.59 (m, 4H), 2.16 (t, J = 7.45, 2H,), 
2.27 (t, J = 7.39, 2H), 2.52 (t, J = 6.64, 2H), 3.41 (t, J = 6.64, 2H), 3.67 (s, 3H). 13C NMR (75 
MHz, CD3OD): 26.0, 26.9, 29.90, 29.92, 34.8, 34.9, 36.4, 36.9, 52.2, 173.9, 176.4, 177.7. 
C12H21NO5: MS (CI, NH3): m/z(%) 260(100, MH+), 277(41).  
 
8-[2-(tert-Butoxycarbonylamino)ethylamino]-8-oxooctanoic acid (28) 
Compound 26 (172 mg, 0.42 mmol) was dissolved in 5 mL MeOH. Pd-C (17 mg) was added 
and the mixture was stirred at 15 bar hydrogen pressure in an autoclave overnight. Pd/C was 
filtered off using celite and MeOH was evaporated. The product was obtained as a white solid 
(120 mg, 90%), m.p. 95 °C. 1H NMR (300 MHz, CDCl3): 1.15 – 1.25 (m, 4H), 1.31 (s, 9H), 
1.40 – 1.55 (m, 4H), 2.00 – 2.10 (m, 2H), 2.10 – 2.20 (m, 2H), 3.00 – 3.10 (m, 2H), 3.10 – 
3.17 (m, 2H), 4.05 (bs, 3H). 13C NMR (75 MHz, CDCl3): 24.5, 25.3, 28.1, 28.5, 28.6, 33.9, 
36.1, 39.6, 39.7, 79.6, 157.1, 174.9, 176.5. C15H28N2O5: MS (ES): m/z(%) 217(100), 261(45), 
317(85, MH+), 339(15), 633(10), 650(25). 
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8-[3-(Benzyloxy)-3-oxopropylamino]-8-oxooctanoic acid (30) 
Octanedioic acid (500 mg, 2.87 mmol), DIPEA (1.11 g, 8.61 mmol) and HOBT ⋅ H2O (427 
mg, 3.16 mmol) were dissolved in ice-cold dichloromethane (20 mL) and EDC (490 mg, 3.16 
mmol) was added under nitrogen atmosphere. After 15 min 3-aminopropanoic acid benzyl 
ester (617 mg, 2.87 mmol) was added and the ice bath was removed. The mixture was stirred 
overnight. Next day an aqueous NaHSO4 solution (5%w, 20 mL) was added and the crude 
product was extracted with dichloromethane (2 x 20 mL), the organic phase was dried over 
MgSO4, filtered and evaporated. The crude material was purified by column chromatography, 
(EA -> EA/MeOH 9:1). The obtained material is a 2:1 mixture of the desired product (420 
mg, 44%) and the appropriate octanedioic acid diamide. The mixture was used in the next 
synthesis step without further purification. 
 
tert-Butyl 2-(pyrene-1-carbonylamino)ethylcarbamate (32) 
Pyrene-1-carboxylic acid (246 mg, 1.00 mmol), DIPEA (387 mg, 3.00 mmol) and HOBT ⋅ 
H2O (149 mg, 1.10 mmol) were dissolved in ice-cold dichloromethane (20 mL). EDC (171 
mg, 1.10 mmol) was added under nitrogen atmosphere. After 15 min Boc-protected 
ethylenediamine (160 mg, 1.0 mmol) was added and the ice bath was removed. The mixture 
was stirred overnight. Next day the reaction mixture was diluted with dichloromethane (40 
mL), washed with aqueous NaHSO4 solution (5%w, 40 mL) and sat. aquoeus NaHCO3 
solution (1 x 40 mL). The organic layer was dried over MgSO4 and evaporated. The crude 
compound was recrystallised from EA yielding the product as a yellow solid (213 mg, 55%), 
m.p. > 190 °C. 1H NMR (300 MHz, DMSO-d6): 1.41 (s, 9H), 3.20 – 3.30 (m, 2H), 3.40 – 
3.50 (m, 2H), 7.00 (t, J = 5.57, 1H), 8.05 – 8.30 (m, 5H), 8.30 – 8.40 (m, 3H), 8.50 – 8.54 (m, 
1H), 8.71 (t, J = 5.37, 1H). 13C NMR (75 MHz, DMSO-d6): 28.2, 39.58, 39.61, 77.6, 123.5, 
123.7, 124.2, 124.7, 125.3, 125.5, 125.7, 126.5, 127.1, 127.9, 128.2, 130.1, 130.6, 131.5, 
131.8, 155.7, 168.9. C24H24N2O3: MS (EI): m/z(%) 201(58), 229(100), 245(57), 258(15), 
389(22, MH+). 
 
2-(Pyren-1-carbonylamino)ethanaminium chloride (33) 
Compound 32 (549 mg, 1.41 mmol) was suspended in a mixture of 20 mL MeOH and 5 mL 
HCl (37%). It was stirred 30 min at 70 °C. The solvent was evaporated completely and a 
yellow solid was obtained (445 mg, 97%), m.p. > 190 °C. 1H NMR (300 MHz, DMSO-d6): 
3.05 – 3.20 (m, 2H), 3.65 – 3.75 (m, 2H), 8.05 – 8.15 (m, 1H), 8.15 – 8.30 (m, 3H), 8.30 – 
8.35 (m, 4H), 8.35 – 8.50 (bs, 3H), 8.62 (m, 1H), 9.02 (t, J = 5.33, 1H). 13C NMR (75 MHz, 
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DMSO-d6): 37.3, 38.4, 123.5, 123.7, 124.2, 124.7, 125.6, 125.7, 125.8, 126.5, 127.1, 128.0, 
128.3, 130.0, 130.6, 130.8, 131.7, 169.2. C19H16N2O: MS (CI, NH3): m/z(%) 289(100, 
MH+). 
 
3-Oxo-1-phenyl-2,5,8,11-tetraoxatridecan-13-oic acid (34) 
3,6,9-Trioxaundecanedioic acid (5.55 g, 25 mmol), benzyl alcohol (2.70 mg, 25 mmol) and 
toluene sulfonic acid (43 mg, 0.25 mmol) were combined in a 250 mL flask and toluene (70 
mL) was added. The flask was connected to a Dean-Stark apparatus. The mixture was heated 
to reflux and the reaction was completed after 1 h. Sat. aqueous NaHCO3 (50 mL) solution 
was added and the phases were separated. The aqueous layer was collected and extracted with 
EA (3 x 100 mL). The organic layer was dried over MgSO4 and evaporated. The product is a 
viscous oil (1.87 g, 24%). 1H NMR (300 MHz, CD3OD): 3.60 – 3.75 (m, 8H), 4.10 (s, 2H), 
4.20 (s, 2H), 5.17 (s, 2H), 7.30 – 7.40 (m, 5H). 13C NMR (75 MHz, CD3OD): 66.7, 68.5, 
68.6, 70.3, 70.5, 70.7, 70.9, 128.44, 128.47, 128.52, 128.63, 128.65, 135.3, 170.5, 173.2. 
C15H20O7: MS (CI, NH3): m/z(%) 242(6), 286(28), 313(2, MH+), 330(100). 
 
Benzyl 1,6-dioxo-1-(pyren-1-yl)-8,11,14-trioxa-2,5-diazahexadecan-16-oate (35) 
Compound 34 (462 mg, 1.48 mmol), DIPEA (476 mg, 3.69 mmol) and HOBT ⋅ H2O (200 mg, 
1.48 mmol) were dissolved in DMF (10 mL) and EDC (229 mg, 1.48 mmol) was added (ice 
bath). After 15 min compound 33 (400 mg, 1.23 mmol) was added and the mixture was 
stirred overnight. Next day DMF was removed completely, the residue was dissolved in 
dichloromethane (20 mL) and washed with aqueous NaHSO4 solution (5%w, 20 mL), sat. 
aqueous NaHCO3 solution (1 x 20 mL) and brine (1 x 20 mL). The crude product was purified 
with column chromatography (PE/EA 1:1 -> EA/MeOH 4:1 Rf = 0.3 [EA/MeOH 9:1]). The 
product is a yellow solid (420 mg, 59%), m.p. > 190 °C. 1H NMR (300 MHz, CDCl3): 3.45 – 
3.80 (m, 12H), 3.97 (s, 2H), 4.02 (s, 2H), 5.07 (s, 2H), 7.20 – 7.40 (m, 6H), 7.64 (t, J = 5.57, 
1H), 7.95 – 8.10 (m, 6H), 8.14 – 8.19 (m, 2H), 8.55 – 8.60 (m, 1H). 13C NMR (75 MHz, 
CDCl3): 38.8, 40.9, 66.6, 68.4, 70.1, 70.27, 70.32, 70.7, 70.9, 124.3, 124.4, 124.6, 124.69, 
124.7, 125.65, 125.72, 126.3, 127.1, 128.39, 128.47, 128.51, 128.55, 128.62, 130.7, 130.95, 
131.12, 132.4, 135.2, 170.1, 170.4, 171.4. C34H34N2O7: MS (ES): m/z(%) 583(100, MH+), 
605(60), 621(10). UV (MeOH): λ(ε) 233(65⋅103), 242(89⋅103), 265(34⋅103), 275(51⋅103), 
326(31⋅103), 340(41⋅103). Fluorescence (MeOH): λ(type) 383 (monomer), 401 (monomer)  
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1,6-Dioxo-1-(pyren-1-yl)-8,11,14-trioxa-2,5-diazahexadecan-16-oic acid (36) 
Compound 35 (203 mg, 0.35 mmol) was dissolved in 5 mL of MeOH. Pd/C (10 mg) was 
added and the mixture was stirred in an autoclave at 1 bar hydrogen pressure for 4 h. After 
that time Pd/C was filtered off with celite and the solvent was removed. The product is a 
yellow solid (172 mg, 100%), m.p. > 190 °C. 1H NMR (300 MHz, CD3OD): 3.50 – 3.58 (m, 
4H), 3.58 – 3.65 (m, 4H), 3.65 – 3.75 (m, 4H), 4.01 (s, 2H), 4.03 (s, 2H), 8.00 – 8.30 (m, 8H), 
8.45 – 8.55 (m, 1H). 13C NMR (75 MHz, DMSO-d6): 38.1, 39.2, 67.5, 69.4, 69.6, 69.7, 69.9, 
70.2, 123.5, 123.7, 124.3, 124.7, 125.2, 125.5, 125.7, 126.5, 127.1, 127.7, 128.0, 128.2, 130.1, 
130.6, 131.5, 131.8, 169.0, 169.6, 171.6. C27H28N2O7: MS (ES): m/z(%) 493(100, MH+), 
510(10), 515(50).  
 
General procedure for the preparation of compounds 4b-4g, 4i, 4k-4q, 4t, 4u 
The appropriate carboxylic acid (1 mmol), HOBT ⋅ H2O (1.2 mmol), EDC (1.2 mmol) and 
DIPEA (2 mmol) were combined in a flask under nitrogen atmosphere with 10 mL of cold 
DMF. After 15 min compound 3 (1 mmol) was added and the mixture was stirred overnight at 
room temperature. Next day the solvent was removed completely and the crude material was 
purified with column chromatography. 
 
 
tert-Butyl (pentacosa-10,12-diynamido)methylthiomethylenecarbamate (4b) 
Column chromatography: (PE/EA 9:1, Rf = 0.3). The product is a white solid (489 mg, 89%), 
m.p. 37 °C. 1H NMR (300 MHz, CDCl3): 0.75 – 0.85 (t, J = 7.24, 3H), 1.10 – 1.70 (m, 41H), 
2.17 (t, J = 6.92, 4H), 2.30 – 2.45 (m, 5H), 12.00 – 12.45 (m, 1H). 13C NMR (75 MHz, 
CDCl3): 14.13, 14.45, 19.18, 19.20, 22.69, 24.50, 27.99, 28.29, 28.36, 28.74, 28.86, 28.91, 
29.06, 29.11, 29.35, 29.49, 29.62, 29.64, 29.65, 31.92, 37.38, 65.25, 65.34, 77.35, 77.54, 
81.17, 160.97, 171.32, 171.49. C32H54N2O3S: MS (LC-MS-I): m/z(%) [tR = 15.3 min]: 
547(100, MH+).  
 
tert-Butyl (hexadecanamido)methylthiomethylenecarbamate (4c) 
Column chromatography: (PE/EA 9:1 Rf = 0.5). The product is a white solid (342 mg, 80%), 
m.p. 62 °C. 1H NMR (300 MHz, CDCl3): 0.82 (t, J = 6.68, 3H), 1.18 – 1.28 (m, 24 H), 1.46 
(s, 9H), 1.60 (m, 2H), 2.33 (s, 3H), 2.37 (m, 2H), 12.40 (bs, 1H). 13C NMR (75 MHz, 
CDCl3): 14.1, 14.5, 28.0, 22.7, 29.1 – 29.7, 31.9, 80.2. C23H44N2O3S: MS (CI, NH3): m/z(%) 
329(15), 429(100, MH+). 
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tert-Butyl-[4-(pyren-1-yl)butanamido]methylthiomethylenecarbamate (4d) 
Column chromatography (PE/EA 9:1 -> PE/EA 3:1, Rf = 0.4 [PE/EA 3:1]). The product was 
obtained as a white solid (299 mg, 65%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
CDCl3): 1.53 (s, 9H), 2.18 – 2.32 (m, 2H), 2.32 – 2.43 (m, 3H), 2.45 – 2.70 (m, 2H), 3.41 (t, J 
= 7.46, 2H), 7.80 – 7.90 (m, 1H), 7.95 – 8.05 (m, 3H), 8.05 – 8.20 (m, 4H), 8.25 – 8.35 (m, 
1H), 12.15 – 12.55 (m, 1H). 13C NMR (75 MHz, CDCl3): 14.6, 26.1, 28.1, 32.5, 36.7, 81.3, 
123.3, 124.86, 124.97, 125.01, 125.10, 125.88, 126.76, 127.32, 127.43, 127.47, 127.53, 
128.74, 130.02, 130.03, 131.43, 135.26, 150.98, 161.04, 171.24. C27H28N2O3S: MS (LC-MS-
I): m/z(%) [tR = 15.5 min]: 461(100, MH+). 
 
tert-Butyl-(pyren-1-carbonylamino)methylthiomethylenecarbamate (4e) 
Column chromatography (PE/EA 9:1, Rf = 0.1). The product was obtained as a bright yellow 
solid (190 mg, 45%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, CDCl3): 1.54 – 1.63 (m, 
9H), 2.53 – 2.67 (m, 3H), 7.95 – 8.40 (m, 7H), 8.90 – 9.00 (m, 1H), 9.40 – 9.50 (m, 1H), 
12.60 – 13.40 (m, 1H). 13C NMR (75 MHz, CDCl3): 15.1, 28.1, 83.6, 124.03, 124.36, 124.99, 
125.55, 126.07, 126.21, 127.27, 127.38, 129.09, 129.54, 129.67, 130.42, 130.47, 131.05, 
131.25, 134.25, 151.25, 171.15, 178.73. C24H22N2O3S: MS (LC-MS-I): m/z(%) [tR = 16.3 
min]: 419(100, MH+), 837(10). 
 
tert-Butyl 5,15,20-trioxo-20-(pyren-1-yl)-7,10,13-trioxa-2-thia-4,16,19-triazaicosan-3-
ylidenecarbamate (4f) 
Column chromatography (EA -> EA/MeOH 9:1, Rf = 0.3 [EA/MeOH 9:1]). The product was 
obtained as a light yellow solid (485 mg, 73%), m.p. > 190 °C (decomp.). 1H NMR (300 
MHz, CDCl3): 1.49 (s, 9H), 2.20 – 2.40 (m, 3H), 3.50 – 3.75 (m, 10H), 3.75 – 3.85 (m, 2H), 
3.90 – 4.05 (m, 4H), 7.10 – 7.90 (m, 2H), 7.95 – 8.15 (m, 6H), 8.15 – 8.25 (m, 2H), 8.55 – 
8.65 (m, 1H), 11.80 – 12.90 (m, 1H). 13C NMR (75 MHz, CDCl3): 14.4, 28.0, 39.0, 40.9, 
70.4, 70.5, 70.6, 70.8, 70.9, 71.5, 77.2, 124.4, 124.6, 124.7, 125.7, 125.8, 126.3, 127.1, 128.6, 
128.7, 130.7, 131.2, 132.5, 165.9, 169.1, 170.4. C34H40N4O8S: MS (ES): m/z(%) 565(50), 
665(100, MH+), 687(15). 
 
Benzyl 3-{8-[(Boc-amino)-methylthio-methyleneamino]-8-oxooctanamido} 
propanoate (4g = 4o)a  
Column chromatography (PE/EA 1:1 -> PE/EA 3:7, Rf = 0.15[PE/ EA 1:1]). The product is a 
viscous oil (364 mg, 72%). 1H NMR (300 MHz, CDCl3): 1.25 – 1.40 (m, 4H), 1.51 (s, 9H), 
20 
 
1.55 – 1.70 (m, 4H), 2.05 – 2.15 (m, 2H), 2.35 – 2.50 (m, 2H), 2.38 (s, 3H), 2.55 – 2.60 (m, 
2H), 3.45 – 3.55 (m, 2H), 5.13 (s, 2H), 6.02 (s, 1H), 7.30 – 7.40 (m, 5H), 12.45 (bs, 1H). 13C 
NMR (75 MHz, CDCl3): 14.5, 25.4, 28.0, 28.7, 34.1, 34.8, 36.6, 66.6, 77.3, 128.3, 128.4, 
128.7, 135.6, 172.6, 172.9. C25H37N3O6S: MS (ES): m/z(%) 408(25), 508(100, MH+). 
a
 This compound was used for preparation of 1g and 1o. 
 
(2R,3R,4S,5R)-6-[(Boc-amino)-methylthio-methyleneamino]-6-oxohexane-1,2,3,4,5-
pentayl pentaacetate (4i) 
Column chromatography (PE/EA 3:1, Rf = 0.1). Compound 4i (252 mg, 44%) was obtained as 
a viscous oil. 1H NMR (300 MHz, CDCl3): 1.48 (s, 9H), 2.00 – 2.10 (m, 12H), 2.23 (s, 3H), 
2.42 (s, 3H), 4.19 (dd, J1 = 5.84, J2 = 12.33, 1H), 4.34 (dd, J1 = 3.53, J2 = 12.33, 1H), 5.05 
(dt, J1 = 3.53, J2 = 5.84, 1H), 5.40 (d, J = 3.08, 1H), 5.52 (dd, J = 5.84, 1H), 5.90 (dd, J1 = 
3.08, J2 = 5.84, 1H), 11.88 (bs, 1H). 13C NMR (75 MHz, CDCl3): 14.8, 20.5, 20.6, 20.7, 20.8, 
21.1, 27.9, 61.5, 69.1, 69.3, 70.1, 74.5, 84.1, 150.5, 169.5, 169.7, 169.8, 170.2, 170.5, 174.5, 
176.8. C23H34N2O13S: MS (ES): m/z(%) 579(100, MH+). 
 
Methyl 3-{8-[boc-amino(methylthio)methyleneamino]-8-oxooctanamido} 
propanoate (4k) 
Column chromatography (PE/EA 1:1 -> EA, Rf = 0.4 [EA]). The product is a colorless oil 
(337 mg, 78%). 1H NMR (300 MHz, CDCl3): 1.33 (m, 4H), 1.51 (s, 9H), 1.63 (m, 4H), 2.14 
(m, 2H), 2.35 – 2.50 (m, 5H), 2.53 (m, 2H), 3.47 – 3.54 (dd, J1 = 6.07, J2 = 11.94, 2H), 3.70 
(s, 3H), 6.04 (bs, 1H), 12.00 – 12.70 (bs, 1H). 13C NMR (75 MHz, CDCl3): 14.5, 24.3, 25.4, 
28.0, 28.7, 28.8, 33.9, 34.7, 36.6, 37.3, 51.8, 77.2, 81.3, 171.3, 172.9, 173.3. C19H33N3O6S: 
MS (CI, NH3): m/z(%) 332(14), 432(100, MH+). 
 
tert-Butyl-{4-[4-(tert-butoxymethyl)-1H-1,2,3-triazol-1-yl]butanamido} 
methylthio-methylenecarbamate (4l) 
Column chromatography (PE/EA 3:1 -> PE/ EA 4:6, Rf = 0.4[PE/EA 4:6]). Compound 4l 
(254 mg, 62%) was obtained as a white solid, m.p. 93 °C. 1H NMR (300 MHz, CDCl3): 1.26 
(s, 9H), 1.49 (s, 9H), 2.15 – 2.30 (m, 2H), 2.37 (s, 3H), 2.40 – 2.60 (m, 2H), 4.40 (t, J = 6.33, 
2H), 4.57 (s, 2H), 7.52 (s, 1H), 12.10 – 12.50 (m, 1H). 13C NMR (75 MHz, CDCl3): 14.6, 
25.2, 27.6, 28.0, 35.3, 49.1, 56.5, 73.8, 81.5, 83.6, 122.1, 147.0, 171.0, 171.4. C18H31N5O4S: 
MS (CI): m/z(%) 314(18), 414(100, MH+). 
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tert-Butyl {4-[4-(Boc-aminomethyl)-1H-1,2,3-triazol-1-yl]butanamido} 
methylthio-methylenecarbamate (4m) 
Column chromatography (PE/EA 3:1 -> PE/ EA 4:6, Rf = 0.3[PE/EA 4:6]). Compound 4m 
(341 mg, 75%) was obtained as a colorless, viscous oil. 1H NMR (300 MHz, CDCl3): 1.34 (s, 
9H), 1.41 (s, 9H), 2.10 – 2.25 (m, 2H), 2.29 (s, 3H), 2.30 – 2.50 (m, 2H), 4.25 – 4.40 (m, 4H), 
5.20 – 5.40 (bs, 1H), 7.49 (s, 1H), 11.70 – 12.50 (m, 1H). 13C NMR (75 MHz, CDCl3): 14.5, 
24.9, 27.9, 28.3, 33.9, 37.6, 49.4, 79.5, 122.0, 145.6, 155.9, 160.7, 169.9, 184.5. 
C19H32N6O5S: MS (LC-MS-II): m/z(%) [tR = 7.3 min]: 457(100, MH+), 913(40).  
 
((3aR,5R,5aS,8aS,8bR)-2,2,7,7-Tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-
d]pyran-5-yl)methyl 4-((boc-amino)-methylthio-methyleneamino)-4-oxobutanoate (4n) 
Column chromatography (PE/EA 9:1 -> PE/EA 3:1, Rf = 0.2 [PE/EA 9:1]). Compound 4n 
(396 mg, 74%) was obtained as a colorless, viscous oil. 1H NMR (300 MHz, CDCl3): 1.29 (d, 
J = 2.47, 6H), 1.40 (s, 3H), 1.42 – 1.50 (m, 12H), 2.34 (s, 3H), 2.60 – 2.85 (m, 4H), 3.90 – 
4.00 (m, 1H), 4.19 (dd, J1 = 1.55, J2 = 7.85, 2H), 4.24 (d, J = 4.96, 1H), 4.28 (dd, J1 = 2.50, 
J2 = 4.99, 1H), 4.57 (dd, J1 = 2.46, J2 = 7.88, 1H), 5.48 (d, J = 4.98, 1H), 12.05- 12.49 (m, 
1H). 13C NMR (75 MHz, CDCl3): 14.5, 24.5, 24.9, 25.9, 26.0, 27.9, 28.3, 29.3, 31.8, 35.8, 
63.5, 63.8, 65.9, 70.4, 70.7, 71.0, 81.3, 83.4, 96.3, 108.7, 109.6, 150.9, 169.8, 170.9, 171.8, 
172.8, 184.3. C23H36N2O10S: MS (ES): m/z(%) 533(100, MH+). 
 
tert-Butyl [17,17-dimethyl-13-(methylthio)-4,11,15-trioxo-16-oxa-3,12,14-triazaoctadec-
13-en-1-yl]carbamate (4p) 
Column chromatography (PE/EA 1:1 -> PE/EA 3:7, Rf = 0.1 [PE/EA 1:1]). The product was 
obtained as a white solid (368 mg, 77%), m.p. 95 °C 1H NMR (300 MHz, CDCl3): 1.25 – 
1.35 (m, 4H), 1.37 (s, 9H), 1.40 – 1.50 (m, 9H), 1.50 – 1.65 (m, 4H), 2.05 – 2.15 (m, 2H), 
2.32 (s, 3H), 2.32 – 2.50 (m, 2H), 3.15 – 3.35 (m, 4H), 4.80 – 4.95 (bs, 1H), 6.00 – 6.20 (bs, 
1H), 12.00 – 12.50 (m, 1H). 13C NMR (75 MHz, CDCl3): 14.5, 24.3, 25.4, 28.0, 28.4, 28.6, 
28.8, 36.5, 37.2, 40.3, 40.8, 79.7, 81.3, 157.0, 161.0, 171.3, 171.5, 173.7. C22H40N4O6S: MS 
(ES): m/z(%) 389(18), 489(100, MH+). 
 
tert-Butyl-16,16-dimethyl-5,14-dioxo-15-oxa-2-thia-4,11,13-triazaheptadecane-3,12-
diylidenedicarbamate (4q) 
Column chromatography (PE/EA 3:1, Rf = 0.35) Compound 4q (413 mg, 76%) was obtained 
as a white solid, m.p. 116-120 °C. 1H NMR (300 MHz, CDCl3): 1.30 – 1.45 (m, 2H), 1.48 (s, 
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9H), 1.49 (s, 9H), 1.52 (s, 9H), 1.55 – 1.75 (m, 4H), 2.30 – 2.55 (m, 5H), 3.35 – 3.45 (m, 2H), 
8.30 (bs, 1H), 11.49 (bs, 1H), 12.16 – 12.48 (m, 1H). 13C NMR (75 MHz, CDCl3): 14.5, 24.2, 
26.3, 28.0, 28.1, 28.3, 28.8, 37.1, 40.6, 79.2, 81.3, 83.1, 153.3, 156.1, 161.0, 163.6, 171.2, 
171.3. C24H43N5O7S: MS (LC-MS-I): m/z(%) [tR = 14.2 min]: 546(100, MH+), 1092(10).  
 
Di-tert-butyl-17,17-dimethyl-5,8,15-trioxo-16-oxa-2-thia-4,9,12,14-tetraaza-octadecane-
3,13-diylidenedicarbamate (4t) 
Column chromatography (PE/EA 4:6, Rf = 0.2). The product was obtained as a colorless, 
viscous oil (180 mg, 31%). 1H NMR (300 MHz, CDCl3): 1.43 – 1.52 (m, 27H), 2.34 (s, 3H), 
2.50 – 2.90 (m, 4H), 3.35 – 3.75 (m, 4H), 7.60 – 7.90 (m, 1H), 8.40 – 8.70 (m, 1H), 11.37 (bs, 
1H), 11.75 – 12.50 (m, 1H). 13C NMR (75 MHz, CDCl3): 14.5, 27.99, 28.04, 28.25, 38.6, 
38.8, 40.4, 41.6, 79.6, 83.2, 83.6, 153.0, 153.1, 156.9, 157.4, 162.8, 177.5. C24H42N6O8S: MS 
(LC-MS-I): m/z(%) [tR = 12.9 min]: 575(100, MH+), 1149(15). 
 
tert-Butyl 14-boc-amino-12-boc-5,8-dioxo-2-thia-4,9,12-triazatetradecan-3-
ylidenecarbamate (4u) 
Column chromatography (PE/EA 1:1 -> EA, Rf = 0.15 [PE/EA 1:1]). The product was 
obtained as a colorless, viscous oil (386 mg, 67%). 1H NMR (300 MHz, CDCl3): 1.40 (s, 
9H), 1.45 (s, 9H), 1.48 (s, 9H), 2.35 (s, 3H), 2.40 – 2.90 (m, 4H), 3.10 – 3.50 (m, 8H), 4.85 – 
5.10 (m, 1H), 6.50 – 7.00 (m, 1H), 11.70 – 12.60 (m, 1H). 13C NMR (75 MHz, CDCl3): 14.5, 
28.0, 28.2, 28.3, 28.4, 39.0, 39.6, 47.2, 47.9, 79.4, 80.5, 156.1, 156.7, 170.5, 171.2. 
C25H45N5O8S: MS (ES): m/z(%) 576(100, MH+). 
 
tert-Butyl 11-boc-amino-5,8-dioxo-2-thia-4,9-diazaundecan-3-ylidenecarbamate (4s) 
DIPEA (0.37 g, 2.84 mmol) and TBTU (0.96 g, 3.0 mmol) were added to a solution of 22 
(0.74 g, 2.84 mmol) in DMF (5 mL). The mixture was stirred under argon for 15 min prior to 
the addition of 3 (0.595 g, 3.13 mmol) and DIPEA (0.74 g, 2.84 mmol). After stirring over 
night glacial acetic acid (162 µL, 2.84 mmol) was added and the solvent was removed under 
reduced pressure (1 mbar) at a temperature of 45 °C. Purification with column 
chromatography (dichloromethane/EA 3:1 -> 1:2, Rf = 0.45[dichloromethane/EA 3:1]) 
yielded the product as a white solid (1.17 g, 95%). 1H NMR (300 MHz, DMSO-d6): 1.37 (s, 
9H), 1.42 (s, 9H), 2.27(2.25) (s, 3H), 2.30 – 2.38 (m, 2H), 2.53 – 2.59 (m, 2H), 2.09 – 2.99 
(m, 2H), 2.99 – 3.10 (m, 2H), 6.75 – 6.90 (m, 1H), 7.86 – 7.99 (m, 1H), 11.24(10.98) (s, 1H). 
C18H32N4O6S: (LC-MS-II): m/z(%) [tR = 6.87 min]: 433(100, MH+). 
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General procedure for the preparation of compounds 1b-1g, 1i, 1k-1q and 1s-1u 
The appropriate S-methylisothiourea derivative 4 (0.2 mmol), compound 5 (0.2 mmol) and 
HgCl2 (0.2 mmol) were dissolved separately in small amounts of DMF (1-2 mL). The 
solutions of the compounds 4 and 5 were combined in a small flask under nitrogen 
atmosphere. NEt3 (2 mmol) was added under stirring, then the HgCl2 solution was added and 
the mixture was stirred overnight at room temperature. Next day DMF was removed 
completely and the residue was dissolved in DCM. The precipitate of mercury salts was 
filtered off and the organic phase was concentrated. The crude products were purified by 
column chromatography (PE/EA mixtures). The Boc- and tBu-protected target molecules 
were deprotected to the corresponding target compounds 1b-1g, 1i, 1k-1q and 1s-1u without 
further characterisation: The corresponding protected compound was dissolved in a 
dichloromethane/TFA 1:1 mixture (5 mL) and stirred for two hours. After that time the 
solvent was removed completely under reduced pressure and the oily residue was repeatedly 
dissolved in dichloromethane and the solvent evaporated to remove TFA. Except for 1b and 
1s (1b: purified by column chromatography, 1s: no purification after deprotection) the 
deprotected compounds were purified with preparative HPLC. The given yield corresponds to 
the coupling step in the first part of this procedure, the deprotection step was quantitative. 
 
(R)-1-[4-(2,2-Diphenylacetamido)-5-(4-hydroxybenzylamino)-5-oxopentyl]-2-pentacosa-
10,12-diynoylguanidinium 2,2,2-trifluoroacetate (1b) 
The product is a light yellow solid (170 mg, 72%), m.p. > 190 °C (decomp). 1H NMR (300 
MHz, DMSO-d6): 0.85 (t, J = 6.51, 3H), 1.00 – 1.80 (m, 36H), 2.26 (t, J = 6.67, 4H), 2.41 (t, 
J = 7.19, 2H), 3.15 – 3.30 (m, 2H), 4.00 – 4.25 (m, 2H), 4.30 – 4.40 (m, 1H), 5.12 (s, 1H), 
6.67 (d, J = 8.43, 2H), 7.00 (d, J = 8.41, 2H), 7.15 – 7.35 (m, 10H), 8.00 – 9.70 (m, 6H), 11.50 
– 11.80 (m, 1H). 13C NMR (75 MHz, DMSO-d6): 13.8, 18.2, 22.0, 23.73, 27.57, 27.59, 
28.05, 28.06, 28.15, 28.27, 28.45, 28.60, 28.75, 28.83, 28.90, 31.19, 36.02, 52.15, 55.80, 
65.23, 77.84, 77.90, 114.87, 126.47, 128.04, 128.07, 128.29, 128.38, 128.40, 129.00, 140.15, 
140.34, 152.71, 156.15, 170.86, 170.91, 175.17. C52H71N5O4: MS (LC-MS-I): m/z(%) [tR = 
12.3 min]: 830(100, MH+).  
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(R)-1-[4-(2,2-Diphenylacetamido)-5-(4-hydroxybenzylamino)-5-oxopentyl]-2-
hexadecanoylguanidinium 2,2,2-trifluoracetate (1c) 
The product is a white solid (48 mg, 53%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
CDCl3): 0.88 (t, 3H), 1.20 – 1.35 (m, 26H), 1.40 – 1.70 (m, 4H), 2.42 (t, 2H), 2.70 - 3.10 (m, 
2H), 3.90 – 4.10 (m, 1H), 4.15 – 4-35 (m, 2H), 4.99 (s, 1H), 5.80 – 6.50 (bs, 1H), 6.60 (d, 
2H), 6.90 (d, 2H), 7.15 – 7.30 (m, 10H), 7.40 – 7.90 (m, 3H), 8.87 (bs, 1H), 9.45 (bs, 1H), 
12.13 (bs, 1H), C43H61N5O4: MS (ES): m/z(%) 712(100, MH+). HPLC: 100% (ELSD, tR = 
23.8 min). 
 
(R)-1-[4-(2,2-Diphenylacetamido)-5-(4-hydroxybenzylamino)-5-oxopentyl]-2-[4-(pyren-
1-yl)butanoyl]guanidinium 2,2,2-trifluoroacetate (1d) 
The product is a white solid (82 mg, 74%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
DMSO-d6): 1.30 – 1.80 (m, 4H), 2.00 – 2.15 (m, 2H), 2.55 – 2.65 (t, J = 6.98, 2H), 3.15 – 
3.25 (m, 2H), 3.35 – 3.45 (m, 2H), 4.05 – 4.20 (m, 2H), 4.25 – 4.40 (m, 1H), 5.12 (s, 1H), 
6.67 (d, J = 8.48, 2H), 7.00 (d, J = 8.47, 2H), 7.10 – 7.30 (m, 10H), 7.90 – 8.00 (m, 1H), 8.00 
– 8.10 (m, 1H), 8.15 (bs, 2H), 8.20 – 8.35 (m, 4H), 8.35 – 8.65 (m, 5H), 8.80 – 8.95 (m, 1H), 
9.31 (bs, 1H), 11.32 (bs, 1H). C47H45N5O4: MS (LC-MS-I): m/z(%) [tR = 10.2 min]: 744(100, 
MH+). HPLC: 100% (ELSD, tR = 19.1 min). UV (MeCN): λ(ε) 264 (20⋅103), 275 (31⋅103), 
312 (10⋅103), 326 (17⋅103), 342 (23⋅103). Fluorescence (λex. = 340 nm, MeCN): 397 nm 
(monomer), 419 nm (monomer). 
 
(R)-1-[4-(2,2-Diphenylacetamido)-5-(4-hydroxybenzylamino)-5-oxopentyl]-2-(pyrene-1-
carbonyl)guanidinium 2,2,2-trifluoroacetate (1e) 
The product is a yellow solid (106 mg, 68%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
CD3CN): 1.50 – 1.90 (m, 4H), 3.20 – 3.40 (m, 2H), 4.10 – 4.30 (m, 2H), 4.35 – 4.45 (m, 1H), 
5.05 (s, 1H), 6.72 (d, J = 8.51, 2H), 7.04 (d, J = 8.47, 2H), 7.15 – 7.40 (m, 13H), 8.05 – 8.40 
(m, 8H), 8.50 – 8.60 (m, 1H), 9.25 – 10.30 (m, 2H), 13.05 (s, 1H). C44H39N5O4: MS (LC-
MS-I): m/z(%) [tR = 9.7 min]: 702(100, MH+). HPLC: 99% (ELSD, tR = 17.8 min). UV 
(MeCN): λ(ε) 242 (45⋅103), 277 (33⋅103), 348 (28⋅103). Fluorescence (λex. = 340 nm, MeCN): 
406 nm (very broad).  
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(R)-23-(4-Hydroxybenzylcarbamoyl)-1,6,16,25-tetraoxo-26,26-diphenyl-1-(pyren-1-yl)-
8,11,14-trioxa-2,5,17,19,24-pentaazahexacosan-18-iminium 2,2,2-trifluoroacetate (1f) 
The product is a white solid (52 mg, 46%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
DMSO-d6): 1.30 – 1.80 (m, 4H), 3.10 – 3.80 (m, 14H), 3.94 (s, 2H), 4.05 – 4.20 (m, 2H), 
4.19 (s, 2H), 4.28 – 4.38 (m, 1H), 5.12 (s, 1H), 6.67 (d, J = 8.45, 2H), 7.00 (d, J = 8.45, 2H), 
7.15 – 7.30 (m, 10H), 7.98 (t, J = 5.65, 1H), 8.08 – 8.45 (m, 9H), 8.45 – 8.55 (m, 2H), 8.55 – 
8.85 (m, 3H), 8.95 – 9.05 (m, 1H), 9.32 (bs, 1H), 10.61 (bs, 1H). C54H57N7O9: MS (ES): 
m/z(%) 474(88), 948(100, MH+). HPLC: 99% (ELSD, tR = 16.3 min). UV (H2O): λ(ε) 267 
(26⋅103), 277 (35⋅103), 330 (24⋅103), 343 (30⋅103). Fluorescence (λex.= 340 nm, H2O): λ(type) 
401(monomer). 
 
(R)-2-{8-[3-(Benzyloxy)-3-oxopropylamino]-8-oxooctanoyl}-1-[4-(2,2-diphenyl-
acetamido)-5-(4-hydroxybenzylamino)-5-oxopentyl]guanidinium 2,2,2-trifluoroacetate 
(1g) 
The product is a white solid (58 mg, 78%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
DMSO-d6): 1.00 –1.80 (m, 12H), 1.95 –3.50 (m, 10H), 4.05 – 4.20 (m, 2H), 4.25 – 4.40 (m, 
1H), 5.08 (s, 2H), 5.12 (s, 1H), 6.67 (d, J = 8.36, 2H), 7.00 (d, J = 8.40, 2H), 7.20 –7.40 (m, 
15H), 7.85 – 7.95 (m, 1H), 8.30 – 8.60 (m, 4H), 8.70 – 8.90 (bs, 1H), 9.31 (bs, 1H), 11.20 (bs, 
1H). C45H54N6O7: MS (ES): m/z(%) 791(100, MH+), 1582(1). HPLC: 100% (ELSD, tR = 
16.2 min). 
 
(4R,12R,13S,14R,15R)-12,13,14,15-Tetraacetoxy-4-(2,2-diphenylacetamido)-1-(4-
hydroxyphenyl)-3,11,18-trioxo-17-oxa-2,8,10-triazanonadecan-9-iminium 2,2,2-
trifluoroacetate (1i) 
The product is a white solid (197 mg, 66%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
DMSO-d6): 1.30 – 1.70 (m, 4H), 1.90 – 2.20 (m, 15H), 3.20 – 3.30 (m, 2H), 4.00 – 4.40 (m, 
5H), 5.00 – 5.10 (bs, 1H), 5.12 (s, 1H), 5.24 (bs, 1H), 5.35 – 5.45 (m, 1H), 5.45 – 5.55 (m, 
1H), 6.67 (d, J = 8.45, 2H), 7.00 (d, J = 8.45, 2H), 7.15 – 7.35 (m, 10H), 8.36 (t, J = 5.58, 1H), 
8.47 (d, J = 8.14, 1H), 8.50 – 8.90 (m, 2H), 9.30 (bs, 1H), 11.80 (bs, 1H). C43H51N5O14: MS 
(ES): m/z(%) 862(100, MH+), 884(60). HPLC: 100% (ELSD, tR = 16.2 min). 
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(R)-21-(4-Hydroxybenzylcarbamoyl)-3,7,14,23-tetraoxo-24,24-diphenyl-2-oxa-
6,15,17,22-tetraazatetracosan-16-iminium 2,2,2-trifluoroacetate (1k) 
The product is a white solid (149 mg, 64%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
CDCl3): 1.10 – 1.70 (m, 12H), 2.16 (t, J = 7.28, 2H), 2.35 (t, J = 6.51, 2H), 2.54 (t, J = 5.66, 
2H), 2.95 (bs, 1H), 3.15 (bs, 1H), 3.50 (m, 2H), 3.69 (s, 3H), 4.00 – 4.35 (m, 3H), 4.98 (s, 
1H), 6.48 (t, J = 5.40, 1H), 6.70 (d, J = 7.86, 2H), 6.94 (d, J = 7.82, 2H), 7.15 – 7.30 (m, 10H), 
7.40 – 7.70 (m, 3H), 8.89 (bs, 1H), 9.70 (bs, 1H), 12.19 (bs, 1H). C39H50N6O7: MS (ES): 
m/z(%) 715(100, MH+), 737(5). HPLC: 100% (ELSD, tR = 14.1 min). 
 
(R)-1-[4-(2,2-Diphenylacetamido)-5-(4-hydroxybenzylamino)-5-oxopentyl]-2-{4-[4-
(hydroxymethyl)-1H-1,2,3-triazol-1-yl]butanoyl}guanidinium 2,2,2-trifluoroacetate (1l) 
The product is a white solid (90 mg, 66%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
DMSO-d6): 1.25 – 1.80 (m, 4H), 2.00 – 2.15 (m, 2H), 2.40 – 2.50 (m, 2H), 3.15 – 3.30 (m, 
2H), 4.00 – 4.50 (m, 5H), 4.51 (s, 2H), 5.12 (s, 1H), 6.67 (d, J = 8.38, 2H), 7.00 (d, J = 8.38, 
2H), 7.15 – 7.35 (m, 10H), 7.98 (s, 1H), 8.37 (t, J = 5.69, 1H), 8.40 – 8.70 (m, 3H), 8.80 – 
10.50 (m, 2H), 11.48 (bs, 1H). C34H40N8O5: MS (ES): m/z(%) 641(100, MH+). HPLC: 99% 
(ELSD, tR = 12.6 min). 
 
(R)-2-{4-[4-(Ammoniomethyl)-1H-1,2,3-triazol-1-yl]butanoyl}-1-[4-(2,2-
diphenylacetamido)-5-(4-hydroxybenzylamino)-5-oxopentyl]guanidinium 2,2,2-
trifluoroacetate (1m) 
The product is a white solid (139 mg, 73%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
DMSO-d6): 1.30 – 1.80 (m, 4H), 2.09 (p, J = 7.20, 2H), 2.45 – 2.50 (m, 2H), 3.15 – 3.30 (m, 
2H), 4.05 – 4.20 (m, 4H), 4.25 – 4.40 (m, 1H), 4.45 (t, J = 7.08, 2H), 5.12 (s, 1H), 6.67 (d, J = 
8.45, 2H), 7.00 (d, J = 8.45, 2H), 7.15 – 7.35 (m, 10H), 8.15 (s, 1H), 8.20 – 8.35 (bs, 2H), 
8.37 (t, J = 5.79, 1H), 8.50 (d, J = 8.02, 1H), 8.55 – 9.10 (m, 2H), 9.33 (bs, 1H), 12.11 (s, 1H). 
C34H41N9O4: MS (LC-MS-I): m/z(%) [tR = 7.5 min]: 320(100), 341(35), 640(50, MH+). 
HPLC: 100% (ELSD, tR = 10.7 min). 
 
(13R)-13-(4-Hydroxybenzylcarbamoyl)-3,6,15-trioxo-16,16-diphenyl-1-((2R,3R,4S,5R)-
3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-yl)-2-oxa-7,9,14-triazahexadecan-8-iminium 
2,2,2-trifluoroacetate (1n) 
The product is a white solid (35 mg, 76%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
DMSO-d6): 1.30 – 1.80 (m, 4H), 2.55 – 2.80 (m, 4H), 3.20 – 3.90 (m, 5H), 3.90 – 4.80 (m, 
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8H), 4.85 – 5.00 (m, 2H), 5.12 (s, 1H), 5.20 – 6.50 (m, 1H), 6.67 (d, J = 8.41, 2H), 7.00 (d, J 
= 8.41, 2H), 7.15 – 7.35 (m, 10H), 8.38 (t, J = 5.63, 1H), 8.50 (d, J = 8.06, 1H), 8.50 – 8.70 
(bs, 2H), 8.86 (bs, 1H), 9.30 (bs, 1H), 11.49 (bs, 1H). C37H45N5O11: MS (ES): m/z(%) 
736(100, MH+), 758(20). HPLC: 100% (ELSD, tR = 12.1 min). 
 
(R)-21-Carboxy-4-(2,2-diphenylacetamido)-1-(4-hydroxyphenyl)-3,11,18-trioxo-
2,8,10,19-tetraazahenicosan-9-iminium 2,2,2-trifluoroacetate (1o) 
1.) Removal of the benzyl-group: The Boc- and tBu-protected precursor of compound 1o (35 
mg, 0.04 mmol) was dissolved in 2-propanol (5 mL). Pd/C (10 mg) was added and the 
mixture was stirred at 15 bar hydrogen pressure in an autoclave. After two hours TLC control 
confirmed complete conversion. Pd/C was filtered off over celite and the solvent was 
evaporated. The product was obtained quantitative.  
2.) The N-Boc and O-tBu protected compound was deprotected as described in general 
procedure 4.4. 
The product is a white solid (30 mg, 78%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
DMSO-d6): 1.10 – 1.80 (m, 12H), 2.03 (t, J = 7.28, 2H), 2.30 – 2.45 (m, 4H), 3.15 – 3.30 (m, 
4H), 4.05 – 4.25 (m, 2H), 4.25 – 4.40 (m, 1H), 5.12 (s, 1H), 6.67 (d, J = 8.41, 2H), 7.00 (d, J 
= 8.38, 2H), 7.15 – 7.35 (m, 10H), 7.86 (t, 1H), 8.30 – 8.70 (m, 4H), 8.80 – 9.00 (m, 1H), 9.20 
– 9.40 (bs, 1H), 11.30 – 11.40 (bs, 1H). C38H48N6O7: MS (ES): m/z(%) 351(11), 701(100, 
MH+). HPLC: 99% (ELSD, tR = 13.7 min). 
 
(R)-4-(2,2-Diphenylacetamido)-1-(4-hydroxyphenyl)-9-iminio-3,11,18-trioxo-2,8,10,19-
tetraazahenicosan-21-aminium 2,2,2-trifluoroacetate (1p) 
The product is a white solid (125 mg, 70%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
DMSO-d6): 1.10 – 1.70 (m, 12H), 2.00 – 2.15 (m, 2H), 2.35 – 2.45 (m, 2H), 2.75 – 2.90 (m, 
2H), 3.15 – 3.30 (m, 4H), 4.10 – 4.20 (m, 2H), 4.25 – 4.40 (m, 1H), 5.12 (s, 1H), 6.67 (d, J = 
8.36, 2H), 7.00 (d, J = 8.36, 2H), 7.15 – 7.30 (m, 10H), 7.78 (bs, 3H), 8.00 (t, J = 5.52, 1H), 
8.38 (t, J = 5.72, 1H), 8.51 (d, J = 8.02, 1H), 8.65 – 8.80 (bs, 2H), 9.12 (bs, 1H), 9.32 (bs, 
1H), 11.73 (bs, 1H). C37H49N7O5: MS (ES): m/z(%) 336(100), 672(25, MH+). HPLC: 97% 
(ELSD, tR = 11.2 min). 
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(R)-18-Amino-4-(2,2-diphenylacetamido)-1-(4-hydroxyphenyl)-3,11-dioxo-2,8,10,17-
tetraazaoctadecane-9,18-diiminium 2,2,2-trifluoroacetate (1q) 
The product is a white solid (93 mg, 71%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
CD3CN): 1.25 –1.40 (m, 2H), 1.45 – 1.85 (m, 8H), 2.40 – 2.48 (t, J = 7.27, 2H), 3.00 – 3.10 
(dd, J1 = 6.68, J2 = 12.84, 2H), 3.10 – 3.30 (m, 2H), 4.10 – 4.25 (m, 2H), 4.30 – 4.40 (m, 
1H), 5.02 (s, 1H), 6.40 (bs, 4H), 6.71 (d, J = 8.50, 2H), 6.90 – 7.40 (m, 5H), 7.03 (d, J  = 8.42, 
2H), 7.20 – 7.35 (m, 10H), 9.45 (bs, 1H), 9.85 (bs, 1H), 12.73 (bs, 1H). 13C NMR (75 MHz, 
CD3CN): 23.2, 23.4, 25.0, 27.4, 28.6, 35.9, 40.1, 40.8, 41.8, 52.4, 57.0, 114.8, 126.67, 126.73, 
128.14, 128.17, 128.34, 128.40, 129.6, 154.1, 155.7, 171.9, 176.3. C34H44N8O4: MS (LC-
MS-I): m/z(%) [tR = 7.6 min]: 315(95), 335(100), 629(85, MH+), 675(30), 743(5). HPLC: 
100% (ELSD, tR = 11.2 min). 
 
(R)-4-(2,2-diphenylacetamido)-1-(4-hydroxyphenyl)-9-iminio-3,11,14-trioxo-2,8,10,15-
tetraazaheptadecan-17-aminium 2,2,2-trifluoroacetate (1s) 
The product is a white solid (0.74 g, 68%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
DMSO-d6): 1.32 –1.60 (m, 3H), 1.60 – 1.76 (m, 1H), 2.46 (t, J = 6.71, 2H), 2.66 (t, J = 6.48, 
2H), 2.80 – 2.88 (m, 2H), 3.18 – 3.31 (m, 4H), 4.11 (dd, J1 = 15.02, J2 = 5.76, 1H), 4.18 (dd, 
J1 = 15.05, J2 = 5.93, 1H), 4.28 – 4.38 (m, 1H), 5.12 (s, 1H), 6.67 (d, J = 8.53, 2H), 7.00 (d, J 
= 8.54, 2H), 7.18 – 7.32 (m, 10H), 7.76 (bs, 3H), 8.14 (t, J = 5.62, 1H), 8.38 (t, J = 5.74, 1H), 
8.50 (d, J = 8.06, 1H), 8.71 (bs, 2H), 9.16 (t, non-res., 1H), 9.31 (bs, 1H), 11.88 (s, 1H). 
C33H41N7O5: MS (LC-MS-I): m/z(%) [tR = 7.44 min]: 308.5(100), 616(27, MH+). HPLC: 
96% (220 nm, tR = 16.5 min). 
 
(R)-1-Amino-16-(4-hydroxybenzylcarbamoyl)-6,9,18-trioxo-19,19-diphenyl-2,5,10,12,17-
pentaazanonadecane-1,11-diiminium 2,2,2-trifluoroacetate (1t) 
The product is a white solid (35 mg, 49%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
CD3CN): 1.40 –1.80 (m, 4H), 2.49 (t, J = 6.59, 2H), 2.66 (t, J = 6.55, 2H), 3.10 – 3.30 (m, 
6H), 4.10 – 4.25 (m, 2H), 4.25 – 4.40 (m, 1H), 5.02 (s, 1H), 6.10 – 7.50 (m, 10H), 6.70 (d, J = 
8.50, 2H), 7.03 (d, J = 8.43, 2H), 7.20 – 7.35 (m, 10H), 9.39 (bs, 1H), 9.79 (bs, 1H), 12.82 
(bs, 1H). C34H43N9O5: MS (LC-MS-I): m/z(%) [tR = 7.5 min]: 329(100), 658(20, MH+). 
HPLC: 99% (ELSD, tR = 10.7 min). 
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(R)-N1-[4-(2,2-Diphenylacetamido)-1-(4-hydroxyphenyl)-9-iminio-3,11,14-trioxo-
2,8,10,15-tetraazaheptadecan-17-yl]ethane-1,2-diaminium 2,2,2-trifluoroacetate (1u) 
The product is a white solid (62 mg, 39%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, 
DMSO-d6): 1.30 – 1.80 (m, 4H), 2.62 – 2.70 (t, J = 6.29, 2H), 3.00 – 3.40 (m, 12H), 4.00 – 
4.20 (m, 2H), 4.25 – 4.40 (m, 1H), 5.12 (s, 1H), 6.70 (d, J = 8.45, 2H), 7.00 (d, J = 8.45, 2H), 
7.15 – 7.35 (m, 10H), 7.90 – 9.40 (m, 12H), 12.03 (bs, 1H). C35H46N8O5: MS (ES): m/z(%) 
330(100), 659(20, MH+). HPLC: 99% (ELSD, tR = 9.1 min). 
 
(R)-1-(4-Fluorophenyl)-16-(4-hydroxybenzylcarbamoyl)-1,6,9,18-tetraoxo-19,19-
diphenyl-2,5,10,12,17-pentaazanonadecan-11-iminium 2,2,2-trifluoroacetate (1j) 
Compound 1s (24 mg, 28.4 µmol) and NEt3 (21 µL, 152 µmol) were dissolved in DMF (200 
µL) followed by the addition of active ester 37 (4.5 mg, 19 µmol). The reaction was stopped 
by addition of 10% aq. TFA (corresponding to 60 µmol of TFA) after an incubation period of 
3.5 h at rt. Purification with preparative HPLC (column: Eurospher-100 C18 (250 × 32 mm, 5 
µm), Knauer, Berlin, Germany) and lyophilisation afforded the product as white fluffy solid 
(10.55 mg, 65%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, DMSO-d6): 1.31 –1.60 (m, 
3H), 1.60 – 1.73 (m, 1H), 2.45 (t, J = 6.60, 2H), 2.64 (t, J = 6.38, 2H), 3.16 – 3.34 (m, 6H), 
4.10 (dd, J1 = 14.80, J2 = 5.66, 1H), 4.18 (dd, J1 = 15.06, J2 = 5.76, 1H), 4.28 – 4.38 (m, 1H), 
5.12 (s, 1H), 6.67 (d, J = 8.52, 2H), 7.00 (d, J = 8.52, 2H), 7.18 – 7.33 (m, 12H), 7.86 – 7.93 
(m, 2H), 8.11 (t, J = 5.51, 1H), 8.38 (t, J = 5.78, 1H), 8.47 – 8.62 (m, 4H), 8.87 (t, non-res., 
1H), 9.30 (bs, 1H), 11.44 (s, 1H). C40H44FN7O6: (LC-MS-I): m/z(%) [tR = 8.69 min]: 
738(100, MH+). HPLC: 98% (220 nm, tR = 23.7 min). 
 
(R)-4-(2,2-Diphenylacetamido)-1-(4-hydroxyphenyl)-9-iminio-3,11,14-trioxo-N-(2-
propionamidoethyl)-2,8,10,15-tetraazaheptadecan-17-aminium 2,2,2-trifluoroacetate 
(1r) 
Compound 1u (35 mg, 35 µmol) and NEt3 (23 µL, 186 µmol) were dissolved in DMF (200 
µL) followed by the addition of active ester 38 (2.4 mg, 14 µmol). The reaction was stopped 
by addition of 10% aq. TFA (corresponding to 80 µmol of TFA) after an incubation period of 
3 h at rt. Purification with preparative HPLC (column: Eurospher-100 C18 (250 × 32 mm, 5 
µm), Knauer, Berlin, Germany) and lyophilisation afforded the product as white fluffy solid 
(2.71 mg, 21%), m.p. > 190 °C (decomp.). 1H NMR (600 MHz, DMSO-d6): 0.99 (t, J = 7.59, 
3H), 1.35 –1.47 (m, 2H), 1.48 – 1.56 (m, 1H), 1.62 – 1.69 (m, 1H), 2.11 (q, J = 7.58, 2H), 
2.45 (t, J = 6.73, 2H), 2.49 – 2.52 (m, 4H) 2.65 (t, J = 6.53, 2H), 2.95 – 3.01 (m, 2H), 3.19 – 
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3.24 (m, 2H), 3.27 – 3.33 (m, 2H), 4.10 (dd, J1 = 14.76, J2 = 5.66, 1H), 4.17 (dd, J1 = 14.83, 
J2 = 6.03, 1H), 4.30 – 4.35 (m, 1H), 5.11 (s, 1H), 6.66 (d, J = 8.52, 2H), 6.99 (d, J = 8.53, 
2H), 7.19 – 7.31 (m, 10H), 8.00 (t, J = 5.64, 1H), 8.17 (t, J = 5.73, 1H), 8.35 (t, J = 5.82, 1H), 
8.44 (bs, 2H), 8.47 (d, J = 8.15, 1H), 8.59 (bs, 2H), 8.93 (t, non-res., 1H), 9.28 (bs, 1H), 11.56 
(s, 1H). C38H50N8O6: (LC-MS-I): m/z(%) [tR = 7.54 min]: 358(100), 715(18, MH+). HPLC: 
97% (220 nm, tR = 17.3 min). 
 
 
1.4.3 Experimental determination of logD values with HPLC 
 
The logD values of compounds 1a, 1d, 1f, 1g, 1i, 1l, 1n, 1p, 1q and 1u were determined by 
RP-HPLC. A Luna C18 column (3.0 µm, 150 x 2 mm, Phenomenex, Aschaffenburg, 
Germany) with a flow of 0.30 mL/min was used. An ammonium acetate buffer (10 mM, pH 
7.4) was used as solvent A. Solvent B was acetonitrile. The gradient was: 0 min [A/B 95/5], 
30 min [A/B 2/98]. A volume of 2 µL of a solution of the analytes, dissolved in DMSO (1 
mM), was injected. Column temperature was 25 °C. The compounds were detected with a 
diode array detector. The logD value was calibrated to the retention time (tR) by running a 
mixture of  6 reference compounds and plotting the tR vs. logD (supporting information).  
 
1.4.4 Investigation of stability 
 
Decomposition of the NG-acylated argininamides to 1a was investigated at neutral pH in the 
buffer used for radioligand binding4 (10 mM HEPES, pH 7.4, filtered: 0.45 µm). Incubation 
was started by addition of 15 µL of a 1 mM solution of the compounds in DMSO to 285 µL 
of buffer to give a final concentration of 50 µM (in case of 1c 60 µL of a 0.25 mM solution 
were added to 240 µL of buffer). After 20 and 90 min a 125 µL aliquot was taken and diluted 
with a mixture of MeCN, H2O and 1% aq. TFA (for compounds 1c – 1j: 5:1:4, 125 µL; for 
compounds 1k – 1u: 1:1:1.33, 125 µL). 100 µL of the resulting solution (pH ≈ 2) were 
analysed with analytical HPLC on a RP-column (Eurospher-100 C18, 250 × 4 mm, 5 µm; 
Knauer, Berlin, Germany) using a system from Thermo Separation Products (composed of a 
SN400 controller, a P4000 pump, a degasser (Degassex DG-4400, phenomenex), an AS3000 
autosampler and a Spectra Focus UV-VIS detector). Mixtures of 0.05 % aq. TFA (A) and 
acetonitrile (B) were used as mobile phase. The flow rate was set to 0.80 mL/min and the 
column temperature to 30 °C. Due to the wide range of logD values of the compounds two 
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different gradients were used for HPLC analysis (compounds 1c – 1j: 0 min [A/B 75/25], 28 
min [A/B 80/20], 30 min [A/B 5/95], 38 min [A/B 5/95]; compounds 1k – 1u: 0 min [A/B 
85/15], 28 min [A/B 55/45], 32 min [A/B 5/95], 40 min [A/B 5/95]). A five-point calibration 
curve (0.3, 1.5, 4, 10 and 25 µM) of BIBP 3226 (1a) was acquired for quantification of the 
decomposition product 1a.  
To study the decomposition products of 1j with LC-MS, 1j was incubated in 10 mM HEPES 
buffer as described above, but at a concentration of 30 µM (30 µL of a 0.5 mM solution of 1j 
in MeCN/0.05% aq. TFA (20:80) to 470 µL of buffer). After 20 and 90 min a 125 µL aliquot 
was taken and diluted with a mixture of MeCN, H2O and 1% aq. TFA (1:1:1.33, 125 µL). 10 
µL of the resulting solution were injected into the LC-MS system and analysed with LC-MS 
method II (cf. general experimental conditions) (source type: ESI (capillary temperature: 250  
°C, spray voltage: 4.0 kV, sheath and auxiliary gas: on). 
 
 
1.4.5 Radioligand competition binding assay 
 
Radioligand competition experiments at SK-N-MC neuroblastoma cells using the radioligand 
[3H]UR-MK114 (1.5 nM) were performed as described elsewhere.4  
 
1.4.6 Fura-2 assay on HEL cells 
 
The Fura assay was performed with HEL cells as previously described using a Perkin-Elmer 
LS50 B spectrofluorimeter (Perkin Elmer, Überlingen, Germany).19  
 
1.4.7 Data processing 
 
Data from radioligand competition experiments were analyzed by 4 parameter sigmoidal fits 
(SigmaPlot 9.0, Systat Software). IC50 values from radioligand competition studies were 
converted to Ki values according to the Cheng-Prusoff equation34 using the respective KD 
value of the radioligand. Three data points (between 20 and 80 % inhibition, from fura-2 
assays) served for the calculation of IC50 values after logit-log transformation. IC50 values 
were converted to Kb values according to the Cheng-Prusoff equation33 using an EC50 value of 
1.8 nM for pNPY (mean value from 4 independently determined concentration-effect curves 
on HEL cells). 
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CHAPTER 2 
 
Pyrene Labeled Neuropeptide Y1 Receptor Antagonists for the 
Detection of  Y1 Receptor Homodimers 
 
 
 
 
2.1 Introduction 
 
Dimerisation and oligomerisation are a common phenomenon for the important class of G 
protein-coupled receptors (GPCR).1 In many cases these trans-membrane receptors are not 
separated in the cell membrane, but form larger aggregates, as it is known for the clustering of 
the rhodopsine receptors.2 The oligomerisation of GPCR´s has an influence on the modulation 
of signaling in the cell. For example the dimerisation of two different subtypes of receptors  
(heterodimers)  as reported for the neuropeptide Y1/Y5 receptors3 can alter the affinity of the 
receptors to agonists and antagonists and influence the internalisation behavior. Also the 
aggregation of two equal receptors (homodimers) can influence function and signal 
transduction of the receptors.4 Homodimerisation is known for many GPCR´s, for example 
the β2-adrenergic receptor and the dopamine receptors. There is also some evidence for the 
existence of NPY Y1 receptor homodimers.5 
The detection of the aggregation state of GPCR´s is therefore of great interest for 
pharmaceutical research. Fluorescence resonance energy transfer (FRET) experiments with 
fluorescent labeled neuropeptide Y (NPY) receptors5  and bioluminescence resonance energy 
transfer (BRET) experiments with opioid receptors6 were performed to observe GPCR 
oligomerisation, but there is some concern that the modification of the receptor protein could 
influence the binding of agonists and antagonists and alter the aggregation behavior.  
The use of labeled small NPY Y1 receptor antagonists should not alter the aggregation state of 
the receptors. The high affinity Y1 receptor antagonist BIBP 3226 (BIBP)7 was therefore 
derivatized with the fluorescent label pyrene. The pyrene moiety can form excited dimers 
(excimers) when in a high local concentration.8, 9 The fluorescence of the excimer (500 nm) is 
red-shifted compared to the pyrene monomer fluorescence (410 nm). This effect was 
successfully applied for chemosensors,10 for the investigation of the structure of micelles11 
and the hybridization of DNA.12  The binding of two pyrene labeled antagonists to a 
hypothetical Y1 receptor dimer in close proximity (high local pyrene-derivative concentration) 
should enable us to observe excimer fluorescence in case of a spacer with sufficient length. 
The advantage of this method compared to FRET is that only one type of probe molecule is 
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required. The application of two differently labeled antagonists like in FRET experiments can 
cause problems, because of their different physico-chemical properties and binding affinities. 
We therefore synthesized pyrene labeled Y1 receptor antagonists that exhibit a nanomolar 
affinity to the Y1 receptor and investigated their fluorescent properties and their binding to 
MCF-7 cells. 
 
 
Scheme 1. Excimer formation at a hypothetical Y1 receptor dimer. In picture A two pyrene 
labeled antagonists bind to two Y1 receptors. One of the pyrene moieties (left) is excited with 
UV light. In case a) the excited pyrene moiety emits light before it could combine with 
another pyrene moiety (in ground state). In case b) the excited pyrene forms an excimer with 
the second pyrene moiety and the excimer emits light with a longer wavelength.      
 
 
2.2 Results and Discussion 
 
2.2.1 Synthesis and binding affinity of the pyrene-labeled Y1R antagonists 
 
The synthesis of compounds 1a, 1b and 1e is described elsewhere.13 The first step in our 
approach was to connect the high potent Y1R antagonist BIBP 3226 1 to the pyrene moiety. 
The synthesis started with pyrene that was converted to pyrene-1-carboxylic acid 4 in two 
steps. The target compounds 1c and 1d were prepared from their corresponding amines 5 and 
6 respectively. The amines were treated with NHS ester 7 in THF and compounds 1c and 1d 
were obtained in moderate yield. Compound 1f was obtained via a one pot reaction of the 
dicarboxylic acid 8 with the amines 9 and 10. The yield was low, because of the statistical 
product distribution, but still a sufficient amount of product 11 was obtained to continue 
synthesis. This compound was guanidinylated with amine 12 and target compound 1f was 
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obtained after deprotection with DCM/TFA. Compound 1g was synthesized starting from 
precursor 4 that was converted with diethylenetriamine 13 to the double pyrene labeled amine 
14. Acylation of the primary amines of compound 13 is much faster than the acylation of the 
secondary amine, so product 14 was obtained in good yield. The secondary amine was then 
acylated with succinic acid anhydride 15 and acid 16 was obtained. Guanidinylation with 
amine 12 and subsequent deprotection resulted in compound 1g. Compounds 18 and 19 were 
synthesized as control compounds for the unspecific binding.  
The binding affinities differ significantly. Direct attachment of the pyrene moiety to the BIBP 
3226 scaffold caused a complete loss of affinity. Also the very bulky compound 1g with two 
pyrene units has no affinity to the Y1R. An increase in spacer length restored some affinity. 
However, compounds 1b – 1d exhibit only moderate affinity to the Y1R due to their high 
lipophilicity and low water solubility. The two antagonists 1e and 1f that contain a gylcol 
chain in their spacer were the antagonists with the best affinities; compound 1e showed a Ki 
of about 60 nM.    
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Figure 1. Structures and Y1R affinities of the pyrene labeled Y1R antagonists 1a-1g. Ki values 
determined from the displacement of 1.5 nM [3H]-UR-MK11414 on SK-N-MC cells; all mean 
values ± SEM from two or three independent experiments (1c, 1d: one single determination ).  
 
 
 
Scheme 2. Synthesis of the precursor pyrene-1-carboxylic acid. a) ZnCl2, AcOH, Ac2O, 55%; 
b) H2O, THF, NaOCl, NaOH, 63%.  
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Scheme 3. Synthesis of the Y1R antagonists 1c – 1g. a) THF, NEt3, 56% (1c), 50% (1d); b) 
EDC, HOBt, DIPEA, DMF, 11%; c) DMF, HgCl2, NEt3, compound 12, 63%; d) TFA/DCM 
1:1, quantitative; e) EDC, HOBt, DIPEA, DCM, 64%; f) DMF, NEt3, 55%; g) EDC, HOBt, 
DIPEA, DCM, compound 9, 60%; h) DMF, HgCl2, NEt3, compound 12, 55%; i) TFA/DCM 
1:1, quantitative. 
 
 
 
Scheme 4. Control compounds 18 and 19 for the detection of unspecific binding; synthesis of 
compound 19. a) DMF, EDC, HOBt, DIPEA, 75%. 
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2.2.2 Optical properties of the pyrene-labeled compounds 
 
For the detection of the fluorescent labeled Y1R anatgonists the quantum yield is a crucial 
factor. A disadvantage of the pyrene fluorophore compared with cyanine dyes is the excitation 
in the UV region, so there will be background fluorescence in the cell assay. A good quantum 
yield improves the signal to noise ratio and could therefore reduce the detection limit. The 
quantum yield of the pyrene labeled compounds 1b – 1g was determined in buffered aqueous 
solution and in acetonitrile. The mode of connection to the pyrene moiety has an influence on 
the quantum yield. Compounds 1b – 1d that were connected via the 1-pyrene butanoic acid 
spacer have only moderate quantum yields in acetonitrile and buffer. Addition of 1% bovine 
serum albumine (BSA) increased the quantum yields of these compounds. The situation is 
different for the compounds 1e – 1g containing the 1-pyrene carboxylic acid substructure. In 
this case the quantum yields are good in acetonitrile and moderate in buffered solution. An 
exception is the carboxylic acid 18. Its quantum yield was highly increased in aqueous 
buffered solution. This effect can be caused by a strong self organisation (e.g. micelles or 
large hydrated anions) as more rigid systems can not loose their excitation energy via 
rotational deactivation. This effect disappears when BSA is present and the pre-organised 
structure is destroyed. 
 
The absorption and emission spectra were also dependent on the substituent of the pyrene 
moiety. In case of the 1-pyrene butanoic acid spacer the maxima of the peaks in the 
absorption spectrum are slightly red shifted compared to pyrene. The first maxima of the 
compounds 1b – 1d is at 342 nm in contrast to pyrene with 334 nm. The emission maximum 
is also slightly red shifted from 390 nm (pyrene) to 394 nm. In case of compounds 1e – 1f 
containing the 1-pyrene carboxylic acid substructure the peak maxima in the absorption 
spectrum are equal to compounds 1b – 1d, but there is a broadening of the absorption bands. 
The fluorescence maximum is further red shifted to 400 nm. Compound 1g substituted with 
two pyrenes is similar in its absorption properties to compounds 1e – 1f, but has an additional 
strong excimer band. The effect of the substituent is striking for compound 1a. The direct 
connection of the pyrene moiety to the acyl-guanidine caused a strong broadening of the 
absorption and fluorescence maxima and diminished the emission intensity.  
 
Another important factor for the understanding of the fluorescence properties of the pyrene 
labeled compounds is the monomer to excimer fluorescence ratio. This ratio is dependent on 
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the local concentration, the rotational degrees of freedom and the self aggregation behavior. In 
acetonitrile only the compounds 1g and 19 that contain both two pyrene moieties in a single 
molecule emit a significant amount of excimer radiation, because of the high local 
concentration of pyrene units. The concentration of the dyes was 0.5 µM and is therefore too 
low for intermolecular excimer formation that is normally observed for concentrations above 
100 µM. The situation in aqueous solution is different. Compounds 1b, 1d and 1g are hardly 
water soluble. A high degree of excimer fluorescence was observed for the compounds due to 
self-aggregation of the pyrene rings. For the better water soluble compounds 1c, 1e, 1f and 18 
this effect was less pronounced. Addition of BSA had a significant effect on the ratio of 
monomer and excimer fluorescence: The aggregation of the hydrophobic molecules 1b, 1d 
and 1g in aqueous solution was reduced upon binding to BSA and the excimer fluorescence 
was therefore diminished.  
 
Table 1.  Pyrene dye substructure and quantum yields of BIBP 3226 derivatives 1b – 1g and 
control compounds 18 and 19. 
 
Acetonitrile Bufferb  Bufferb + 1% BSA 
No. Dye 
substructure Φ [%] (m/e)a Φ [%] (m/e)a         Φ [%] (m/e)a 
1b Pyr-(CH2)3-CO- 14 95/5 11 36/64       19 68/32 
1c Pyr-(CH2)3-CO- 20 92/8 18 85/15        28 80/20 
1d Pyr-(CH2)3-CO- 12 96/4 16 41/59        40 85/15 
1e Pyr-CO- 43 96/4 16 87/13        13 85/15 
1f Pyr-CO- 41 97/3 37 91/9         8 81/19 
1g Pyr-CO- 38 50/50 15 17/83        17 26/74 
18 Pyr-CO- 29 95/5 85 94/6        28 91/9 
19 Pyr-CO- 31 22/78 27 23/77        12 80/20 
a
 ratio monomer fluorescence (360 nm – 450 nm) to excimer fluorescence (450 nm – 600 nm); the cut off at 
450 nm was  chosen for the best separation of the two emission bands, small values in the excimer rate (< 10) 
do not necessarily imply the presence of excimers. The dye concentration was 0.5 µM in the fluorescence 
measurements.   
b
 HEPES buffer, pH 7.4 (25 mM HEPES, 1.0 mM MgCl2, 2.5 mM CaCl2) 
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Figure 2. Absorbance (A) and Fluorescence spectra (λex = 342 nm, B) of different types of 
pyrene derivatives in acetonitrile. The concentration of the compounds was 10 µM. Picture A: 
absorbance of compound 1b (red), 1e (blue) and 1a (black, dashed line). Picture B: 
fluorescence spectra of compound 1b (red), 1e (blue), 1a (black, dashed line) and compound 
1g (green; forms an internal excimer).  
 
2.2.3 Fluorescence microscopy on MCF-7 cells  
 
The pyrene-labeled compounds were investigated for the detection of NPY Y1 receptor 
dimers on MCF-7 cells with fluorescence microscopy. The cells were therefore grown on 8-
well slides and incubated with the pyrene-labeled compounds. Unspecific binding was 
determined with BIBP 3226. The first attempt using a Leica DM RBE microscope was 
performed to compare specific and unspecific binding (monomer and excimer channel not 
separated). Unfortunately the auto-fluorescence (picture A) was as bright as the stained cells 
(picture B). There was also no difference between total (B) and unspecific binding (D) visible. 
The staining of the MCF-7 cell nuclei with DAPI (C) was possible. There is no fluorescence 
in the cell nuclei without DAPI, so the fluorescent ligands and other fluorescent bio-
molecules are in the cytoplasm or at the cell membrane. In a second attempt the cells were 
investigated with a 2-photon laser. With this technique only a small segment of the cells was 
excited at 680 nm and therefore the background fluorescence was diminished compared to the 
standard fluorescence microscopy. But the autofluorescence was still a major problem. The 
addition of the fluorescent ligand 1e did not increase the fluorescence signal significantly. 
There was also no difference between total and unspecific binding.  
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Figure 3. MCF-7 cells and fluorescent ligands (excitation: 340 – 380 nm, emission filter: 425 
nm longpass), incubation time 20 minutes. Picture A: autofluorescence; B: 100 nM 1f; C: 
DAPI (1.5 mg/mL); D: 100 nM 1f + 10 µM BIBP. 
 
 
 
2.2.4 FACS analysis of MCF-7 cells 
 
An alternative strategy for the detection of Y1R dimers using the pyrene dyes was the 
investigation of MCF-7 cells with FACS measurements. The cells were incubated with the 
pyrene labeled antagonists for 20 minutes and then analyzed. The result was exemplarily 
shown for compound 1f in Figure 4 (pictures A and B). A right shift of the signal maximum is 
correlated with a binding of the fluorescent ligand to the cell. There was no difference in the 
monomer channel (395 nm – 415 nm; A) between unlabeled cells (black), total binding (blue) 
and unspecific binding (red). The excimer channel (515 nm – 545 nm) also shows no 
significant right-shift. The other pyrene labeled compounds behave equal. Only the red 
fluorescent compound 2014 that can be excited at 488 nm has a strong right shift compared to 
the unlabeled cells, but there is also some unspecific binding. In summary, the strong 
autofluorescence of the MCF-7 cells under UV light and the weak fluorescence of the pyrene 
derivatives do not permit the determination of total and unspecific binding of the pyrene 
labeled antagonists.    
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Figure 4. Histogram: Binding of compound 1f to MCF-7 cells, monomer channel (A) and 
excimer channel (B); unlabeled cells (black), total binding (blue) and unspecific binding (red). 
Picture C shows the binding of the red fluorescent Y1R antagonist 20 (505 nm longpass filter) 
for comparision. Specific binding was only detected for compound 20 (right shift of the blue 
curve).  
 
 
2.3 Conclusion and Outlook 
 
In this study we successfully prepared pyrene labeled derivatives of the Y1 receptor antagonist 
BIBP 3226 that exhibited nanomolar affinity to the NPY Y1 receptor. The new derivatives 
have a moderate quantum yield between 11% and 37% in aqueous buffered solution. Despite 
the good properties of the pyrene moiety (long lifetime of the excited state, fast excimer 
formation combined with a strong red-shift; small molecule with less sterical demand as other 
dyes) the strong autofluorescence of the MCF-7 cells decreased the signal to noise ratio and 
inhibits the detection of the specific antagonist binding at the Y1 receptor. There are two ways 
to overcome this problem. One option is the investigation of the pyrene dyes with a time-
resolved confocal microscope that has an UV laser (no standard equipment). The more 
convenient and more applicable solution for this problem is the investigation of dyes that 
absorb light in the visible part of the spectra (488 nm argon laser or 633 nm He-laser, standard 
equipment) and exhibit a long lifetime of the excited state, so that they can form excimers. 
Platinum-(II)-complexes like compound 21 as described in literature15 (excimer: λmax = 690 
nm, τ = 7 µs) can be useful candidates. In summary, the study shows that pyrene-labeled NPY 
Y1 antagonists are not suitable to proof the proposed excimer approach for the detection of 
GPCR dimers, but other excimer dyes may do. 
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Figure 5. A platinum-(II)-complex that forms excimers with an emission maximum of ca. 
700 nm.  
 
2.4 Experimental 
 
2.4.1 General experimental conditions 
 
Unless otherwise noted, solvents (analytical grade) were purchased from commercial 
suppliers and used without further purification. Ethyl acetate (EA), petrol ether (PE, 60 – 70  
°C), methanol and dichloromethane were obtained in technical grade and distilled before 
application. Acetonitrile (MeCN) for HPLC was obtained from Merck (Darmstadt, Germany). 
Pyrene (Aldrich, Sigma-Aldrich Chemie GmbH, Munich, Germany), 1-pyrene butyric acid  
(Aldrich, Sigma-Aldrich Chemie GmbH, Munich, Germany) and diethylenetriamine (Acros,  
Fisher Scientific GmbH, Schwerte) were purchased. Preparative HPLC was performed with a 
system from Knauer (Berlin, Germany) consisting of two K-1800 pumps and a K-2001 
detector. A Nucleodur 100-5 C18 (250 × 21 mm, 5 µm; Macherey-Nagel, Germany) and a 
Eurospher-100 C18 (250 × 32 mm, 5 µm; Knauer, Germany) served as RP-columns at flow 
rates of 20 and 38 mL/min, respectively. Mixtures of MeCN and diluted aqueous TFA (0.1 %) 
were used as mobile phase. 1H-NMR spectra were recorded at 300 MHz on a Bruker Avance 
300 spectrometer or at 600 MHz on a Bruker Avance III 600 with cryogenic probehead 
(Bruker, Karlsruhe, Germany). 13C-NMR spectra were recorded at 75 MHz on a Bruker 
Avance 300 spectrometer. All chemical shifts values are reported in ppm. UV/VIS spectra 
were recorded with a Varian Cary BIO 50 UV/VIS/NIR spectrophotometer (Varian Inc., CA, 
USA). Fluorescence spectra were recorded with a Cary Eclipse spectrofluorimeter (Varian 
Inc., CA, USA). Mass spectra: Finnigan SSQ 710A (EI), Finnigan MAT 95 (CI), Finnigan 
MAT TSQ 7000 (Thermo FINNIGAN, USA) (ES/LC-MS). LC-system for LC-MS: Agilent 
1100 (Palo Alto, USA). LC-MS method I (LC-MS-I): Column: Phenomex Luna C18, 3.0 µm, 
100 x 2 mm HST (Phenomenex, Aschaffenburg, Germany); flow: 0.30 mL/min; solvent A 
(water + 0.1% TFA), solvent B (MeCN); gradient: 0 min [A/B 95/5], 1 min [A/B 95/5], 11 
min [A/B 2/98], 18 min [A/B 2/98], 19 min [A/B 95/5], 24 min [A/B 95/5]. LC-MS method II 
(LC-MS): Column: Phenomex Luna C18, 2.5 µm, 50 x 2 mm HST (Phenomenex, 
Aschaffenburg, Germany); flow: 0.40 mL/min; solvent A (water + 0.1% TFA), solvent B 
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(MeCN); gradient: 0 min [A/B 95/5], 8 min [A/B 2/98], 11 min [A/B 2/98], 12 min [A/B 
95/5], 15 min [A/B 95/5]. Melting points were determined with a Lambda Photometrics 
Optimelt MPA100 apparatus (Lambda photometrics, Harpenden, UK), they are not corrected. 
Thin layer chromatography (TLC) was performed on alumina plates coated with silica gel 
(Merck silica gel 60 F245, thickness 0.2 mm). Column chromatography (CC) was performed 
with Merck Geduran SI 60 silica gel as the stationary phase.  
Compounds 1a,13 1b,13 1e,13 3,16 4,16 5,14 6,13 7,17 8,18 9,18 10,13 1219 and 1813 were prepared 
according to literature procedures.  
 
 
2.4.2 Synthetic protocols and analytical data 
 
(R)-4-(2,2-Diphenylacetamido)-1-(4-hydroxyphenyl)-3,11,18-trioxo-21-(pyren-1-yl)-
2,8,10,12,17-pentaazahenicosan-9-iminium 2,2,2-trifluoroacetate (1c) 
The amine 5 (7.6 mg, 9.3 µmol) was dissolved in THF (3 mL) and NEt3 (9.3 mg, 93 µmol) 
was added. Then a solution of the NHS ester 7 (3.6 mg, 9.3 µmol) in THF (1 mL) was added 
slowly. Mixture was stirred until TLC control demonstrated complete conversion (1h). TFA 
was added dropwise until the pH was below 3. Then the mixture was concentrated and the 
crude material was purified with prep. HPLC. The product is a white solid (5.0 mg, 56%), 
m.p. > 190°C (decomp.). 1H NMR (300 MHz, DMSO-d6): 1.00 – 1.80 (m, 10H), 1.95 – 2.05 
(m, 2H), 2.20 – 2.25 (m, 2H), 3.00 – 3.20 (m, 6H), 4.05 – 4.20 (m, 2H), 4.25 – 4.40 (m, 1H), 
5.12 (s, 1H), 6.67 (d, J=8.45, 2H), 7.00 (d, J=8.45, 2H), 7.15 – 7.35 (m, 10H), 7.40 – 7.55 (bs, 
1H), 7.80 – 8.60 (m, 14 H), 8.75 – 9.55 (m, 2H). C52H55N7O5: MS (LC-MS-I): m/z(%) [tr=9.9 
min.]: 858(100, M+). 
 
(R)-(4-(2,2-Diphenylacetamido)-5-(4-hydroxybenzylamino)-5-oxopentylamino)(4-(4-((4-
(pyren-1-yl)butanamido)methyl)-1H-1,2,3-triazol-1-yl)butanamido)methan-iminium 
2,2,2-trifluoroacetate (1d) 
The amine 6 (30.1 mg, 34.7 µmol) was dissolved in THF (3 mL) and NEt3 (35 mg, 347 µmol) 
was added. A solution of the NHS ester 7 (12.2 mg, 35.6 µmol) in THF (2 mL) was added 
slowly. The mixture was stirred until TLC control demonstrated complete conversion (2h). 
TFA was added dropwise until the pH was below 3. Then the mixture was concentrated and 
the crude material was purified with prep. HPLC. The product is a white solid (18.0 mg, 
50%), m.p. > 190°C (decomp.). 1H NMR (300 MHz, DMSO-d6): 1.30 – 1.80 (m, 4H), 1.95 – 
2.10 (m, 4H), 2.20 – 2.35 (t, J=7.21, 2H), 2.35 – 2.45 (t, J=7.13, 2H), 3.15 – 3.25 (m, 2H), 
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3.25 – 3.35 (m, 2H), 4.05 – 4.20 (m, 2H), 4.25 – 4.40 (m, 5H), 5.12 (s, 1H), 6.67 (d, J=8.45, 
2H), 7.00 (d, J=8.45, 2H), 7.15 – 7.35 (m, 10H), 7.90 – 7.95 (m, 2H), 8.00 – 8.45 (m, 10H), 
8.45 – 9.80 (m, 4H), 11.41 (s, 1H). C54H55N9O5: MS (LC-MS-I): m/z(%) [tr=9.8 min.]: 
455(35), 910(100, M+). 
 
tert-Butyl-methylthio(4-(4-(15-(1-(4-oxo-4-(2-(pyrene-1-carboxamido)- 
ethylamino)butyl)-1H-1,2,3-triazol-4-yl)-2,5,8,11,14-pentaoxapentadecyl)-1H-1,2,3-
triazol-1-yl)butanamido)methylenecarbamate (11) 
Compound 8 (243 mg, 0.46 mmol), DIPEA (271 mg, 2.10 mmol) and HOBT ⋅ H2O (124 mg, 
0.92 mmol) were dissolved in 15 mL DMF and the mixture was cooled in an icebath under 
nitrogen atmosphere. Under vigorous stirring EDC (130 mg, 0.84 mmol) was added. After 15 
minutes a mixture of the compounds 9 (80 mg, 0.42 mmol) and 10 (135 mg, 0.42 mmol) in 5 
mL DMF was added. After the addition the ice bath was removed and the mixture was stirred 
at ambient temperature overnight. The next day DMF was evaporated completely and the 
residue was dissolved in DCM. It was washed with diluted NaHSO4 solution (10%, 1 x 30 
mL) and the organic layer was separated and dried over MgSO4. The solvent was removed 
and the crude material was purified with column chromatography (EA/EtOH 8:2 -> EtOH, 
Rf=0.2[EA/EtOH 1:1]). A white solid was obtained (43 mg, 11%), m.p. > 190°C (decomp.).  
1H NMR (300 MHz, CDCl3): 1.49 (s, 9H), 2.05 - 2.45 (m, 11H), 3.45 – 3.75 (m, 20H), 4.20 – 
4.35 (m, 4H), 4.40 – 4.60 (m, 4H), 7.40 – 7.70 (m, 4H), 7.90 – 8.20 (m, 8H), 8.45 – 8.55 (m, 
1H), 11.50 – 13.00 (m, 1H). C48H62N10O10S: MS (LC-MS): m/z(%) [tr=11.3 min.]: 486(100), 
971(35, MH+). 
 
(R)-(4-(2,2-Diphenylacetamido)-5-(4-hydroxybenzylamino)-5-oxopentylamino)(4-(4-(15-
(1-(4-oxo-4-(2-(pyrene-1-carboxamido)ethylamino)butyl)-1H-1,2,3-triazol-4-yl)-
2,5,8,11,14-pentaoxapentadecyl)-1H-1,2,3-triazol-1-yl)butanamido)methaniminium 
2,2,2-trifluoroacetate (1f) 
Compound 11 (43 mg, 44 µmol) and amine 12 (22 mg, 44 µmol) were dissolved separately in  
DMF (1 mL). The solutions were combined in a small flask under nitrogen atmosphere. NEt3 
(0.5 mL) was added under stirring, then a HgCl2 solution (44 µmol) in 0.5 mL DMF was 
added and the mixture was stirred overnight at room temperature. The next day DMF was 
removed completely and the residue was dissolved in DCM. The precipitate of mercury salts 
was removed by filtering over celite, the organic phase was washed with citric acid (1 x 20 
mL) and dried over magnesium sulphate.  
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The DCM solution was concentrated and a 1:1 mixture of TFA and DCM was added (4 mL). 
The mixture was stirred for two hours. Then it was again concentrated and the residue was 
purified with HPLC. A white solid was obtained (38 mg, 63%), m.p. > 190°C (decomp.). 1H 
NMR (300 MHz, CDCl3): 1.30 – 1.80 (m, 4H), 2.00 – 2.20 (m, 8H), 2.20 – 3.70 (m, 22H), 
4.05 – 4.20 (m, 2H), 4.30 – 4.40 (m, 5H), 4.45 (s, 2H), 4.50 (s, 2H), 5.12 (s, 1H), 6.67 (d, 
J=8.49, 2H), 7.00 (d, J=8.46, 2H), 7.15 – 7.30 (m, 10H), 8.00 – 8.60 (m, 16H), 8.65 – 8.75 
(m, 2H), 9.30 (bs, 1H), 11.11 (bs, 1H). C68H80N13O11: MS (LC-MS): m/z(%) [tr=9.3 min.]: 
628(100), 1255(50, MH+). UV (MeCN): λ(ε) 233 (57⋅103), 242 (71⋅103), 265 (26⋅103), 275 
(37⋅103), 327 (22⋅103), 341 (28⋅103).  
 
N,N'-(2,2'-Azanediylbis(ethane-2,1-diyl))dipyrene-1-carboxamide (14) 
Compound 4 (492 mg, 2.0 mmol), DIPEA (516 mg, 4.0 mmol) and HOBT ⋅ H2O (284 mg, 2.1 
mmol) were dissolved in 10 mL DMF. The mixture was cooled in an ice bath and EDC (310 
mg, 2.0 mmol) was added under nitrogen atmosphere. After 20 minutes the cold solution was 
put into a dropping funnel. The reactive ester solution was dropped slowly into an ice-cooled 
solution of the amine 13 (103 mg, 1.0 mmol) in DMF (10 mL) over a period of 1 h. The 
mixture was stirred overnight at ambient temperature. Next day the mixture was concentrated 
and the solution was dropped into 100 mL diluted NaHSO4 solution (5%). A light yellow 
solid precipitated. The suspension was heated to 100°C for 5 minutes. The hot suspension was 
filtered and the precipitate was washed with H2O. A yellow solid was obtained (360 mg, 
64%), m.p. > 190°C (decomp.). 1H NMR (300 MHz, DMSO-d6): 2.85 – 3.00 (m, 4H), 3.50 – 
3.65 (m, 4H), 8.00 – 8.40 (m, 16H), 8.45 – 8.60 (m, 2H), 8.60 – 8.75 (m, 2H). 13C NMR (75 
MHz, DMSO-d6): 39.6, 48.3, 123.52, 123.63, 124.21, 124.67, 125.10, 125.40, 125.62, 
126.40, 127.03, 127.63, 127.89, 128.08, 130.06, 130.59, 131.33, 132.04, 168.89. 
C38H29N3O2: MS (LC-MS): m/z(%) [tr=9.6 min.]: 560(100, MH+).  
 
4-(bis(2-(Pyrene-1-carboxamido)ethyl)amino)-4-oxobutanoic acid (16) 
Compound 14 (360 mg, 0.64 mmol) was dissolved in 5 mL DMF and NEt3 (130 mg, 1.28 
mmol) was added. Under stirring a solution of the anhydride 15 (77 mg, 0.77 mmol) in 5 mL 
DMF was added. The mixture was heated to 80°C and stirred for 2 h. After that time the 
mixture was cooled to ambient temperature and NaOH (1M, 3 mL) was added and the 
mixture was stirred for one more hour. Diluted NaHSO4 solution was added (30 mL, 5%w) 
and a white solid precipitated. To increase the particle size it was heated to 100°C for 5 
minutes and cooled down slowly. Then the precipitate was filtered. The crude material was 
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recrystallised in EtOH (50 mL), insoluble particles were filtered off. Light yellow crystals 
were obtained (94 mg, 55%), m.p. > 190°C (decomp.). 1H NMR (300 MHz, DMSO-d6): 2.45 
– 2.55 (m, 2H), 2.70 – 2.80 (t, J=6.59, 2H), 3.55 – 3.85 (m, 8H), 8.00 – 8.40 (m, 16H), 8.45 – 
8.55 (m, 2H), 8.80 (t, J=5.35, 1H), 8.96 (t, J=5.03, 1H). 13C NMR (75 MHz, DMSO-d6): 
27.77, 29.38, 37.59, 38.11, 45.07, 46.84, 125.55, 123.57, 123.76, 124.32, 124.35, 124.57, 
124.68, 125.16, 125.21, 125.45, 125.52, 125.66, 125.73, 126.40, 126.44, 127.07, 127.79, 
127.81, 127.98, 128.07, 128.18, 128.26, 130.07, 130.60, 131.43, 131.53, 131.63, 131.78, 
169.07, 169.32, 171.12, 174.12. C42H33N3O5: MS (LC-MS): m/z(%) [tr=11.9 min.]: 660(100, 
MH+), 1319(10). 
 
tert-Butyl-5,8,13-trioxo-13-(pyren-1-yl)-9-(2-(pyrene-1-carboxamido)ethyl)-2-thia-4,9,12-
triazatridecan-3-ylidenecarbamate (17) 
Acid 16 (100 mg, 0.15 mmol), DIPEA (58 mg, 0.45 mmol) and HOBt (23 mg, 0.17 mmol) 
were dissolved in DCM and EDC (26 mg, 0.17 mmol) was added under nitrogen atmosphere. 
After 15 minutes compound 9 was added and the mixture was stirred overnight. The next day 
the reaction mixture was washed with NaHSO4 solution (5%, 1 x 30 mL). Organic phase was 
dried over MgSO4 and the solvent was evaporated. The crude product was purified with 
column chromatography (EA, Rf=0.1) yielding compound 17 (493 mg, 60%) as a white solid, 
m.p. > 190°C (decomp.). 1H NMR (300 MHz, CDCl3): 1.25 – 1.50 (m, 9H), 1.80 – 2.05 (m, 
3H), 2.50 – 2.65 (bs, 2H), 2.65 – 2.80 (bs, 2H), 3.60 – 3.90 (m, 8H), 7.00 – 7.20 (m, 1H), 7.50 
– 8.20 (m, 17H), 8.35 – 8.55 (m, 2H), 11.30 – 12.30 (m, 1H). 13C NMR (75 MHz, CDCl3): 
14.20, 27.94, 35.11, 39.09, 46.20, 48.43, 77.27, 124.12, 124.23, 124.47, 124.53, 124.71, 
125.61, 125.69, 125.76, 126.14, 126.17, 126.85, 126.98, 128.32, 128.42, 128.56, 128.68, 
130.05, 130.43, 130.48, 130.98, 132.35, 132.49, 170.51, 170.79. C49H45N5O6S: MS (LC-
MS): m/z(%) [tr=13.9 min.]: 832(100, MH+). 
 
(R)-16-(4-Hydroxybenzylcarbamoyl)-1,6,9,18-tetraoxo-19,19-diphenyl-1-(pyren-1-yl)-5-
(2-(pyrene-1-carboxamido)ethyl)-2,5,10,12,17-pentaazanonadecan-11-iminium 2,2,2-
trifluoroacetate (1g) 
Compound 17 (45 mg, 54 µmol) and amine 12 (26 mg, 54 µmol) were dissolved separately in  
DMF (1 mL). The solutions were combined in a small flask under nitrogen atmosphere. NEt3 
(0.5 mL) was added under stirring, then a HgCl2 solution (54 µmol) in 0.5 mL DMF was 
added and the mixture was stirred overnight at room temperature. The next day DMF was 
removed completely and the residue was dissolved in DCM. The precipitate of mercury salts 
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was removed by filtering over celite, the organic phase was washed with citric acid (1 x 20 
mL) and dried over magnesium sulphate.  
The DCM solution was concentrated and a 1:1 mixture of TFA and DCM was added (4 mL). 
The mixture was stirred for two hours. Then it was again concentrated and the residue was 
purified with HPLC. A white solid was obtained (36 mg, 55%), m.p. > 190°C (decomp.). 1H 
NMR (300 MHz, DMSO-d6): 1.30 – 1.70 (m, 4H), 2.65 – 2.80 (m, 2H), 2.85 – 3.00 (m, 2H), 
3.10 – 3.30 (m, 2H), 3.55 – 3.85 (m, 8H), 4.00 – 4.25 (m, 2H), 4.25 – 4.40 (m, 1H), 5.11 (bs, 
1H), 6.60 – 6.70 (m, 2H), 6.95 – 7.05 (m, 2H), 7.15 – 7.35 (m, 10H), 8.05 – 8.40 (m, 19H), 
8.40 – 8.60 (m, 4H), 8.70 – 8.85 (bs, 2H), 8.90 – 9.05 (bs, 1H), 9.31 (bs, 1H), 10.50 – 11.40 
(m, 1H).  C69H63N8O7: MS (LC-MS): m/z(%) [tr=10.2 min.]: 558(15), 1115(100, MH+). UV 
(MeCN): λ(ε) 265 (57⋅103), 276 (77⋅103), 328 (47⋅103), 342 (61⋅103). Fluorescence (λex. = 340 
nm, MeCN): 401 (monomer), 494 (excimer) nm. 
 
N,N'-(4,14-Dioxo-6,9,12-trioxa-3,15-diazaheptadecane-1,17-diyl)dipyrene-1-
carboxamide (19) 
Compound 8 (38 mg, 0.12 mmol), DIPEA (93 mg, 0.72 mmol) and HOBt (34 mg, 0.25 
mmol) were dissolved in a 4 mL of DMF and EDC (39 mg, 0.25 mmol) was added. After 15 
minutes amine 10 (78 mg, 0.24 mmol) was added. The next day DMF was evaporated 
completely and the residue was purified with column chromatography (EE/MeOH 4:1 Rf = 
0.1). The product was obtained as a bright yellow solid (69 mg, 75%), m.p. > 190°C 
(decomp.). 1H NMR (300 MHz, DMSO-d6): 3.20 – 3.70 (m, 16H), 3.93 (s, 4H), 7.98 (t, 2H,  
J=5.55), 8.05 – 8.40 (m, 16H), 8.50 (d, 2H, 9.28), 8.76 (t, 2H, J=5.33). 13C NMR (75 MHz, 
DMSO-d6): 38.1, 39.2, 66.5, 69.9, 70.1, 123.5, 123.7, 124.3, 124.7, 125.2, 125.5, 125.7, 
126.5, 127.1, 127.9, 128.2, 130.1, 130.6, 131.5, 131.8, 168.9. MS (ES-MS): m/z(%) 763(100, 
MH+), 785(25).  UV (MeOH):  λ(ε) 234(68⋅103), 243(92⋅103), 265(36⋅103), 276(53⋅103), 
328(33⋅103), 341(43⋅103).  
 
2.4.3 Determination of the quantum yield 
 
The quantum yield of the compounds 1b – 1g was determined with quinine (Aldrich, Sigma-
Aldrich Chemie GmbH, Munich, Germany) as a standard (quantum yield 58%).20 Stock 
solutions (1 mM) of the compounds 1b – 1g in DMSO were prepared. The final 
concentrations of the compounds were 5⋅10-6 M for UV absorption spectra and 5⋅10-7 M for 
fluorescence spectra. Acetonitrile, HEPES-buffer (25 mM HEPES, 1.0 mM MgCl2, 2.5 mM 
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CaCl2; pH 7.4) and HEPES buffer containing 1% BSA were applied as solvents. The quinine 
standard was prepared in 0.1 M H2SO4 (10-5 M for absorption and 10-6 for fluorescence). For 
the excitation wavelength of compounds 1b – 1g  the first maximum of the pyrene excitation 
pattern (330 – 345 nm) was choosen. Fluorescence spectra were recorded using the following 
parameters: excitation slit 5 nm, emission slit 10 nm, photomultiplier voltage 550 V, 
scanspeed medium. All spectra were recorded in silica glass cuvettes.  
For the determination of reference spectra the pure solvents with the same DMSO content 
were used. From every emission spectrum the corresponding reference spectrum was 
substracted and the resulting spectrum was integrated up to 600 nm. The quantum yield was 
calculated according to the equation:  
ΦF(X) = (As/Ax) ⋅ (Fx/Fs) ⋅ (nx/ns)2⋅ ΦF(S)  
where As is the absorbance and Fs is the integral of the corrected emission spectrum of the 
quinine standard solution. Ax and Fx stand for the absorbance and the integral of the corrected 
emission spectrum of the fluorescent ligand. The refraction indices of the solvents are nx and 
ns. ΦF(S) is the reported quantum yield of quinine (58%). 
 
2.4.4 MCF-7 Cell culture and fluorescence microscopy 
 
MCF-7 cells were cultivated at 37 °C for two days in 8 well µ-slides (Ibidi GmbH, Munich) 
with EMEM medium (Sigma, Deisenhofen, Germany) containing 5% FCS (Biochrom AG, 
Berlin, Germany). Estradiol (1 nM) was added to the cultivation medium to stimulate Y1R 
expression. After two days, shortly before the experiment the medium was replaced by 
Leibovitz L15 medium (LM). The pyrene labeled compounds were prepared as 10 µM stock 
solutions in DMSO. Shortly before the assay  a 100 nM solution of the compounds in LM was 
prepared. The cells were then incubated 15 minutes with the pyrene labeled compounds and 
pictures were taken. The fluorescence microscope was a Leica DM RBE microscope (Leica 
Mikrosystems, Bensheim, Germany). The dyes were excited with at 340 – 380 nm and 
emission was detected after a 425 nm long-pass filter (excimer and monomer fluorescence). 
The cell nucleus was stained with DAPI (1.5 mg/mL; Vectashield Fluoromount). 
The cells were also observed with a Zeiss LSM 710 microscope (Carl Zeiss AG, Oberkochen, 
Germany) equipped with a 2-photon laser and a  Plan-Apochromat 20x/0.8 M27 objective. 
The dyes were excited with the 2-photon laser at 680 nm. Fluorescence was detected at  380 – 
420 nm (monomer) and 450 – 700 nm (excimer).  
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2.4.5 FACS analysis of MCF-7 cells 
 
The MCF-7 cells were cultivated in a big cell culture flask under the same conditions as 
described above. The cells were suspended in HEPES-buffer (25 mM HEPES, 1.0 mM 
MgCl2, 2.5 mM CaCl2; pH 7.4) shortly before the experiment. FACS analysis was performed 
with a BD LSR-II flow cytometer (BD Biosciences, San Jose, USA), equipped with a UV 
trigon laser (355 nm). The emission filter set was 395 – 415 nm (monomer channel) and 515 – 
545 nm (excimer channel). The pyrene labeled compounds were prepared as 10 µM stock 
solutions in DMSO/H2O 1:1. The cell suspension (106 cells/mL) was then separated in FACS 
tubes (495 µL/tube) and 5 µL of the corresponding stock solution was added in each tube 
(100 nM final concentration). BIBP 3226 was applied for the determination of the unspecific 
binding (10 µM). The compounds were incubated for 20 minutes and then the cells were 
analyzed. The red labeled compound 20 (for comparison) was used at a final concentration of 
20 nM and was excitated with a 488 nm argon laser. 
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CHAPTER 3 
 
Towards Target Specific Fluorescent Liposomes for the 
Neuropeptide Y1 Receptor 
 
 
 
3.1 Introduction 
 
The selective interaction of liposomes with cells is a very important task in modern medicinal 
chemistry. Liposomes are spherical vesicles that form lipid bilayers in aqueous solution and 
enclose a small aqueous volume in their interior.1 They are widely-used as biocompatible and 
biodegradable drug carriers for several drugs like for example doxorubicin1, 2 and as 
chemosensors in analytical chemistry.3  Compared to the administration of the drug alone 
these preparations can increase the effectiveness of the drug via an enrichment in malignant or 
inflamed tissues.2 In this case it is not a receptor mediated selectivity, but an effect of the 
more penetrable tissue. The selectivity of the liposomes can be further improved by attaching 
a receptor selective antagonist or antibody to the liposome bilayer. This was studied for 
example for neuroblastoma cells overexpressing the disialoganglioside GD2 structure on the 
cell surface.4 A liposome preparation containing an antibody against GD2 exhibited a strong 
target specific liposome accumulation at the cancer cells.4 This antibody-antigen interaction is 
further amplified by multiligand binding, when many antibodies that are located on the same 
liposome bind to many antigens simultaneously.5  
The neuropeptide Y1 receptor (Y1R)  has an incidence of 85% in breast carcinoma cells and 
100% in lymph node metastases.6 Therefore this receptor is an important target for the 
detection of cancer cells. Agonist and antagonist decorated quantum dots (QD) as diagnostic 
tools for this receptor were already prepared and demonstrated a high selectivity for the Y1R.7 
Despite the strong fluorescence of the quantum dots and the good receptor selectivity the long 
term toxicity is a big problem. The core of the polyethylene glycol (PEG) covered QDs 
consists of cadmium selenide. A metabolic degradation of the particles can deliver cadmium 
ions that are highly toxic. So fluorescent labeled liposomes can be a promising non toxic 
alternative to the QDs. In this study we prepared liposomes containing a substructure of the 
Y1R selective antagonist BIBP 3226 (BIBP)8 and lipophilic fluorescein derivatives for the 
detection of the MCF-7 breast cancer cells. A further advantage for the application of 
liposomes is their fast accessibility and the high diversity by just changing the mixture of the 
lipid composition. 
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Figure 1. Antagonist mediated binding of a fluorescent labeled liposome to the NPY Y1 
receptors at the cell surface. The factual binding pocket for the antagonist is in the 
transmembrane domain.  
 
 
3.2 Results and Discussion 
 
3.2.1 Synthesis of the lipophilic Y1R antagonists and dyes 
 
Lipophilic antagonists for the Y1R were synthesized that can be included into the lipid bilayer 
as shown in Figure 1. Their structures are shown in Figure 2. The long hydrophobic tail of the 
compounds 1a and 1b is part of the lipid bilayer. Compound 1b was prepared as an 
alternative to compound 1a to gain a larger distance between the liposome bilayer and the 
antagonist moiety. The thiol modified antagonist 1c was synthesized to obtain a molecule that 
can be “clicked” to a completed liposome via a Michael addition of the thiol to a 
maleinimide.9 The synthesis of compound 1a is described elsewhere.10 The compounds 1b 
and 1c were synthesized starting with the antagonist precursor amine 1. Compound 1b was 
prepared via an acylation reaction of the dicarboxylic acid 2 and two amines simultaneously. 
Due to the statistical product distribution the yield was low. Compound 1c was prepared from 
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Boc-protected 2-mercaptoacetic acid. After acylation with compound 1 the intermediate was 
deprotected with TFA and compound 1c was obtained.  
Carboxyfluorescein was chosen as scaffold for the preparation of lipophilic dyes due to its 
availability and good quantum yield. It was connected to dodecylamine and octadecylamine, 
respectively. The compounds 8 and 9 were obtained in moderate yield.  
 
 
 
 
 
Scheme 1. Synthesis of the Y1R antagonists 1b and 1c and the fluorescent dyes 8 and 9. a) 
DMF, DIPEA, TBTU, 28%; b) DMF, DIPEA, TBTU; c) TFA, 25%; d) n=12: DMF, DIPEA, 
HOBt, DCC, 56%; n=16: DMF, NEt3, TBTU, 55%. 
 
 
3.2.2 Y1R affinity of the lipophilic compounds  
 
The affinities of the free ligands to the NPY Y1R were about 200 to 500 times lower 
compared to the unsubstituted antagonist BIBP.  
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Figure 2. Structures and Y1R affinities of the lipophilic antagonists 1a-1c. Ki values 
determined from the displacement of 1.5 nM [3H]-UR-MK11411 on SK-N-MC cells; the mean 
values ± SEM are from two independent experiments (1, 1a) or from one single experiment 
(1b, 1c).  
 
 
 
3.2.3 Formulation of the liposomes and studies on MCF-7 cells  
 
The liposomes were prepared from the bilayer forming lipids DSPC and DSPE (Figure 3) as 
main components (section 4.3). In some formulations cholesterol was added as a membrane 
stabilizing additive.2  
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Figure 3. Building blocks for the liposomes: DPSC 10, PEGylated DSPE derivatives 11 and 
12 and cholesterol 13. 
 
Table 1.  Composition of the liposome preparations. 
 
entry Antagonist (1a – 1c) 
DSPC 
(comp. 10) 
DSPE-(PEG)n 
(comp. 11 - 12) 
Cholesterol 
(comp. 13) 
Lipophilic dye 
(comp. 8 - 9) 
1 1a 10% 90% -  - 8 0.5% 
2 1a 10% - 11 90% - 8 0.5% 
3 1b 0.5% 99% -  - 9 0.5% 
4 1b 0.5% 97% 11 2% - 9 0.5% 
5 1b 0.5% 94% 11 5% - 9 0.5% 
6 1b 0.5% 89% 11 10% - 9 0.5% 
7 -  94% 11 5% - 9 0.5% 
8 1b 1% 93% 11 5% - 9 0.5% 
9 1b 2% 92% 11 5% - 9 0.5% 
10 1b 0.5% 64% 11 5% 30% 9 0.5% 
11 1c 3% 97% 12 3% - 9 0.5% 
12 1c 3% 68% 12 3% 29% 9 0.5% 
 
The binding of the liposomes was investigated with confocal microscopy on MCF-7 breast 
cancer cells. This cell line has a high density of Y1 receptors (40 000 – 300 000 receptors per 
cell).12 
The best fluorescent properties of the liposomes were achieved with a dye fraction of 0.5%, 
because a higher concentration caused self-quenching of the fluoresceine moieties. So the dye 
concentration was constant for all liposome preparations in Table 1. There was no significant 
difference between the dyes 8 and 9 regarding fluorescence properties and inclusion in the 
lipid bilayer. 
In entry 1 and 2 the liposomes were prepared with the lipophilic Y1R antagonist 1a. The total 
and unspecific binding were determined after 20 minutes. In entry 1 there was a very strong 
receptor independent binding of the liposomes to the cell membrane (high fluorescence 
intensity). The replacement of DSPC with the glycol modified DSPE derivative 11 in entry 2 
reduced the unspecific binding significantly, but there was no difference between total 
binding and the unspecific binding determined with BIBP. A possible reason for this behavior 
is the insufficient distance of the BIBP moiety to the lipid bilayer.  The binding pocket of the 
Y1R is in the transmembrane region of the receptor. To bridge the distance between the 
liposome surface and the receptor binding pocket we prepared and investigated liposomes 
with the antagonist 1b that has a glycol spacer between the hydrophobic part and the BIBP 
moiety.  
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In entry 3 – 6 the concentration of DSPE-PEG 11 was varied to investigate the effect of the 
PEG protection against unspecific binding interactions. The unspecific staining of the cell 
membrane was very strong for entry 3 (0% PEG) and was reduced with increasing 
concentration of PEG modified lipid (2% - 10% PEG). Entry 5 and 6 exhibit only a weak 
unspecific binding to the cells. This is shown in Figure 4. According to literature a content of 
about 10% of the PEG derivative 11 or 2% of derivative 12 is able to completely protect a 
liposome with a diameter of 100 nm.2 The fluorescence intensity of the membrane is also time 
dependent. A longer incubation time of the liposomes with the cells increased the 
fluorescence of the membrane due to an increased accumulation of liposomes on the cell 
surface. After 40 to 50 minutes saturation in fluorescence was reached.  
In entry 7 – 9 the concentration of antagonist 1b was varied while the amount of PEG-lipid 11 
(5%) was constant. This PEG content should reduce unspecific binding and still allow the 
BIBP moieties to bind to the Y1R. The increased density of BIBP moieties resulted in no 
advancement in receptor specific binding of the liposomes. Entry 8 and 9 behave equally to 
the blank sample in entry 7. In entry 10 cholesterol was added as a membrane stabilizing 
compound, but there was no improvement compared with entry 5 without cholesterol.2  
 
The general strategy of the liposome preparation was changed in entry 11 and 12. Here the 
DSPE-maleinimide derivative 12 was included into the liposome membrane together with 
DSPC and the dye. After extrusion the completed unilamellar liposomes were incubated with 
the thiol derivative 1c overnight (Figure 5). Thiols attack maleinimides via a Michael addition 
under mild conditions and form a thioether bond. The thiol reactivity under these conditions 
(aqueous buffered solution, pH 7.4, room temperature) was verified with a test reaction 
between compound 1c and maleinimide-N-propionic acid. Complete conversion in this 
similar system was observed after 24 hours. This post-modification technique placed the 
BIBP moiety in a large distance to the liposome surface (about 45 PEG-units) and leads to a 
much higher flexibility of the antagonist. So compared to the strategy in entry 1 – 10 the 
BIBP moiety should now be able to reach the transmembrane binding pocket of the receptor 
and elicit Y1 receptor specific binding. 
Unfortunately there was also no specific binding observed. A possible reason for this is the 
slightly lipophilic BIBP moiety that can possibly be included into the surface of the lipid 
bilayer. In this case the BIBP moieties would not be available for a specific interaction with 
the Y1 receptor and the liposome preparations lose their selectivity.  
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3.3 Conclusion and Outlook 
 
In this study we prepared liposomes containing a NPY Y1 receptor selective BIBP moiety. 
Although a receptor selective binding of the liposomes to MCF-7 cells was not achieved the 
beneficial effect of PEG-modified liposomes was demonstrated. The PEG chains reduced the 
unspecific interactions of the liposome with the cell membrane significantly. A further 
problem that must be solved is the possible insertion of the BIBP moiety in the hydrophobic 
bilayer. An exchange of the BIBP moiety with a Y1 receptor selective antibody or a thiol 
modified NPY derivative can avoid this problem, because of the lower lipophilicity of the 
proteins. In summary some further improvements of the liposome composition and surface 
modifications can lead to Y1 receptor selective probes.    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Fluorescence of the cell membranes after 20 minutes incubation time with 
liposomes containing different amounts of PEG. Pictures A: entry 3 (0% PEG), B: entry 5 
(5% PEG) and C: entry 6 (10% PEG).  
 
 
 
Figure 5. The antagonist 1c is attached to the liposome over the PEG-maleinimide functional 
group (a). The PEG spacer separates the liposome surface from the receptor selective BIBP 
moiety (blue). Step b illustrates the possibly occurring undesired insertion of the BIBP moiety 
into the bilayer.  
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3.4 Experimental 
 
3.4.1 General experimental conditions 
 
Unless otherwise noted, solvents (analytical grade) were purchased from commercial 
suppliers and used without further purification. Ethyl acetate (EA), petrol ether (PE, 60 – 70  
°C), methanol and dichloromethane were obtained in technical grade and distilled before 
application. Acetonitrile (MeCN) for HPLC was obtained from Merck (Darmstadt, Germany). 
Dodecylamine (Fluka, Sigma-Aldrich Chemie GmbH, Munich, Germany), octadecylamine 
(Fluka, Sigma-Aldrich Chemie GmbH, Munich, Germany), DSPC (Avanti Polar Lipids Inc., 
Alabaster, USA) and compounds 11 – 12 (Avanti Polar Lipids Inc., Alabaster, USA) were 
purchased. Preparative HPLC was performed with a system from Knauer (Berlin, Germany) 
consisting of two K-1800 pumps and a K-2001 detector. A Nucleodur 100-5 C18 (250 × 21 
mm, 5 µm; Macherey-Nagel, Germany) and a Eurospher-100 C18 (250 × 32 mm, 5 µm; 
Knauer, Germany) served as RP-columns at flow rates of 20 and 38 mL/min, respectively. 
Mixtures of MeCN and diluted aqueous TFA (0.1 %) were used as mobile phase. 1H-NMR 
spectra were recorded at 300 MHz on a Bruker Avance 300 spectrometer or at 600 MHz on a 
Bruker Avance III 600 with cryogenic probehead (Bruker, Karlsruhe, Germany). 13C-NMR 
spectra were recorded at 75 MHz on a Bruker Avance 300 spectrometer. All chemical shifts 
values are reported in ppm. UV/VIS spectra were recorded with a Varian Cary BIO 50 
UV/VIS/NIR spectrophotometer (Varian Inc., CA, USA). Fluorescence spectra were recorded 
with a Cary Eclipse spectrofluorimeter (Varian Inc., CA, USA). Mass spectra: Finnigan SSQ 
710A (EI), Finnigan MAT 95 (CI), Finnigan MAT TSQ 7000 (Thermo FINNIGAN, USA) 
(ES/LC-MS). LC-system for LC-MS: Agilent 1100 (Palo Alto, USA). LC-MS method (LC-
MS): Column: Phenomex Luna C18, 2.5 µm, 50 x 2 mm HST (Phenomenex, Aschaffenburg, 
Germany); flow: 0.40 mL/min; solvent A (water + 0.1% TFA), solvent B (MeCN); gradient: 0 
min [A/B 95/5], 8 min [A/B 2/98], 11 min [A/B 2/98], 12 min [A/B 95/5], 15 min [A/B 95/5]. 
Melting points were determined with a Lambda Photometrics Optimelt MPA100 apparatus 
(Lambda photometrics, Harpenden, UK), they are not corrected. Thin layer chromatography 
(TLC) was performed on alumina plates coated with silica gel (Merck silica gel 60 F245, 
thickness 0.2 mm). Column chromatography (CC) was performed with Merck Geduran SI 60 
silica gel as the stationary phase.  
Compounds  1,13 4,14 and 83  were prepared according to literature procedures.  
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3.4.2 Synthetic protocols and analytical data 
 
(R)-4-(2,2-Diphenylacetamido)-1-(4-hydroxyphenyl)-3,11,18,28-tetraoxo-20,23,26-trioxa-
2,8,10,12,17,29-hexaazaheptatetracontan-9-iminium 2,2,2-trifluoroacetate (1b) 
The dicarboxylic acid 2 (5.3 mg, 23.9 µmol) was dissolved in 2 mL of DMF and DIPEA (28 
mg, 217 µmol) and TBTU (15.2 mg, 47.4 µmol) were added. After 10 minutes the reaction 
was started by the addition of the amines 1 (20 mg, 21.5 µmol) and 3 (5.8 mg, 21.5 µmol). 
The next day DMF was removed completely and the oily residue was purified with HPLC. A 
white solid was obtained (7.0 mg, 28%), m.p. > 190°C. 1H NMR (300 MHz, CD3CN): 0.88 
(t, J=6.66, 3H), 1.20 – 1.35 (m, 30H), 1.35 – 1-60 (m, 10H),  3.00 – 3.30 (m, 8H), 3.55 – 3.65 
(m, 8H), 3.88 (s, 2H), 3.89 (s, 2H), 4.10 – 4.30 (m, 2H), 4.30 – 4.30 (m, 1H), 5.02 (s, 1H), 
6.60 – 7.50 (m, 8H), 6.67 (d, J=8.45, 2H), 7.00 (d, J=8.45, 2H), 7.20 – 7.35 (m, 10H), 9.14 
(bs, 1H). C58H90N8O9: MS (LC-MS): m/z(%) [tr= 8.1min.]: 522(25), 1043(100, M+). 
 
(R)-4-(2,2-Diphenylacetamido)-1-(4-hydroxyphenyl)-19-mercapto-3,11,18-trioxo-
2,8,10,12,17-pentaazanonadecan-9-iminium 2,2,2-trifluoroacetate (1c) 
Boc-protected 2-mercaptoacetic acid (4.5 mg, 23.7 µmol) was dissolved in 2 mL of DMF and 
DIPEA (28 mg, 215 µmol) and TBTU (7.6 mg, 23.7 µmol) dissolved in 125 µL of MeCN 
were added. After 5 minutes compound 1 (20 mg, 21.5 µmol) was added and the mixture was 
stirred overnight. The next day DMF was evaporated completely and TFA was added (3 mL) 
and the mixture was stirred for 4 hours at room temperature. TFA was removed and the 
residue was purified with HPLC. A white solid was obtained (4.2 mg, 25%), m.p. > 190°C 
(decomp.). 1H NMR (300 MHz, DMSO-d6): 1.30 – 1.80 (m, 8H), 2.72 (t, J=7.93, 1H), 3.07 
(d, J=7.93, 2H), 3.00 – 3.25 (m, 6H), 4.05 – 4.25 (m, 2H), 4.30 – 4.40 (m, 1H), 5.13 (s, 1H), 
6.67 (d, J=8.47, 2H), 7.00 (d, J=8.47, 2H), 7.15 – 7.35 (m, 10H), 7.49 (bs, 1H), 8.02 (t, 
J=5.35, 1H), 8.39 (t, J=5.50, 3H), 8.50 (d, J=8.24, 1H), 8.87 (bs, 1H), 9.30 (bs, 1H), 9.49 (bs, 
1H). C34H43N7O5S: MS (LC-MS): m/z(%) [tr=5.48]: 662(100, MH+), 1324(5). 
 
3',6'-Dihydroxy-N-octadecyl-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-6-
carboxamide (10, mixture of 5' and 6' isomer) (9) 
Carboxyfluorescein (50 mg, 0.13 mmol, mixture of 5' and 6' isomer) was dissolved in 2 mL of 
DMF and a mixture of NEt3 (50 mg, 0.50 mmol) and TBTU (48 mg, 0.15 mmol) in 1 mL of 
MeCN was added dropwise. After 15 minutes octadecylamine (35 mg, 0.13 mmol) dissolved 
in 1 mL DCM was added slowly. The reaction mixture was stirred 1 hour at 60°C. Then DMF 
was removed completely and the residue was dissolved in 10 mL DCM. Aqueous NaHSO4 
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solution (20 mL, 5%w) was added and an orange solid precipitated. It was filtered off and 
dried. The crude material was purified with HPLC. A light yellow solid was obtained (45 mg, 
55%), m.p. 236°C (decomp.). 1H NMR (300 MHz, MeOD): 0.89 (t, J=6.64, 3H), 1.00 – 1.80 
(m, 32H), 3.20 – 3.50 (m, 2H), 6.50 – 6.80 (m, 5H), 6.85 – 8.80 (m, 4H). C39H49NO6: MS 
(LC-MS): m/z(%) [tr1=11.05 min.; tr2=11.16]: 628(100, MH+), 1256(5). Fluorescence (λex. = 
488 nm, MeOH + 10% NaOH(1M)): 527 nm (broad). 
 
3.4.3 Vesicle preparation 
 
In small glass reaction vessels DSPC was dissolved in chloroform and optionally the 
compounds 1a or 1b and 11 - 13 were added (about 1 µmol final lipid concentration). The 
solvent was completely removed under reduced pressure and an appropriate amount of buffer 
(HEPES 25 mM, pH 7.4) was added to obtain a final lipid concentration of 450 µM. Heating 
to 75 °C and vigorous shaking for 5 – 10 minutes yielded a turbid multi-lamellar vesicle 
suspension. Small uni-lamellar vesicles (SUV) were obtained by extrusion through 100 nm-
pore size polycarbonate membranes with a LiposoFast liposome extruder from Avestin 
(Mannheim, Germany).15 PCS measurements were performed on a Malvern Zetasizer 3000 at 
25 °C using 1 cm disposable polystyrene fluorescence cuvettes (VWR). Three subsequent 
measurements of 60 seconds each were performed for each sample. Data analysis was 
performed using the Malvern PCS software. 
For the post-modification of the liposome preparations entry 11 and 12 the thiol 1c (1.0 eq.) 
was added after the extrusion of the liposomes and the mixture was incubated for 24 hours 
prior to testing. 
 
3.4.4 Size exclusion chromatography 
 
Vesicle dispersions were separated from low molecular weight solutes on minicolumns of 
Sephadex LH-20 gel filtration media by a previously described procedure.16 
 
3.4.5 Cell culture and confocal microscopy 
 
MCF-7 cells were cultivated at 37 °C for two days in 8 well µ-slides (Ibidi GmbH, Munich) 
with EMEM medium (Sigma, Deisenhofen, Germany) containing 5% FCS (Biochrom AG, 
Berlin, Germany). Estradiol (1 nM) was added to the cultivation medium to stimulate Y1R 
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expression.12 After two days, shortly before the experiment the medium was replaced by 
Leibovitz L15 medium (LM).  
Confocal microscopy was performed with a Zeiss Axiovert 200M microscope, equipped with 
a LSM 510 laser scanner. The carboxyfluorescein label was excited with a 488 nm laser. The 
emission was detected after a 505 nm long pass filter. The objective was a Plan-Neofluar 
40x/1.3 with oil immersion. 
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CHAPTER 4 
 
Towards the Catalytic Staining of NPY Y1 Receptors on Living 
MCF-7 Cells with DMAP Modified BIBP 3226 Derivatives 
 
   
 
 
4.1 Introduction 
 
G protein-coupled receptors (GPCR) like the neuropeptide Y1 receptor (Y1R) belong to one of 
the major classes of  biological targets in modern medicinal chemistry.1 There are four 
subtypes of the NPY receptor known to date (Y1, Y2, Y4 and Y5).  
Recent investigations concerning the signalling of GPCR´s revealed the importance of 
receptor-protein interactions, e. g. the interaction with β-arrestins2 that can cause receptor 
internalisation or initiate signalling cascades independent of the G protein (biased agonism).2, 
3
 For the investigation of these interactions a fluorescent label at the receptor protein is 
necessary. Fluorescent labeled antagonists were successfully applied for the investigation of 
the NPY Y1 receptor.4 However, these ligands have two disadvantages concerning the 
investigation of receptor-protein interactions: (1) They do not form a covalent bond and can 
dissociate from the receptor. (2) The ligands bind to the same binding site as the agonist NPY 
and inhibit the binding of NPY to the Y1R. 
A covalent labeling of the receptor protein aside the NPY binding site can circumvent this 
problem. Our strategy was to label the Y1R covalently using a catalyzed acyl-transfer 
reaction. This would still allow binding of agonists and antagonists to the labeled Y1R, as the 
binding site of the receptor is not blocked by an Y1R ligand after a washing step. DMAP is a 
well known nucleophilic acyl-transfer catalyst that was successfully applied for the target-
specific acylation of lectins.5, 6 In our investigations DMAP was connected to the potent Y1R 
antagonist BIBP 32267 to obtain catalytically active Y1R ligands. The BIBP 3226 skeleton 
tolerates acylation at the guanidine N-terminus with moderate loss or gain of affinity.8-11   
A fluorescent active ester should then perform the catalytic Y1R specific staining reaction 
(Scheme 1).6 MCF-7 cells were selected as biological target for our experiments, because they 
express a high density of Y1 receptors (40 000 – 300 000 receptors per cell).12  
In this study we synthesized catalytically active antagonists with nanomolar affinity to the 
Y1R and investigated the catalytic staining reaction (acyl-transfer) with simple nucleophiles 
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and with living MCF-7 cells expressing the Y1R. Acyl-transfer to nucleophiles was studied 
with LC-MS and staining of the receptors was monitored with confocal microscopy. 
 
 
 
Scheme 1. Catalytic staining of the Y1R. The Y1R is simplified in this scheme, it is a 
transmembrane receptor with a transmembrane binding pocket (GPCR). In a) the DMAP 
moiety of a catalytic antagonist attacks a fluorescent active ester. A nucleophilic amino acid 
(e.g. lysine) of the receptor protein is acylated in step b).  
 
 
4.2 Results and Discussion 
 
4.2.1 Synthesis and binding affinity of the catalytic active Y1R antagonists 
 
The first step in our approach was to covalently link the highly potent Y1R antagonist BIBP 
3226 1 to the DMAP moiety. The DMAP substructure was derivatized at one of the N-methyl 
groups, because derivatives with longer alkyl chains at the N-amino nitrogen are as active as 
DMAP itself.13 Synthesis started from 4-aminopyridine 2 that was converted to the catalytic 
precursor acid 5 in two steps. This acid was combined with spacers of different length and 
chemical structure to obtain catalytic compounds with adequate properties (high affinity to the 
Y1R and good catalytic activity, table 1). Compound 1a was synthesized according to scheme 
3. Coupling procedures with N-Boc-S-methylisothiourea 6 and guanidinylation reactions with 
compound 8 are described in literature.10, 11 Compounds 1b and 1c were obtained from a 
coupling reaction of the precursor amines 9 and 10 with the acid 5 in moderate yield. The 
compound with the longest spacer 1d was also obtained from precursor amine 9. It was 
coupled in a one pot reaction with the dicarboxylic acid 13 and amine 12. Amine 12 was 
synthesized from acid 5 and the mono-Boc protected 1,3-propyldiamine. The rigid ligand 1e 
was synthesized starting from 1,4-phenylenediamine. It was converted to the diazide 15 and 
followed by a copper catalysed “click-reaction” amine 16b was obtained. Further coupling 
and guanidinylation resulted azide 18. This was transformed in a cycloaddition with the 
propargyl derivative 20 to the rigid Y1R antagonist 1e.     
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The affinity was best for the antagonists 1c and especially for 1d as they were the most 
flexible and least sterically hindered compounds. A close proximity of the pyridine ring to the 
pharmacophore (1a) is unfavorable. 
 
Table 1. Structures and Y1R affinities of the catalytically active compounds 1a-1e. 
 
 
 
 
aKi values determined from the displacement of 1.5 nM [3H]-UR-MK11414 on SK-N-MC cells; all mean values ± 
SEM from two or three independent experiments.  
 
 
 
 
Scheme 2. Synthesis of the precursor 5 of the catalytic substructure. a) methyl acrylate, 
reflux; b) HCl, 76%; c) NaOH, MeOH; d) HCl, 30%.      
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Scheme 3. Synthesis of Y1R antagonists 1a – 1e. a) EDC, HOBt, DIPEA, DCM, 75%; b) 
DMF, HgCl2, NEt3, 36%; c) TFA/DCM 1:1, quantitative yield; d) DMF, DIPEA, TBTU, 67% 
(1b), 47% (1c); e) MeCN, DIPEA, DCC; f) MeOH/HCl 3:1, 36%; g) DMF, DIPEA, TBTU; 
h) MeCN, TFA, 16%. i) NaNO2, H2SO4, NaN3, 66%; j) Boc-propargylamine, 
CHCl3/MeOH/H2O, ascorbate, copper sulphate pentahydrate, 79%; k) DCM/TFA, 
quantitative; l) triphosgene, DCM, DIPEA; N-Boc-S-methyl-isothiourea, DCM, 46%; m) 
Compound 8, DMF, NEt3, HgCl2, 57%; n) DCM/TFA, quantitative; o) THF, n-BuLi, 
propargylbromide, 10%; p) DMSO, MeOH, H2O, ascorbate, copper sulphate pentahydrate,   
51%.  
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4.2.2 Synthesis and investigation of active esters 
 
For the catalytic staining reaction of the receptors we prepared active esters that can be 
activated with DMAP easily. Two types of fluorescent dyes were modified for their 
application as acyl-donors: the carboxyfluorescein and the cyanine scaffold (Figure 1). 
Compound 23 was prepared according to the procedure of Hamachi and coworkers.6 The 
thiophenolester 26 and the p-nitrophenolester 27 were synthesized from the commercially 
available cyanine dye 24 in one coupling step.  
 
 
 
Figure 1. Structures of the acyl-donors based on the carboxyfluorescein and the cyanine dye 
scaffold  
 
Before we started staining the MCF-7 cells, we investigated the hydrolysis kinetics of the 
active esters 22, 25 and 27 and the acyl-transfer of the Y1R ligands to simple nucleophiles in 
buffered aqueous solution at pH 7.4. For the measurements of the hydrolysis kinetics the dyes 
were incubated at 50 µM for 3 hours in phosphate buffer (30 mM) at pH 7.4. In a second 
series they were incubated with additional 50 µM DMAP. Samples were taken after 30, 90 
and 150 minutes. The amount of decomposition was determined with HPLC (figure 2).    
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Figure 2. Diagram A: Hydrolysis of thiophenolester 22 (red) and p-nitropenolester 27 (blue) 
both 50 µM in presence (solid line) and absence (dashed line) of 50 µM DMAP. Diagram B: 
Hydrolysis graph of NHS ester 25 (50 µM) in presence (solid line) and absence (dashed line) 
of DMAP. 
 
The acceleration of the hydrolysis with DMAP was most significant for thiophenolester 22 
(about 400 % after 150 minutes) and only moderate for p-nitrophenolester 27 (60 %) and 
NHS ester 25 (48 %). Also the hydrolysis rates are not directly comparable to the acyl-
transfer reaction rate to other nucleophiles, it indicates a superior selectivity of the thioester 
compared to the p-nitrophenol and the NHS ester. Active ester reactivity correlates with the 
acidity of the corresponding acid: pKa(NHS): 6.015; pKa(p-nitrophenol): 7.415; 
pKa(thiophenol): 8.316.  
 
 
4.2.3 Acyl-transfer studies  
 
Intermolecular interactions at the cell surface are rather complex. Therefore we studied first 
the catalysed acyl-transfer to simple nucleophiles in buffered aqueous solution optimizing the 
reaction conditions. Incubation of the catalytic compound 1a and the active ester 25 in 
solution and subsequent HPLC analysis demonstrated the complete decomposition of 1a to 
compound 30 after an incubation time of 3 hours. As described in literature acyl-guanidines 
are labile against intra-molecular cleavage.11, 17 We assume the formation of diacylguanidine 
29 (Scheme 4) and fast hydrolysis of this labile intermediate.18 In contrast the catalytic 
compound 1b was not degraded after the incubation with the active ester. The guanidine-
carbamoyl substructure prevents cleavage of the DMAP moiety, because of the electron 
donating effect of the second N-atom at the acyl-guanidine carbon. After the incubation 
period of 3 hours compound 1b and compound 32 were detected by LC-MS. Therefore acyl-
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guanidine 1a was not applicable for the staining reaction, but the more stable carbamoyl-
guanidines 1b – 1e are promising compounds. However, the fast intramolecular self-acylation 
of these compounds competes with the acyl-transfer to other nucleophiles and increases the 
hydrolysis rate of the active ester. The catalytic Y1R antagonist 1e was designed to 
circumvent this problem. The long and rigid spacer between the DMAP moiety and the BIBP 
3226 scaffold prevents the intramolecular self-acylation.  
 
 
 
 
Scheme 4. Self-acylation of the BIBP 3226 scaffold depicted for the Y1R antagonists 1a and 
1b with NHS ester derivative 25. In the case of antagonist 1a the catalytic self-acylation and 
following hydrolysis of the diacyl-guanidine leads to a fast formation of compound 30. In 
case of compound 1b the catalytic DMAP moiety was not cleaved. 
 
 
Catalytic acyl-transfer to small nucleophiles was tested for the Y1R antagonists 1b – 1e. 2-
(Dimethylamino)ethylamine (DMAEA), n-butanol and BIBP 3226 (BIBP) were used as 
nucleophiles. They represent the most common nucleophilic residues in proteins (amine for 
lysine, butanol for serine and threonine, BIBP 3226 for arginine and tyrosine). The NHS ester 
25 was tested exemplarily as acyl-donor. It was incubated 30 minutes with catalyst and 
nucleophile, the acylation products were detected with LC-MS measurements.  
 
The hydrolysis rate of active ester 25 was accelerated in entry 2 – 6 (catalysed) compared 
with entry 1 (uncatalysed). Antagonists 1b – 1e were even more active as DMAP itself and 
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consumed NHS ester 25 completely (entry 3-5) or almost completely (entry 6). Acyl-transfer 
to BIBP 3226 was increased by adding the catalysts (entry 8 – 11) compared to the 
uncatalysed reaction (entry 7). The sterically hindered catalyst 1e still forms an appreciable 
amount of the catalyst-dye byproduct (entry 6, 11, 13, 15). Due to the rigid structure we 
suggest the sideproduct is formed via an intermolecular attack of another molecule of 1e. The 
primary alcohol n-butanol was not attacked by the active ester (entry 14, 15) due to its weak 
nucleophilic properties. 
In summary the catalysts 1b – 1e were promising candidates for the catalytic staining of 
biological targets despite their self-acylation: the BIBP 3226 scaffold binds tightly to the Y1R 
binding pocket and should prevent self-acylation during the nucleophilic attack of the DMAP 
moiety.  
 
Table 2. Catalysed and uncatalysed acyl-transfer of NHS ester 25 to small nucleophiles 
(product yields were not quantified, the peak heights show only detected products and 
reaction tendencies) 
 
    
 (% rel. peak height) after 30 minutes incubation timea 
entry active 
 ester 
catalyst nucleophile free acid  
(hydrolysis 
product) 
active 
 ester 
(educt) 
catalyst-dye 
(byproduct) 
structure 32 
nucleophile-
dye (product) 
structure 33 
1 25 - Water 79 21 - - 
2 25 DMAP Water 92 8 - - 
3 25 1b Water 78 0 22 - 
4 25 1c Water 83 0 17 - 
5 25 1d Water 83 0 17 - 
6 25 1e Water 75 4 21 - 
7 25 - BIBP 57 19 - 24 
8 25 1b BIBP 55 0 11 34 
9 25 1c BIBP 47 0 13 40 
10 25 1d BIBP 45 0 15 40 
11 25 1e BIBP 42 0 8 50 
12 25 - DMAEA 58 13 - 29 
13 25 1e DMAEA 74 0 13 13 
14 25 - n-butanol 77 23 - - 
15 25 1e n-butanol 82 4 14 - 
[a] relative fraction of the compounds in percent (the sum of all four peak heights = 100) 
 
 
 
4.2.4 Catalytic Staining of MCF-7 cells  
 
The active esters 23, 25 - 27 were also attacked by cell-nucleophiles without catalyst, so we 
first monitored the uncatalysed staining of MCF-7 cells. The cells were incubated with 10 µM 
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of active ester and stained for 15 – 60 minutes in PBS (pH 7.4). The thioesters 23 and 26 were 
not applicable for the staining of the Y1R of MCF-7 cells, because they pass the cell 
membrane and accumulate in the cell (exemplarily shown for thioester 26 in Figure 3). The p-
nitropenol ester 27 penetrated the membrane to a significantly lower extent and the NHS ester 
25 proved to be the most applicable active ester, as is can not pass the membrane.  
For the catalytic staining reaction the cells were pre-incubated with the corresponding 
catalytic antagonist, washed with buffer and incubated with the NHS ester 25. This is 
exemplarily shown for the antagonists 1c and 1d. Compared with the non-catalysed staining 
reaction there is no difference visible in the confocal microscopy pictures (Figure 4). The 
fraction of nucleophiles belonging to the Y1R compared with the total amount of nucleophiles 
on the surface of a cell is very small, so the unspecific staining of the cell membranes is a 
problem.    
 
 
 
 
     
 
Figure 3. Picture A: cells were incubated with 20 µM NHS ester 25 for 30 min. Picture B: 10 
µM p-nitrophenol ester 27, 30 min. Picture C: 10 µM thiophenolester 26, 30 min. 
 
 
     
 
 
Figure 4. Pictures D and E: cells were preincubated with 200 nM 1c (D) or 1d (E). 
Subsequently the cells (pictures D – F) were washed and stained with 10 µM NHS ester 25 
for 30 minutes. Pictures were taken after washing the cells with buffer. The fluorescent 
appearance of the catalytically stained cells (D, E) is similar to the non-specific stained cells 
(F).   
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4.3 Conclusion 
 
In this study we successfully prepared catalytically active derivatives of the Y1 receptor 
antagonist BIBP 3226 that exhibited a nanomolar affinity to the NPY Y1 receptor. The acyl-
transfer of active esters to nucleophiles was studied in absence and presence of the catalysts. 
A serious problem was the self-acylation at the catalysts guanidine moiety (32). This 
intramolecular reaction is very fast and is the main reaction in absence of good nucleophiles 
in aqueous solution. The self-acylation was also observed for the rigid compound 1e due to an 
intermolecular reaction. In the cell studies the BIBP moiety is tightly bound to the binding 
pocket of the Y1R and self-acylation is therefore probably reduced. The NHS ester 25 was the 
most applicable staining reagent for MCF-7 cells and was not able to enter the cells (Figure 3, 
A). However, there was no visible difference between the catalysed and uncatalysed staining 
reaction (Figure 4, D and E vs. F). The high reactivity of the NHS ester towards nucleophiles 
caused unspecific staining of the cell membrane. The investigation of more selective staining 
reagents and catalysts that do not interfere with other nucleophiles on the cell membrane is an 
aim for further studies. This approach is not restricted to the NPY field and with modification 
of the pharmacophore moiety a broad variety of catalytically active antagonists for G protein-
coupled receptors can be envisaged.  
 
 
4.4 Experimental 
 
4.4.1 General experimental conditions 
 
Unless otherwise noted, solvents (analytical grade) were purchased from commercial 
suppliers and used without further purification. Ethyl acetate (EA), petrol ether (PE, 60 – 70  
°C), methanol and dichloromethane were obtained in technical grade and distilled before 
application. Acetonitrile (MeCN) for HPLC was obtained from Merck (Darmstadt, Germany). 
Cyanine dye S0436 and NHS ester S0536 (FEW Chemicals, Bitterfeld-Wolfen, Germany), 4-
(methylamino)pyridine (Alfa Aesar, Karlsruhe, Germany), methylacrylate (Merck, Darmstadt, 
Germany), 3,6,9-trioxaundecanedioic acid (Fluka, Sigma-Aldrich Chemie GmbH, Munich, 
Germany), 1,4-diaminobenzene (Fluka, Sigma-Aldrich Chemie GmbH, Munich, Germany), 
butyllithium (Fluka, Sigma-Aldrich Chemie GmbH, Munich, Germany) and 
propargylbromide (Fluka, Sigma-Aldrich Chemie GmbH, Munich, Germany) were purchased. 
Preparative HPLC was performed with a system from Knauer (Berlin, Germany) consisting of 
two K-1800 pumps and a K-2001 detector. A Nucleodur 100-5 C18 (250 × 21 mm, 5 µm; 
Macherey-Nagel, Germany) and a Eurospher-100 C18 (250 × 32 mm, 5 µm; Knauer, 
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Germany) served as RP-columns at flow rates of 20 and 38 mL/min, respectively. Mixtures of 
MeCN and diluted aqueous TFA (0.1 %) were used as mobile phase. 1H-NMR spectra were 
recorded at 300 MHz on a Bruker Avance 300 spectrometer or at 600 MHz on a Bruker 
Avance III 600 with cryogenic probehead (Bruker, Karlsruhe, Germany). 13C-NMR spectra 
were recorded at 75 MHz on a Bruker Avance 300 spectrometer. All chemical shifts values 
are reported in ppm. UV/VIS spectra were recorded with a Varian Cary BIO 50 UV/VIS/NIR 
spectrophotometer (Varian Inc., CA, USA). Mass spectra: Finnigan SSQ 710A (EI), Finnigan 
MAT 95 (CI), Finnigan MAT TSQ 7000 (Thermo FINNIGAN, USA) (ES/LC-MS). LC-
system for LC-MS: Agilent 1100 (Palo Alto, USA). LC-MS method I (LC-MS-I): Column: 
Phenomex Luna C18, 3.0 µm, 100 x 2 mm HST (Phenomenex, Aschaffenburg, Germany); 
flow: 0.30 mL/min; solvent A (water + 0.1% TFA), solvent B (MeCN); gradient: 0 min [A/B 
95/5], 1 min [A/B 95/5], 11 min [A/B 2/98], 18 min [A/B 2/98], 19 min [A/B 95/5], 24 min 
[A/B 95/5]. LC-MS method II: Column: Phenomex Luna C18, 2.5 µm, 50 x 2 mm HST 
(Phenomenex, Aschaffenburg, Germany); flow: 0.40 mL/min; solvent A (water + 0.1% TFA), 
solvent B (MeCN); gradient: 0 min [A/B 95/5], 8 min [A/B 2/98], 11 min [A/B 2/98], 12 min 
[A/B 95/5], 15 min [A/B 95/5]. Melting points were determined with a Lambda Photometrics 
Optimelt MPA100 apparatus (Lambda photometrics, Harpenden, UK), they are not corrected. 
Thin layer chromatography (TLC) was performed on alumina plates coated with silica gel 
(Merck silica gel 60 F245, thickness 0.2 mm). Column chromatography (CC) was performed 
with Merck Geduran SI 60 silica gel as the stationary phase.  
Compounds 413, 513, 610, 814, 918, 1018, 1119, 2120, 21, 226, 236 and Boc-propargylamine22 were 
prepared according to literature procedures. The synthesis of literature known compound 1523 
was improved.   
 
 
 
4.4.2 Synthetic protocols and analytical data 
 
tert-Butyl-{3-[methyl(pyridin-4-yl)amino]propanamido}(methylthio)methylene-
carbamate (7) 
Acid 5 (216 mg, 1.00 mmol), DIPEA (258 mg, 2.00 mmol) and HOBt (149 mg, 1.10 mmol) 
were dissolved in 10 mL cold DCM and EDC (171 mg, 1.10 mmol) was added. After 15 
minutes compound 6 (190 mg, 1.00 mmol) was added. The mixture was stirred overnight. 
Next day the reaction mixture was concentrated and the crude product was purified with 
column chromatography (EA/EtOH 1:1, Rf=0.1). Compound 7 (323 mg, 75%) was obtained 
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as a colorless oil. 1H NMR (300 MHz, CDCl3): 1.48 (s, 9H), 2.36 (s, 3H), 2.79 (t, J=6.87, 
2H), 3.14 (s, 3H), 3.83 (t, J=6.88, 2H), 6.65 – 6.75 (m, 2H), 8.10 – 8.20 (m, 2H), 9.00 – 13.00 
(m, 2H). 13C NMR (75 MHz, CDCl3): 14.7, 27.9, 31.7, 38.6, 48.0, 79.9, 106.8, 141.5, 141.8, 
143.5, 156.0, 170.8. C16H24N4O3S: MS (LC-MS-I): m/z(%) [tr=8.1 min.]: 353(100, MH+), 
705(5). 
 
(R)-4-((3-((4-(2,2-Diphenylacetamido)-5-(4-hydroxybenzylamino)-5-
oxopentylamino)(iminio)methylamino)-3-oxopropyl)(methyl)amino)pyridinium 2,2,2-
trifluoroacetate (1a) 
Compound 7 (123 mg, 0.35 mmol) was dissolved in 4 mL DMF and mixed with compound 8 
(170 mg, 0.35 mmol). NEt3 (0.5 mL) was added and then a solution of HgCl2 (95 mg, 0.35 
mmol) in 1 mL DMF was dropped into the reaction mixture. The mixture was stirred 
overnight. The next day DMF was evaporated under high vacuum and DCM (5 mL) was 
added. The insoluble mercury salts were filtered off and the solution was concentrated. The 
crude material was purified with column chromatography (EA/EtOH 1:1).  
The product was deprotected without further characterisation: a mixture of DCM/TFA (1:1; 4 
mL) was added and the solution was stirred for 2 hours. Then it was concentrated and purified 
with HPLC. A white solid was obtained (109 mg, 36%), m.p. > 190° C (decomp.). 1H NMR 
(300 MHz, CD3CN): 1.40 – 1.90 (m, 4H), 2.78 (t, J=7.05, 2H), 3.15 (s, 3H), 3.15 – 3.30 (m, 
2H), 3.85 (t, J=7.06, 2H), 4.10 – 4.30 (m, 2H), 4.30 – 4.40 (m, 1H), 5.02 (s, 1H), 6.60 – 7.20 
(m, 4H), 6.71 (d, J=8.54, 2H), 7.03 (d, J=8.50, 2H), 7.20 – 7.35 (m, 10H), 7.96 (bs, 2H), 9.47 
(bs, 1H), 9.95 (bs, 1H), 12.13 (bs, 1H), 13.37 (bs, 1H). C36H43N7O4: MS (LC-MS-I): m/z(%) 
[tr=7.6 min.]: 318(100), 339(35), 636(50, MH+).  
 
(R)-4-((4-(2,2-Diphenylacetamido)-1-(4-hydroxyphenyl)-9-iminio-3,11,18-trioxo-
2,8,10,12,17-pentaazaicosan-20-yl)(methyl)amino)pyridinium 2,2,2-trifluoroacetate (1b) 
The acid 5 (5.6 mg, 26 µmol) was dissolved in DMF (2 mL) and DIPEA (28 mg, 0.21 mmol) 
and TBTU (8.3 mg, 26 µmol) were added. After 10 minutes amine 9 (20 mg, 22 µmol) was 
added. The mixture was stirred overnight. The next day DMF was removed under high 
vacuum and the oily residue was  purified with HPLC. A white solid was obtained (14 mg, 
67%), m.p. > 190°C (decomp.). 1H NMR (300 MHz, CD3CN): 1.30 – 1.80 (m, 8H), 2.00 – 
2.80 (m, 2H), 3.10 (s, 3H), 3.10 – 3.30 (m, 6H), 3.80 (t, J=6.45, 2H), 4.10 – 4.40 (m, 3H), 
5.03 (s, 1H), 6.50 – 7.90 (m, 8H), 6.67 (d, J=8.45, 2H), 7.00 (d, J=8.45, 2H), 7.20 – 7.35 (m, 
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10H), 7.90 – 8.05 (m, 2H), 9.00 – 9.20 (bs, 1H), 11.90 – 13.00 (m, 1H). C41H51N9O5: MS 
(LC-MS-II): m/z(%) [tr=4.9 min.]: 375(100), 750(30, M+). 
 
(R)-4-((4-(2,2-Diphenylacetamido)-1-(4-hydroxyphenyl)-9-iminio-3,11,22-trioxo-15,18-
dioxa-2,8,10,12,21-pentaazatetracosan-24-yl)(methyl)amino)pyridinium 2,2,2-
trifluoroacetate (1c) 
Acid 5  (3.0 mg, 13.7 µmol) was dissolved in DMF (2 mL) and DIPEA (14.7 mg, 114 µmol) 
and TBTU (4.4 mg, 13.7 µmol; dissolved in 0.2 mL MeCN) were added. After 10 minutes 
amine 10 (10 mg, 11.4 µmol) was added. The solution was stirred overnight. Next day DMF 
was removed completely and the oily residue was suspended in some MeCN (1 mL). TFA 
was added until pH < 2. MeCN was evaporated and the crude material was purified with 
HPLC. A white solid was obtained (5.5 mg, 47%), m.p. > 190°C (decomp.). 1H NMR (300 
MHz, D2O): 1.20 –1.80 (m, 4H), 2.38 (t, J=6.59, 2H), 2.93 (s, 3H), 3.03 (t, J=7.28, 2H), 3.13 
(t, J=5.41, 2H), 3.25 (t, J=5.16, 2H), 3.34 (t, J=5.39, 2H), 3.40 – 3.55 (m, 6H), 3.64 (t, J=6.61, 
2H), 4.00 – 4.10 (m, 1H), 4.10 – 4.25 (m, 2H), 5.01 (s, 1H), 6.55 – 6.85 (m, 6H), 6.92 – 7.00 
(d, J=8.53, 2H), 7.00 – 7.10 (m, 2H), 7.10 – 7.30 (m, 8H), 7.82 (d, J=7.29, 2H). C43H55N9O7: 
MS (LC-MS-II): m/z(%) [tr=4.98 min.]: 405(100), 810(10, MH+). 
 
4-((3-(3-Ammoniopropylamino)-3-oxopropyl)(methyl)amino)pyridinium chloride (12) 
Acid 5 (216 mg, 1.00 mmol) was dissolved in MeCN (10 mL) and DIPEA (271 mg, 2.10 
mmol) was added. The mixture was cooled in an icebath and DCC (227 mg, 1.10 mmol) was 
added. After 15 minutes amine 11 (174 mg, 1.00 mmol) was added. The turbid reaction 
mixture was stirred at room temperature for five hours and then the mixture was heated to 
50°C for 30 minutes. After that time MeCN was evaporated completely and the residue 
(viscous oil) was redissolved in DCM. The precipitate (DCU) was filtered off and the crude 
material was purified with column chromatography (EA/MeOH 9:1 + 1% NEt3, Rf=0.05). The 
Boc-protected, purified white solid (134 mg, 40%) was deprotected with a 3:1 mixture of 
methanol and concentrated hydrochloric acid (4 mL). After complete deprotection (10 
minutes, room temperature) the solvent was evaporated, water was added (2-3 mL) and the 
solution was lyophilized overnight. A white solid was obtained (110 mg, 36% overall), m.p. > 
190°C (decomp.). 1H NMR (300 MHz, D2O): 1.60 – 1.75 (m, 2H), 2.51 (t, J=6.61, 2H), 2.82 
(t, J=7.62, 2H), 3.00 – 3.15 (m, 5H), 3.78 (t, J=6.61, 2H), 6.70 – 7.00 (bs, 2H), 7.93 (d, 
J=7.48, 2H). C12H20N4O: MS (LC-MS-II): m/z(%) [tr=0.31 min.]:  119(5), 139(65), 160(100), 
237(65, MH+).  
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(R)-4-((4-(2,2-Diphenylacetamido)-1-(4-hydroxyphenyl)-9-iminio-3,11,18,28,34-
pentaoxo-20,23,26-trioxa-2,8,10,12,17,29,33-heptaazahexatriacontan-36-
yl)(methyl)amino)pyridinium 2,2,2-trifluoroacetate (1d) 
Acid 5 (6.6 mg, 30 µmol) was dissolved in DMF (2 mL) and DIPEA (35 mg, 270 µmol) and 
TBTU (18.9 mg, 59 µmol) were added. After 10 minutes the reaction was started with the 
addition of the compounds 9 (25.0 mg, 27 µmol) and 12 (8.3 mg, 27 µmol). The reaction 
mixture was stirred overnight. Next day DMF was removed completely and the oily residue 
was suspended in some MeCN (1 mL). TFA was added until pH < 2. MeCN was evaporated 
and the crude mixture was purified with HPLC. A white solid was obtained (5.5 mg, 16%), 
m.p. > 190°C (decomp.). 1H NMR (300 MHz, D2O):  1.25 – 1.90 (m, 10H), 2.44 (t, J=6.48, 
2H), 2.90 – 3.20 (m, 13H), 3.50 – 3.60 (m, 8H), 3.72 (t, J=6.48, 2H), 3.89 (d, J=1.70, 4H), 
4.05 – 4.15 (m, 1H), 4.15 – 4.30 (m, 2H), 5.05 (s, 1H), 6.60 – 6.90 (m, 4H), 6.95 – 7.30 (m, 
12H), 7.87 (d, J=7.52, 2H). C52H71N11O10: MS (LC-MS-II): m/z(%) [tr=4.99 min.]: 505(100), 
1010(5, MH+). 
 
1,4-Diazidobenzene (15) 
NaNO2 (1.45 g, 21 mmol) was suspended in 10 mL concentrated sulphuric acid at 10°C in 
small amounts. The mixture was stirred 10 minutes at 20°C and then heated to 70°C until a 
clear solution was obtained. The mixture was cooled to 10°C and 1,4-diaminobenzene (1.08 
g, 10 mmol) dissolved in 10 mL glacial acetic acid was dropped slowly into the mixture. A 
yellow solid precipitated. The mixture was stirred one hour at 15°C. After that time the 
mixture was dropped in a 500 mL flask containing 150 mL icecold water (with ice). A clear, 
yellow solution was obtained. NaN3 (1.43 g, 22 mmol) dissolved in 10 mL water was added 
dropwise at 5°C under vigorous stirring (caution: HN3 gas can develop). Nitrogen was formed 
and a yellow solid precipitated. After 2 hours the product was extracted with EA (2 x 75 mL). 
The organic layer was separated and dried over MgSO4. The solvent was concentrated and the 
crude material was recrystallized in PE. Yellow crystalls were obtained (1.06 g, 66%), m.p. 
155°C (decomp.). 
 
tert-Butyl [(1-(4-azidophenyl)-1H-1,2,3-triazol-4-yl)methyl]carbamate (16a) 
1,4-Diazidobenzene (500 mg, 3.13 mmol) was dissolved in 5 mL of CHCl3 and was added to 
a solution of  Boc- propargylamine (484 mg, 3.13 mmol) in 5 mL of MeOH. Then ascorbic 
acid (55 mg, 0.31 mmol, dissolved in 0.5 mL of H2O) and CuSO4 ⋅ 5 H2O (40 mg, 0.16 mmol; 
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dissolved in 0.5 mL of H2O) were added. The mixture was stirred at 60 °C for 1 hour. EA (50 
mL) and water (50 mL) were added and the organic layer was separated. The mixture was 
concentrated and a white solid precipitated (double coupled side product). The precipitate was 
filtered off and the remaining solution was concentrated and purified with column 
chromatography (PE/EA 2:3, Rf=0.5). The product was obtained as a white solid (782 mg, 
79%), m.p. 155 °C (160 °C decomp.). 1H NMR (300 MHz, CDCl3): 1.45 (s, 9H), 4.47 (d, 
J=6.03, 2H), 5.20 (bs, 1H), 7.10 – 7.20 (m, 2H), 7.65 – 7.75 (m, 2H), 7.94 (s, 1H). 13C NMR 
(75 MHz, CDCl3): 28.4, 36.1, 79.9, 120.2, 122.0, 132.1, 133.8, 140.7, 146.4, 155.9. 
C14H17N7O2: MS (LC-MS-II): m/z(%) [tr=3.57 min.]: 216(100, M*H+), 257(20), 431(25). 
The compound was completely Boc-deprotected during LC-MS.  
 
(1-(4-Azidophenyl)-1H-1,2,3-triazol-4-yl)methanaminium 2,2,2-trifluoroacetate (16b) 
Compound 16a (287 mg, 0.91 mmol) was deprotected with a 2:1 mixture of DCM and TFA 
(6 mL). The mixture was stirred for 1h and then the solvent was removed. Water was added 
(5 mL) and the solution was lyophilized. A white solid was obtained (300 mg, quantitative), 
m.p. 157 °C (decomp.). 1H NMR (300 MHz, D2O): 4.36 (s, 2H), 7.14 – 7.17 (m, 2H), 7.63 – 
7.66 (m, 2H), 8.44 (s, 1H). 13C NMR (75 MHz, D2O): 33.9, 120.0, 122.1, 123.4, 132.6, 140.3, 
140.9. C9H9N7: MS (LC-MS-II): m/z(%) [tr=3.57 min.]: 216(100, MH+), 257(20), 431(25). 
IR (ν [cm-1]): 3166, 2757, 2136 (N3), 2095 (N3), 1711, 1618, 1555, 1514.  
 
tert-Butyl (3-((1-(4-azidophenyl)-1H-1,2,3-triazol-4-yl)methyl)ureido) (methylthio) 
methylenecarbamate (17) 
Triphosgene (71 mg, 0.24 mmol) was dissolved in icecold DCM (10 mL) and a solution of 
compound 16b (200 mg, 0.61 mmol) and DIPEA (285 mg, 2.21 mmol) was dropped slowly 
(20 minutes) at 0°C into the triphosgene solution. After complete addition the reaction was 
allowed to warm up to ambient temperature and a solution of Boc-S-methyl-isothiourea 6 
(116 mg, 0.61 mmol) in DCM (10 mL) was added over a period of 10 minutes. The mixture 
was stirred overnight at ambient temperature. The next day the reaction mixture was 
concentrated and the crude material was purified with column chromatography (PE/EA 3:1 -> 
2:3) [Rf=0.3 (PE/EA 3:2)]. A light yellow solid was obtained (122 mg, 46%), m.p. 126 °C 
(162 °C decomp.). 1H NMR (300 MHz, CDCl3): 1.48 (s, 9H), 2.29 (s, 3H), 4.58 (d, J=6.19, 
2H), 6.23 (t, J=5.49, 1H), 7.10 – 7.20 (m, 2H), 7.75 – 7.75 (m, 2H), 7.97 (s, 1H), 12.19 (bs, 
1H). C17H21N9O3S : MS (LC-MS-II): m/z(%) [tr=7.83 min.]: 432(100, MH+), 863(40). 
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(R)-1-(1-(4-Azidophenyl)-1H-1,2,3-triazol-4-yl)-10-(4-hydroxybenzylcarbamoyl) 
-3,12-dioxo-13,13-diphenyl-2,4,6,11-tetraazatridecan-5-iminium 2,2,2-trifluoroacetate 
(18) 
Compound 17 (101 mg, 0.23 mmol), compound 8 (114 mg, 0.23 mmol) and NEt3 (230 mg, 
2.3 mmol) were dissolved in 3 mL DMF. HgCl2 (64 mg, 0.23 mmol) was dissolved in 0.5 mL 
of DMF and added to the mixture. The mixture was stirred overnight. Next day DMF was 
removed completely and the residue was dissolved in 5 mL DCM. Hg-salts were filtered off 
and the crude material was purified with column chromatography (PE/EA 7:3, Rf=0.4). The 
compound was deprotected without further characterization. DCM/TFA was added (1:1 
mixture, 4 mL) and the mixture was stirred for 2 hours. Then it was concentrated and the 
crude material was purified with HPLC. A white solid was obtained (112 mg, 57%), m.p. > 
190° C (decomp.). 1H NMR (600 MHz, DMSO-d6): 1.35 – 1.48 (m, 2H), 1.48 – 1.70 (m, 
2H), 3.10 – 3.25 (m, 2H), 4.05 – 4.20 (m, 2H), 4.30 – 4.35 (m, 1H), 4.46 (d, J=5.29, 2H), 5.12 
(s, 1H), 6.67 (d, J=8.45, 2H), 7.00 (d, J=8.45, 2H), 7.15 – 7.30 (m, 10H), 7.30 – 7.35 (m, 2H), 
7.88 – 7.92 (m, 2H), 8.13 (bs, 1H), 8.36 (t, J=5.80, 1H), 8.37 – 8.46 (bs, 1H), 8.47 (d, J=8.11, 
1H), 8.67 (s, 1H), 8.89 (bs, 1H), 9.28 (s, 1H), 9.73 (bs, 1H). 13C NMR (HSQC, HMBC, 
ROESY) (151 MHz, DMSO-d6): 24.55, 29.42, 34.82, 41.58, 52.23, 55.88, 114.97, 120.47, 
121.10, 121.59, 126.56, 128.13, 128.17, 128.38, 128.46, 128.48, 129.11, 133.46, 139.70, 
140.24, 140.42, 156.23, 170.93, 170.98. C37H38N12O4: MS (LC-MS-II): m/z(%) [tr=6.01 
min.]: 715(100, MH+). UV (MeCN): λ(ε) 272 (20⋅103). IR (ν [cm-1]): 3277, 2130 (N3), 2100 
(N3), 1686, 1638, 1542, 1512, 1446, 1364.     
 
4-(Methyl(prop-2-ynyl)amino)pyridinium chloride (20) 
N-Methylpyridin-4-amine 19 (200 mg, 1.85 mmol) was dissolved in 5 mL of dry THF. Then a 
BuLi solution (1.6M in hexanes; 1.4 mL, 2.22 mmol) was added at room temperature under 
nitrogen. After 10 minutes, when no more gas was formed, a propargylbromide solution 
(80%w in toluene; 330 mg, 2.22 mmol) was added slowly at –5°C over a period of 1h. The 
mixture was stirred overnight. The next day water was added (5 mL) and then THF was 
removed completely under reduced pressure. NaOH (1M, 20 mL) and EA (20 mL) were 
added and the organic layer was collected. Organic phase was acidified with NaHSO4 solution 
(20 mL, 5%w) and the aqueous layer was collected. NaOH (1M, 40 mL) and EA (40 mL) 
were added and the organic layer was collected. The organic layer was washed several times 
with water until not converted N-methylpyridin-4-amine 19 was removed completely. The 
organic layer was dried over MgSO4 and the solvent was removed. A brown oil was obtained. 
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Diluted hydrochloric acid (10%) was added dropwise until pH < 2. A yellow precipitate was 
formed. It was collected and recrystallized with CHCl3/PE. Light yellow-brown crystalls were 
obtained (33 mg, 10%), m.p. 193 °C (decomp.).  1H NMR (300 MHz, D2O): 2.63 (t, J=2.47, 
1H), 3.15 (s, 3H), 4.26 (d, J=2.47, 2H), 6.92 (d, J=7.26, 2H), 8.00 (d, J=7.67, 2H). 13C NMR 
(75 MHz, D2O): 38.0, 41.5, 74.1, 77.0, 107.8, 138.9, 157.3. C9H10N2: MS (LC-MS-II): 
m/z(%) [tr=0.56 min.]: 147(100, MH+), 188(10), 293(10). 
 
(R)-4-(((1-(4-(4-(10-(4-Hydroxybenzylcarbamoyl)-5-iminio-3,12-dioxo-13,13-diphenyl-
2,4,6,11-tetraazatridecyl)-1H-1,2,3-triazol-1-yl)phenyl)-1H-1,2,3-triazol-4-
yl)methyl)(methyl)amino)pyridinium 2,2,2-trifluoroacetate (1e) 
Compound 18 (10 mg, 12.1 µmol) was dissolved in 0.5 mL of DMSO and alkyne 20 (2.2 mg, 
12.1 µmol) was added. The solution was diluted with a of 3:1 mixture of MeOH and H2O (0.5 
mL). Then ascorbic acid (1.1 mg,  6.1 µmol [stock solution 100 mg/mL in 1M NaOH]) and 
CuSO4 ⋅ 5 H2O (0.91 mg, 3.6 µmol [stock solution 100 mg/mL in H2O]) were dropped into 
the mixture. Copper (I) stabilizing ligand 21 (0.8 mg, 1.21 µmol) was added and the mixture 
was heated to 65 °C for 1h. After that time TLC control demonstrated complete conversion. 
TFA was added until pH < 2 and the crude material was purified with HPLC. A white solid 
was obtained (6.7 mg, 51%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, DMSO-d6): 1.35 
– 1.75 (m, 4H), 3.15 – 3.25 (m, 2H), 3.32 (s, 3H), 4.05 – 4.25 (m, 2H), 4.25 – 4.40 (m, 1H), 
4.40 – 4.55 (m, 2H), 5.02 (s, 2H), 5.12 (s, 1H), 6.67 (d, J=8.45, 2H), 7.00 (d, J=8.45, 2H), 
7.05 – 7.40 (m, 12H), 8.05 – 8.20 (m, 5H), 8.25 – 8.60 (m, 6H), 8.81 (s, 1H), 8.91 (bs, 1H), 
8.96 (s, 1H), 9.30 (s, 1H), 9.86 (bs, 1H), 13.44 (bs, 1H). C46H58N14O4: MS (LC-MS-II): 
m/z(%) [tr=5.18 min.]: 431(100), 861(5, MH+), 975(2).    
 
S0436-thiophenolester (26)  
Compound 24 (3.00 mg, 4.96 µmol) was mixed with DIPEA (1.92 mg, 14.9 µmol), DMAP 
(0.06 mg, 0.49 µmol) and TBTU (1.91 mg, 5.95 µmol). After 10 minutes the reaction was 
started with the addition of thiophenole (0.65 mg, 5.95 µmol). Next day DMF was removed 
completely and the crude material was purified with HPLC. A blue solid was obtained (2.40 
mg, 69%). C41H49N2O4S2: MS (LC-MS-II): m/z(%) [tr=7.87]: 697(100, M+), 1395(15). 
 
S0436-p-nitrophenolester (27) 
Compound 24 (2.70 mg, 4.46 µmol) was dissolved in in 1 mL of DMF and DIPEA (2.7 mg, 
21 µmol) was added. Then bis(4-nitrophenyl) carbonate (3.1 mg, 10.20 µmol) was added. The 
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mixture was stirred overnight at room temperature. The next day DMF was removed 
completely and the residue was purified with HPLC. A blue solid was obtained (2.90 mg, 
91%). C41H48N3O7S: MS (LC-MS-II): m/z(%) [tr=7.61]: 726(100, M+). 
 
4.4.3 Radioligand competition binding assay 
 
Radioligand competition experiments at SK-N-MC neuroblastoma cells using the radioligand 
[3H]UR-MK114 (1.5 nM) were performed as described elsewhere.14  
 
4.4.4 Fura-2 assay on HEL cells 
 
The Fura assay was performed with HEL cells as previously described using a Perkin-Elmer 
LS50 B spectrofluorimeter (Perkin Elmer, Überlingen, Germany).24  
 
4.4.5 Active ester kinetics 
 
The acyl-transfer studies were performed in 2 mL Eppendorf Cups. 285 µL phosphate buffer 
(30 mM, pH 7.4) was put into the cups. Stock solutions of the active esters (1 mM) and 
DMAP (10 mM) in DMSO were prepared. Then 1.5 µL of the DMAP solution was added to 
the corresponding cups. Reaction was started with the addition of 15 µL of the corresponding 
active ester solution (vortexed). Active ester concentration was 50 µM. After 30, 90 and 150 
minutes 75 µL aliquots were taken and put into 75 µL quenching solution [25%vol MeCN, 
62.5%vol H2O, 37.5%vol. TFAaq(1%)]. 5 µL of internal standard (1 mM in MeCN) was added 
to every cup and the samples were analyzed with HPLC. The integrals of active ester and free 
acid were determined and the total amount of active ester was calculated (calibration with 
different concentrations of the free acids from 0.5 µM to 25 µM). 
 
4.4.6 Acyl-transfer studies 
 
The acyl-transfer studies were performed in 2 mL Eppendorf Cups. 200 µL phosphate buffer 
(30 mM, pH 7.4) was put into the cups. Stock solutions of the catalysts, nucleophiles and 
active esters in DMSO were prepared (10 mM).  According to the particular experiment 1 µL 
of catalyst and 1 µL of nucleophile were added to the buffer and the mixture was vortexed. 
The acyl-transfer was started with the addition of 1 µL of the active ester (vortexed). Then it 
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was incubated for 30 minutes. After that time the reaction was quenched with the addition of 
10 µL AcOH. 1 µL of a 10 mM solution of an internal standard was added and the samples 
were analyzed with LC-MS. The internal standard peak height was set as 100% and the 
relative peak intensities were determined. 
 
4.4.7 Cell culture and confocal microscopy 
 
MCF-7 cells were cultivated at 37 °C for two days in 8 well µ-slides (Ibidi GmbH, Munich) 
with EMEM medium (Sigma, Deisenhofen, Germany) containing 5% FCS (Biochrom AG, 
Berlin, Germany). Estradiol (1 nM) was added to the cultivation medium to stimulate Y1R 
expression12. After two days, shortly before the experiment the medium was replaced by 
Leibovitz L15 medium (LM). Cells were incubated with 200 nM catalyst (in LM, 200 µL per 
well) for 15 minutes at room temperature. Then the medium was removed and the cells were 
washed once with PBS. Cells without catalyst were also washed once with PBS. Then a 10 
µM solution of NHS ester 25 in PBS was added (150 µL per well) and the cells were 
incubated without light for 30 minutes at room temperature. After that time the cells were 
washed carefully three times with LM to remove all not covalent bound NHS ester and the 
free acid 24 from the membranes. Then 100 nM pNPY (in LM, 200 µL) was added to the 
corresponding wells and cells were incubated at room temperature. Pictures were taken after 
90 minutes pNPY incubation.  
Confocal microscopy was performed with a Zeiss Axiovert 200M microscope, equipped with 
a LSM 510 laser scanner. The dye S0436 was excited with a 633 nm laser, carboxyfluorescein 
was excitated at 488 nm. The emission of S0436 dyes was detected after a 650 nm long pass 
filter and the emission of carboxyfluorescein after a 505 nm long pass filter. The objective 
was a Plan-Neofluar 40x/1.3 with oil immersion. 
 
4.4.8 Data processing 
 
Data from radioligand competition experiments were analyzed by 4 parameter sigmoidal fits 
(SigmaPlot 9.0, Systat Software). IC50 values from radioligand competition studies were 
converted to Ki values according to the Cheng-Prusoff equation25 using the respective KD 
value of the radioligand.  
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CHAPTER 5 
 
Ligand Dependent Irreversible Blockade of the Neuropeptide Y1 
Receptor  
  
 
 
5.1 Introduction 
 
G protein-coupled receptors (GPCR) are one of the most important classes of targets in 
modern medicinal chemistry.1 Approximately 40 – 50% of all currently marketed drugs target 
GPCRs, so an understanding of the molecular functionality of these receptors is highly 
clinically and commercially relevant. Most of these drugs bind to their receptors in a 
competitive, reversible manner and can be displaced by the natural agonist or receptor 
specific synthetic agonists or antagonists. However, there is a growing number of antagonists 
that bind to GPCRs and can not be displaced anymore.2, 3 Two modes of irreversible binding 
of antagonists are conceivable: (1) The ligand is covalently bound to the receptor protein as 
described, e. g., for the alkylation of α-adrenergic receptors and histamine H1 receptors with 
phenoxybenzamine and dibenamine, respectively.4, 5 (2) The dissociation of the ligand is 
extremely slow (pseudo-irreversible binding) or the receptor is stabilized in a conformation 
with reduced affinity for the natural ligand.3 Examples of such non-covalently binding 
insurmountable antagonists are described in the literature, e. g., certain ligands of histamine 
H2 and neuropeptide (NPY) Y5 receptors, respectively.6, 7 Irrespective of the mode of 
irreversible binding, such ligands diminish the number of free receptors accessible to an 
agonist, resulting in concentration- and/or time-dependent decrease in the maximum response 
in functional assays, unless there is a sufficient number of spare receptors. Irreversible 
antagonists can be useful as drugs with long-lasting biological effects and as pharmacological 
tools, for instance, for the determination of a receptor reserve.8-10  
The NPY Y1 receptor (Y1R) is a GPCR and is highly conserved in mammals. It is for example 
present in the central nervous system and regulates mood, anxiety and food intake.11 BIBP 
3226 (BIBP) is a very potent, fully reversibly binding antagonist and a useful selective tool 
for the investigation of the NPY Y1 receptor.12 Derivatization of the BIBP scaffold at the NG-
terminus is tolerated with moderate loss or gain of affinity.13-15 With respect to the 
development of irreversible antagonists, two prototypical derivatives 1a and 1h substituted 
with an aromatic azide moiety were designed that should covalently bind to the receptor after 
irradiation with UV light via a nitrene intermediate.16 Aromatic azides were successfully 
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applied as photo affinity labels for many targets in medicinal chemistry.17, 18 Investigation of 
compound 1a in microscopy studies with MCF-7 breast cancer cells revealed ligand 
dependent irreversible Y1 receptor blockade without irradiation and decomposition of the 
azide group. In contrast compound 1h is only irreversible after UV irradiation. To elucidate 
the molecular mechanism of the non-covalent ligand dependent irreversible binding of 
compound 1a a series of structural analogues, most of them lacking the light-sensitive azide 
group, was synthesized and investigated for Y1 receptor binding. Previously described 
derivatives such as 1i and 1j14 and a complete series of acylguanidines with different logD 
values15 from earlier investigations were included in this study. Some of these compounds 
blocked the Y1R irreversibly with respect to NPY and a fluorescent Y1R ligand, although a 
covalent bond was not formed.  
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Table 1. Structures and Y1R binding data of the compounds 1a-1k. 
 
 
 
a Ki values were determined from the displacement of 1.5 nM [3H]-UR-MK114 on SK-N-MC cells (simultaneous 
incubation of radioligand and antagonist);14 all mean values ± SEM from two independent experiments. Except 
entity 1 all depicted compounds exhibit irreversible binding properties at the Y1R with respect to NPY and the 
fluorescent Y1R antagonist 29  (1h only with UV irradiation).   
b, c
 Ki values were taken from literature.14, 19  
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Scheme 1. Synthesis of the Y1R antagonists 1a – 1h. a) CHCl3, MeOH, H2O, ascorbic acid, CuSO4, 29%; b) 
DCM/TFA, quantitative; c) DCM, DIPEA, triphosgene, compound 6, 46%; d) DMF, NEt3, HgCl2, 57%; e) 
DCM/TFA, quantitative; f) Pd/C, MeOH, quantitative; g) THF, BuLi, propargylbromide, 10%; h) Compound 1a, 
DMSO, MeOH, H2O, ascorbic acid, CuSO4, 51%; i) MeOH, H2O, ascorbic acid, CuSO4, 38 - 86%; j) DCM/TFA 
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(19) or MeOH/HClaq, quantitative; k) DCM, DIPEA, triphosgene, 25 - 79%; l) DMF, NEt3, HgCl2, 21 – 76%; m) 
DCM/TFA, quantitative; n) NaN3, MeI, TBA+BF4-, Et2O, H2O; 2.) CuSO4, MeOH, Et2O, H2O, ascorbic acid, 
72%; o) MeOH, HCl, quantitative; p) DCM, DIPEA, triphosgene, 38%; q) DMF, NEt3, HgCl2, 55%; r) 
DCM/TFA, quantitative; s) DMF, DIPEA, TBTU, 61%. 
 
5.2 Results and Discussion 
 
5.2.1 Synthesis 
 
The synthesis of compound 1a started with a single “click-reaction” of 1,4-diazidobenzene 
and N-Boc-propargylamine. The cycloaddition product 4 was obtained in moderate yield, 
because of the undesired formation of the double cycloaddition byproduct. After Boc-
deprotection with TFA the amine was converted into the isocyanate with triphosgene and this 
was converted with N-Boc-S-methylisothiourea 6 to compound 7. A guanidinylation reaction 
with compound 8 and subsequent deprotection with TFA gave compound 1a in moderate 
yield. Compound 1c was prepared from 1a via a simple Pd-catalyzed hydrogenation reaction 
in quantitative yield. Derivative 1g was obtained by a cycloaddition reaction of compound 1a 
and alkyne 10, catalyzed with CuI and the CuI stabilizing ligand 11, in moderate yield. 
Compounds 1b, 1d and 1e were prepared according to the synthesis strategy for compound 
1a. The yields were dependent on the substitution pattern. The best yields were obtained for 
the unsubstituted phenylazide 12 and Boc-protected propargylamine 3. Methylazide, required 
for the preparation of compound 1f, was prepared from methyliodide and sodium azide in a 
water/diethylether mixture with phase transfer catalyst. To circumvent the isolation of the 
explosive methylazide, the ethereal methylazide solution was allowed to react with compound 
3 yielding the cycloaddition product 24. After Boc-deprotection the free amine was converted 
into the antagonist 1f following the same route as for compound 1a.  
 
 
5.2.2 Fluorescence based ligand binding studies 
 
Ligand 1a was detected to inhibit the binding of the fluorescent labeled Y1R antagonist 29 (Ki 
= 26 nM)20 to the Y1R on MCF-7 or adherent HEL cells without UV irradiation during 
confocal microscopy experiments. This Y1R blockade with respect to ligand 29 was 
dependent on the concentration and the preincubation time of compound 1a prior to the 
washing step and the following incubation with ligand 29. A concentration of 50 nM and an 
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incubation time of 15 minutes was sufficient to inhibit binding of compound 29 and resulted 
in a complete loss of fluorescence compared with untreated cells. The binding of fluorescent 
labeled Cy5-NPY to MCF-7 cells was also inhibited under the same experimental conditions 
and even after a incubation time of 50 minutes no binding of Cy5-NPY was observed. In 
further experiments MCF-7 cells were preincubated with other potentially irreversible Y1R 
blockers from earlier investigations14, 15 and from this study (compounds 1a – 1h). The 
compounds were incubated at a concentration that was the tenfold Ki value from Table 1 
(receptor saturation) for 15 minutes, washed and incubated with fluorescent labeled 
compound 29. A complete loss of fluorescence intensity (picture B in Figure 1) compared to 
the fluorescence of untreated cells (picture A) indicated an irreversible blockade of the Y1R 
with respect to ligand 29. This was the case for all compounds listed in Table 1. However, the 
majority of NG-substituted BIBP derivatives bind reversible to the Y1R. For the investigation 
whether the irreversible ligands bind in a competitive manner to the Y1R on the same binding 
site as the reversible ligands and NPY co-incubation experiments were performed. Antagonist 
1a (50 nM) was incubated with an excess of BIBP (100 nM) simultaneously and the Y1 
receptors were partially protected against irreversible blockade with respect to antagonist 29. 
This is a proof of the competition for the same binding site (Figure 1) and excludes an 
allosteric receptor blockade of ligand 1a. Additionally the (S)-enantiomer (distomer) of 
compound 1k has no affinity to the BIBP binding pocket of the Y1R and did not affect the 
binding of compound 29 to the receptor.  
Further displacement studies of ligand 1a were performed: MCF-7 cells were preincubated 
with compound 1a as described above, washed twice with buffer, treated with fluorescent 
ligand 29 and investigated by flow cytometry, but there was no binding observed on a 
timescale of hours. 
The irreversible blockade of a receptor can be the result of an alkylation of the receptor 
protein resulting in a covalently blocked receptor. This was not observed in these studies and 
is rather implausible, as the ligand dependent irreversible Y1R blockers 1d, 1f or 1i for 
example possess no azido or other reactive functional group. Further incubation studies of 
antagonist 1a with different amino acids in buffered solution (pH 7.4) never demonstrated any 
decomposition of 1a in absence of UV light. Therefore the ligand dependent irreversible 
receptor blockade is most likely a result of a very slow dissociation of the ligand from the 
receptor binding pocket (Koff-value is very low) or the conformation of the receptor R is 
changed to a ligand specific conformation R´ (R -> R´) that has a drastically reduced affinity 
to ligand 29 and Cy5-NPY after binding of such a ligand. 
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Figure 1. MCF-7 cells were incubated with 30 nM of the fluorescent antagonist 29 for 20 minutes. A: Cells were 
incubated with compound 29 (total binding). B: Cells were 15 min. pre-incubated with 50 nM 1a, washed and 
incubated with compound 29. C: Cells were 15 min. pre-incubated with 50 nM 1a and 100 nM BIBP 
simultaneously, washed and incubated with compound 29. Co-incubation of compound 1a and BIBP in picture 
C preserved some receptors, while sole incubation of the cells with compound 1a in picture B blocked the 
receptors completely. 
 
5.2.3 Structure and irreversible binding properties 
 
The structure of the NG-substituent on the BIBP scaffold is crucial for ligand dependent 
irreversible binding, as the majority of NG-substituted BIBP derivatives were in contrast 
reversible, competitive antagonists for the Y1R.15, 19-22 The azido group and the phenyl 
substituent like in compound 1a were not necessary. The N-methylated compound 1e showed 
reduced affinity compared with 1d and was irreversible regarding antagonist 29 at higher 
concentration. A methyltriazolyl-carbamoyl substituent as in compound 1f was sufficient to 
turn the reversible into irreversible binding, nevertheless, irreversible binding ligands were 
obtained with various NG-substituents as demonstrated by compounds 1i - 1k. Even very 
bulky substituents like in compound 1g were tolerated.  
 
 
5.2.4 Radioligand binding studies 
 
After the detection of the irreversible binding of compound 1a to the Y1R regarding ligand 29 
and Cy5-NPY we investigated if the binding of radioligand 30 ([3H]-UR-MK114) was also 
inhibited. Therefore SK-N-MC cells were preincubated with 50 nM of compound 1a for 15 
minutes (tenfold higher concentration compared to Ki value, saturation of the receptor), 
washed twice and then incubated with 1.5 nM radioligand 30. The amount of specifically 
bound radioligand was determined at different points in time. Interestingly, the binding of 
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radioligand 30 was still possible and the binding of ligand 1a was not irreversible with respect 
to the radioligand. The association speed was reduced compared to untreated cells (Figure 2) 
and the maximum number of accessible binding sites (Bmax) was reduced slightly compared to 
untreated cells (Bmax was 84% of the untreated cells). As the displacement of 1a was possible 
within a relatively short period of time, slow dissociation of ligand 1a cannot explain the 
irreversible receptor blockade regarding ligand 29 and Cy5-NPY.  
This different behavior of the pretreated cells towards the radioligand and the fluorescent 
labeled compounds lead to the assumption that the conformation of the receptor has changed 
(R -> R´) after binding of ligand 1a. It can be speculated that compound 30 still has high 
affinity for the receptor in a ligand specific conformation R´ due to the small propionyl 
substituent, i. e. the lack of bulk, at the guanidine group in radioligand 30. By contrast, the 
sterically demanding NG-substituted ligand 29 and the labeled peptide possess no or strongly 
reduced affinity for the receptor in state R´.   
 
 
 
 
Figure 2. Association kinetics for the specific Y1R binding of radioligand 30 on SK-N-MC cells after treatment 
with 50 nM ligand 1a for 15 minutes. As the association of radioligand 30 is very fast concerning untreated cells 
(Kon = 0.19 min-1 nM-1)14 the reduced association speed of compound 30 in graph A (Kob = 0.039 min-1) is due to 
a reduced affinity of the ligand to the Y1R in conformation R´ or the slow dissociation of ligand 1a. Radioligand 
concentration was 1.5 nM and the experiment was performed at room temperature.  
 
 
5.2.5 Functional studies on HEL cells 
 
Functional studies (Ca2+-response) were performed on HEL cells expressing the NPY Y1 
receptor. Therefore the cells were preincubated with compound 1a at different concentrations 
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in the dark for 15 minutes. After washing of the cells, the agonist pNPY was added at 
increasing concentrations (Figure 3). There was a rightward shift of the concentration-
response curves with increasing concentrations of compound 1a, indicating that a portion of 
the receptors remained (irreversibly) blocked against pNPY by antagonist 1a under these 
conditions. Preincubation with compound 1a at a concentration as low as 3 nM resulted in a 
decrease in the maximal NPY-induced Ca2+-response by 50%. Increasing the concentrations 
of 1a up to 100 nM did not further decrease the maximum Ca2+-response. A partial agonistic 
behavior of compound 1a was excluded, as there was no calcium response observed without 
pNPY even at the highest preincubation concentration of 100 nM. These findings lead to the 
assumption that there is a strong signal amplification in HEL cells caused by the occupancy of 
the small fraction of remaining free receptors with pNPY. Therefore a high concentration of 
pNPY is necessary. Compound 1a shows partially insurmountable antagonism3, 23 regarding 
pNPY, as the maximum calcium response can not be elicited anymore after preincubation 
with concentrations above 1 nM.  
 
 
 
 
Figure 3. Concentration-response curves of pNPY on HEL cells preincubated for 15 minutes with different 
concentrations of the irreversible (with respect to pNPY) Y1R blocker ligand 1a. The cells were washed and 
centrifuged twice before addition of pNPY. 
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5.3 Conclusion 
 
A series of ligand dependent irreversible receptor blockers for the NPY Y1R was detected and 
investigated on the basis of ligand 1a. The irreversible binding with respect to ligand 29 and 
NPY is most probably due to a conformational change (R -> R´) of the Y1R after binding of 
these ligands, because the displacement of compound 1a with the radioligand 30 was still 
possible on a timescale of minutes. The fluorescent antagonist 29 and Cy5-NPY were in 
contrast not able to bind to the receptor anymore. This supports the hypothesis that the NPY 
Y1 receptor can adopt different ligand specific conformations R´ that possess altered affinities 
for agonists and antagonists.3 Compound 1a is a partially insurmountable antagonist on HEL 
cells regarding pNPY, this is most probably due to a strong signal amplification in this cell 
line. The principle of ligands that act as insurmountable antagonists is not restricted to the 
field of NPY receptors, but is a frequent phenomenon concerning GPCR´s, an example is the 
recent detection of an insurmountable histamine H2 receptor radioligand.24 The exact 
molecular mechanism of the ligand dependent irreversible binding and the reason for partially 
insurmountable antagonism is an aim for further studies.  
 
 
 
5.4 Experimental  
 
5.4.1 General experimental conditions 
 
Unless otherwise noted, solvents (analytical grade) were purchased from commercial 
suppliers and used without further purification. Ethyl acetate (EA), petrol ether (PE, 60 – 70  
°C), methanol and dichloromethane were obtained in technical grade and distilled before 
application. Acetonitrile (MeCN) for HPLC was obtained from Merck (Darmstadt, Germany). 
4-(methylamino)pyridine (Alfa Aesar, Karlsruhe, Germany), 1,4-diaminobenzene (Fluka, 
Sigma-Aldrich Chemie GmbH, Munich, Germany), butyllithium (Fluka, Sigma-Aldrich 
Chemie GmbH, Munich, Germany) and propargylbromide (Fluka, Sigma-Aldrich Chemie 
GmbH, Munich, Germany) were purchased. Preparative HPLC was performed with a system 
from Knauer (Berlin, Germany) consisting of two K-1800 pumps and a K-2001 detector. A 
Nucleodur 100-5 C18 (250 × 21 mm, 5 µm; Macherey-Nagel, Germany) and a Eurospher-100 
C18 (250 × 32 mm, 5 µm; Knauer, Germany) served as RP-columns at flow rates of 20 and 
38 mL/min, respectively. Mixtures of MeCN and diluted aqueous TFA (0.1 %) were used as 
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mobile phase. 1H-NMR spectra were recorded at 300 MHz on a Bruker Avance 300 
spectrometer or at 600 MHz on a Bruker Avance III 600 with cryogenic probehead (Bruker, 
Karlsruhe, Germany). 13C-NMR spectra were recorded at 75 MHz on a Bruker Avance 300 
spectrometer or at 151 MHz on a Bruker Avance III 600. All chemical shifts values are 
reported in ppm. UV/VIS spectra were recorded with a Varian Cary BIO 50 UV/VIS/NIR 
spectrophotometer (Varian Inc., CA, USA). Mass spectra: Finnigan SSQ 710A (EI), Finnigan 
MAT 95 (CI), Finnigan MAT TSQ 7000 (Thermo FINNIGAN, USA) (ES/LC-MS). LC-
system for LC-MS: Agilent 1100 (Palo Alto, USA). LC-MS method: Column: Phenomex 
Luna C18, 2.5 µm, 50 x 2 mm HST (Phenomenex, Aschaffenburg, Germany); flow: 0.40 
mL/min; solvent A (water + 0.1% TFA), solvent B (MeCN); gradient: 0 min [A/B 95/5], 8 
min [A/B 2/98], 11 min [A/B 2/98], 12 min [A/B 95/5], 15 min [A/B 95/5]. Melting points 
were determined with a Lambda Photometrics Optimelt MPA100 apparatus (Lambda 
photometrics, Harpenden, UK), they are not corrected. Thin layer chromatography (TLC) was 
performed on alumina plates coated with silica gel (Merck silica gel 60 F245, thickness 0.2 
mm). Column chromatography (CC) was performed with Merck Geduran SI 60 silica gel as 
the stationary phase.  
Compounds 3,25 6,22 8,14 11,26 12,27 13,28 14,29 2730 and 2821 were prepared according to 
literature procedures. The synthesis of literature known compound 231 was improved.   
 
5.4.2 Synthetic protocols and analytical data 
 
General procedure A: 
Triphosgene (116 mg, 0.39 mmol) was dissolved in 10 mL of ice-cold DCM or MeCN (26) 
and a solution of the appropriate amine (1.00 mmol) in the same solvent and DIPEA (396 mg, 
3.07 mmol) was added slowly for 20 minutes at 0 °C under vigorous stirring. After that time 
the mixture was warmed up to ambient temperature and a solution of compound 6 (200 mg, 
1.00 mmol) in 10 mL of DCM was added over a period of 10 minutes. The mixture was 
stirred overnight at ambient temperature. The next day it was concentrated and purified with 
column chromatography. 
 
General procedure B: 
The appropriate S-methylisothiourea derivative (0.2 mmol), compound 8 (0.2 mmol) and 
HgCl2 (0.2 mmol) were dissolved separately in small amounts of DMF (1-2 mL). The 
solutions were combined in a small flask under nitrogen atmosphere. NEt3 (2 mmol) was 
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added under stirring, then the HgCl2 solution was added and the mixture was stirred overnight 
at room temperature. The next day DMF was removed completely and the residue was 
dissolved in DCM. The precipitate of mercury salts was filtered off and the organic phase was 
concentrated. The crude products were purified by column chromatography (PE/EA 
mixtures). The Boc- and tBu-protected target molecules were deprotected to the 
corresponding target compounds without further characterisation: The corresponding 
protected compound was dissolved in a DCM/TFA 1:1 mixture (5 mL) and stirred for two 
hours. After that time the solvent was removed completely under reduced pressure and the 
oily residue was repeatedly dissolved in dichloromethane and the solvent evaporated to 
remove TFA. The deprotected compounds were purified with preparative HPLC except 
compound 1e. The given yield corresponds to the coupling step in the first part of this 
procedure, the deprotection step was quantitative. 
 
General procedure C:  
The appropriate Boc-protected alkyne derivative 3 or 14 (2.0 mmol) and azide 12 or 13 (2.0 
mmol) were dissolved in 5 mL of MeOH. Then ascorbic acid (35 mg, 0.2 mmol) dissolved in 
0.5 mL H2O was added. Then CuSO4 · 5 H2O (25 mg, 0.1 mmol) dissolved in 0.5 mL H2O 
was added. The mixture was stirred at 60 °C for 1h. Then it was concentrated and the residue 
was purified with column chromatography. 
 
General procedure D:  
The appropriate Boc-protected compound was dissolved in 4 mL MeOH/HClaq. 3:1 or in 4 mL 
DCM/TFA 2:1 (19). After 30 minutes the reaction was finished and the mixture was 
concentrated. The products were obtained in quantitative yield. 
 
1,4-Diazidobenzene (2) 
NaNO2 (1.45 g, 21 mmol) was suspended in 10 mL concentrated sulphuric acid at 10 °C in 
small amounts. The mixture was stirred 10 minutes at 20 °C and then heated to 70 °C until a 
clear solution was obtained. The mixture was cooled to 10 °C and 1,4-diaminobenzene (1.08 
g, 10 mmol) dissolved in 10 mL glacial acetic acid was dropped slowly into the mixture. A 
yellow solid precipitated. The mixture was stirred one hour at 15 °C. After that time the 
mixture was dropped in a 500 mL flask containing 150 mL ice-cold water (with ice). A clear, 
yellow solution was obtained. NaN3 (1.43 g, 22 mmol) dissolved in 10 mL water was added 
dropwise at 5 °C under vigorous stirring (caution: HN3 gas can develop). Nitrogen was 
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formed and a yellow solid precipitated. After 2 hours the product was extracted with EA (2 x 
75 mL). The organic layer was separated and dried over MgSO4. The solvent was 
concentrated and the crude material was recrystallized in PE. Yellow crystals were obtained 
(1.06 g, 66%), m.p. 155°C (decomp.). 
 
tert-Butyl [(1-(4-azidophenyl)-1H-1,2,3-triazol-4-yl)methyl]carbamate (4) 
1,4-Diazidobenzene (500 mg, 3.13 mmol) was dissolved in 5 mL of CHCl3 and was added to 
a solution of  Boc-propargylamine (484 mg, 3.13 mmol) in 5 mL of MeOH. Then ascorbic 
acid (55 mg, 0.31 mmol, dissolved in 0.5 mL of H2O) and CuSO4 ⋅ 5 H2O (40 mg, 0.16 mmol; 
dissolved in 0.5 mL of H2O) were added. The mixture was stirred at 60 °C for 1 hour. EA (50 
mL) and water (50 mL) were added and the organic layer was separated. The mixture was 
concentrated and a white solid precipitated (double coupled side product). The precipitate was 
filtered off and the remaining solution was concentrated and purified with column 
chromatography (PE/EA 2:3, Rf=0.5). The product was obtained as a white solid (782 mg, 
79%), m.p. 155 °C (160 °C decomp.). 1H NMR (300 MHz, CDCl3): 1.45 (s, 9H), 4.47 (d, 
J=6.03, 2H), 5.20 (bs, 1H), 7.10 – 7.20 (m, 2H), 7.65 – 7.75 (m, 2H), 7.94 (s, 1H). 13C NMR 
(75 MHz, CDCl3): 28.4, 36.1, 79.9, 120.2, 122.0, 132.1, 133.8, 140.7, 146.4, 155.9. 
C14H17N7O2: MS (LC-MS): m/z(%) [tr=3.57 min.]: 216(100, M*H+), 257(20), 431(25). The 
compound was completely Boc-deprotected during LC-MS.  
 
(1-(4-Azidophenyl)-1H-1,2,3-triazol-4-yl)methanaminium 2,2,2-trifluoroacetate (5) 
Compound 4 (287 mg, 0.91 mmol) was deprotected with a 2:1 mixture of DCM and TFA (6 
mL). The mixture was stirred for 1h at room temperature and then the solvent was removed. 
Water was added (5 mL) and the solution was lyophilized. A white solid was obtained (300 
mg, quantitative), m.p. 157 °C (decomp.). 1H NMR (300 MHz, D2O): 4.36 (s, 2H), 7.14 – 
7.17 (m, 2H), 7.63 – 7.66 (m, 2H), 8.44 (s, 1H). 13C NMR (75 MHz, D2O): 33.9, 120.0, 
122.1, 123.4, 132.6, 140.3, 140.9. C9H9N7: MS (LC-MS): m/z(%) [tr=3.57 min.]: 216(100, 
MH+), 257(20), 431(25). IR (ν [cm-1]): 3166, 2757, 2136 (N3), 2095 (N3), 1711, 1618, 1555, 
1514.  
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tert-Butyl (3-((1-(4-azidophenyl)-1H-1,2,3-triazol-4-yl)methyl)ureido)(methylthio) 
methylenecarbamate (7) 
The compound was prepared according to general procedure A. Column chromatography: 
(PE/EA 3:1 -> 2:3) [Rf=0.3 (PE/EA 3:2)]. A light yellow solid was obtained (200 mg, 46%), 
m.p. 126 °C (162 °C decomp.). 1H NMR (300 MHz, CDCl3): 1.48 (s, 9H), 2.29 (s, 3H), 4.58 
(d, J=6.19, 2H), 6.23 (t, J=5.49, 1H), 7.10 – 7.20 (m, 2H), 7.75 – 7.75 (m, 2H), 7.97 (s, 1H), 
12.19 (bs, 1H). C17H21N9O3S: MS (LC-MS): m/z(%) [tr=7.83 min.]: 432(100, MH+), 
863(40). 
 
(R)-1-(1-(4-Azidophenyl)-1H-1,2,3-triazol-4-yl)-10-(4-hydroxybenzylcarbamoyl)-3,12-
dioxo-13,13-diphenyl-2,4,6,11-tetraazatridecan-5-iminium 2,2,2-trifluoroacetate (1a) 
The compound was prepared according to general procedure B. A white solid was obtained 
(97 mg, 57%), m.p. > 190° C (decomp.). 1H NMR (600 MHz, DMSO-d6): 1.35 – 1.48 (m, 
2H), 1.48 – 1.70 (m, 2H), 3.10 – 3.25 (m, 2H), 4.05 – 4.20 (m, 2H), 4.30 – 4.35 (m, 1H), 4.46 
(d, J=5.29, 2H), 5.12 (s, 1H), 6.67 (d, J=8.45, 2H), 7.00 (d, J=8.45, 2H), 7.15 – 7.30 (m, 10H), 
7.30 – 7.35 (m, 2H), 7.88 – 7.92 (m, 2H), 8.13 (bs, 1H), 8.36 (t, J=5.80, 1H), 8.37 – 8.46 (bs, 
1H), 8.47 (d, J=8.11, 1H), 8.67 (s, 1H), 8.89 (bs, 1H), 9.28 (s, 1H), 9.73 (bs, 1H). 13C NMR 
(HSQC, HMBC, ROESY) (151 MHz, DMSO-d6): 24.55, 29.42, 34.82, 41.58, 52.23, 55.88, 
114.97, 120.47, 121.10, 121.59, 126.56, 128.13, 128.17, 128.38, 128.46, 128.48, 129.11, 
133.46, 139.70, 140.24, 140.42, 156.23, 170.93, 170.98. C37H38N12O4: MS (LC-MS): m/z(%) 
[tr=6.01 min.]: 715(100, MH+). UV (MeCN): λ(ε) 272 (20⋅103). IR (ν [cm-1]): 3277, 2130 
(N3), 2100 (N3), 1686, 1638, 1542, 1512, 1446, 1364.     
 
1-(1-(4-Aminophenyl)-1H-1,2,3-triazol-4-yl)-10-(4-hydroxybenzylcarbamoyl)-3,12-dioxo-
13,13-diphenyl-2,4,6,11-tetraazatridecan-5-iminium 2,2,2-trifluoroacetate (1c) 
Azide 1a (6.2 mg, 7.5 µg) was dissolved in 5 mL MeOH and 5 mg Pd/C were added. The 
mixture was stirred under 1 bar hydrogen pressure for 2 hours. Then the mixture was filtered 
over cellite and concentrated. The crude material was purified with HPLC. A white solid was 
obtained (6.0 mg, quantitative), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, DMSO-d6): 
1.40 – 1.70 (m, 4H), 3.15 – 3.25 (m, 2H), 4.05 – 4.25 (m, 2H), 4.30 – 4.40 (m, 1H), 4.40 – 
4.45 (d, J=5.21, 2H), 5.12 (s, 1H), 6.63 – 6.75 (m, 4H), 7.00 (d, J=8.47, 2H), 7.15 – 7.35 (m, 
11H), 7.45 (d, J=8.80, 2H), 8.08 (s, 1H), 8.30 – 8.60 (m, 5H), 8.70 – 9.40 (m, 2H), 9.62 (s, 
1H). C37H40N10O4: MS (LC-MS): m/z(%) [tr=5.27 min.]:  345(80), 386(50), 689(100, MH+). 
UV (MeCN): λ(ε) 276 (13⋅103). 
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4-(Methyl(prop-2-ynyl)amino)pyridinium chloride (10) 
N-Methylpyridin-4-amine 9 (200 mg, 1.85 mmol) was dissolved in 5 mL of dry THF. Then 
BuLi solution (1.6M in hexanes; 1.4 mL, 2.22 mmol) was added at room temperature under 
nitrogen. After 10 minutes, when no more gas was formed, a propargylbromide solution 
(80%w in toluene; 330 mg, 2.22 mmol) was added slowly at –5 °C over a period of 1h. The 
mixture was stirred overnight. The next day water was added (5 mL) and then THF was 
removed completely under reduced pressure. NaOH (1M, 20 mL) and EA (20 mL) were 
added and the organic layer was collected. The organic phase was acidified with NaHSO4 
solution (20 mL, 5%w) and the aqueous layer was collected. NaOH (1M, 40 mL) and EA (40 
mL) were added and the organic layer was collected. The organic layer was washed several 
times with water until not converted compound 9 was removed completely. The organic layer 
was dried over MgSO4 and the solvent was removed. A brown oil was obtained. Diluted 
hydrochloric acid (10%) was added dropwise until pH < 2. A yellow precipitate was formed. 
It was collected and recrystallized with CHCl3/PE. Light yellow-brown crystalls were 
obtained (33 mg, 10%), m.p. 193 °C (decomp.).  1H NMR (300 MHz, D2O): 2.63 (t, J=2.47, 
1H), 3.15 (s, 3H), 4.26 (d, J=2.47, 2H), 6.92 (d, J=7.26, 2H), 8.00 (d, J=7.67, 2H). 13C NMR 
(75 MHz, D2O): 38.0, 41.5, 74.1, 77.0, 107.8, 138.9, 157.3. C9H10N2: MS (LC-MS): m/z(%) 
[tr=0.56 min.]: 147(100, MH+), 188(10), 293(10). 
 
(R)-4-(((1-(4-(4-(10-(4-Hydroxybenzylcarbamoyl)-5-iminio-3,12-dioxo-13,13-diphenyl-
2,4,6,11-tetraazatridecyl)-1H-1,2,3-triazol-1-yl)phenyl)-1H-1,2,3-triazol-4-
yl)methyl)(methyl)amino)pyridinium 2,2,2-trifluoroacetate (1g) 
Compound 1a (10 mg, 12.1 µmol) was dissolved in 0.5 mL of DMSO and alkyne 10 (2.2 mg, 
12.1 µmol) was added. The solution was diluted with a of 3:1 mixture of MeOH and H2O (0.5 
mL). Then ascorbic acid (1.1 mg,  6.1 µmol [stock solution 100 mg/mL in 1M NaOH]) and 
CuSO4 ⋅ 5 H2O (0.91 mg, 3.6 µmol [stock solution 100 mg/mL in H2O]) were dropped into 
the mixture. Copper (I) stabilizing ligand 11 (0.8 mg, 1.21 µmol) was added and the mixture 
was heated to 65 °C for 1h. After that time TLC control demonstrated complete conversion. 
TFA was added until pH < 2 and the crude material was purified with HPLC. A white solid 
was obtained (6.7 mg, 51%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, DMSO-d6): 1.35 
– 1.75 (m, 4H), 3.15 – 3.25 (m, 2H), 3.32 (s, 3H), 4.05 – 4.25 (m, 2H), 4.25 – 4.40 (m, 1H), 
4.40 – 4.55 (m, 2H), 5.02 (s, 2H), 5.12 (s, 1H), 6.67 (d, J=8.45, 2H), 7.00 (d, J=8.45, 2H), 
7.05 – 7.40 (m, 12H), 8.05 – 8.20 (m, 5H), 8.25 – 8.60 (m, 6H), 8.81 (s, 1H), 8.91 (bs, 1H), 
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8.96 (s, 1H), 9.30 (s, 1H), 9.86 (bs, 1H), 13.44 (bs, 1H). C46H58N14O4: MS (LC-MS): m/z(%) 
[tr=5.18 min.]: 431(100), 861(5, MH+), 975(2).    
 
tert-Butyl (1-phenyl-1H-1,2,3-triazol-4-yl)methylcarbamate (15) 
The compound was prepared according to general procedure C. Column chromatography: 
(PE/EA 2:3, Rf=0.45). A white solid was obtained (471 mg, 86%). The compound was 
deprotected without further characterisation. 
 
tert-Butyl (1-(3-azidophenyl)-1H-1,2,3-triazol-4-yl)methylcarbamate (16) 
The compound was prepared according to general procedure C. Column chromatography: 
(PE/EA 2:3, Rf=0.6). A yellow solid was obtained (237 mg, 38%). The compound was 
deprotected without further characterisation. 
 
tert-Butyl methyl((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)carbamate (17) 
The compound was prepared according to general procedure C. Column chromatography: 
(PE/EE 7:3, Rf=0.45). A white solid was obtained (469 mg, 81%). The compound was 
deprotected without further characterisation. 
 
(1-Phenyl-1H-1,2,3-triazol-4-yl)methanaminium chloride (18) 
The compound was prepared according to general procedure D. A white solid was obtained, 
m.p. 244 °C. 1H NMR (300 MHz, D2O): 4.40 (s, 2H), 7.50 – 7.65 (m, 3H), 7.65 – 7.80 (m, 
2H), 8.52 (s, 1H). 13C NMR (75 MHz, D2O): 34.0, 121.0, 123.8, 129.7, 129.9, 136.0, 140.3. 
C9H10N4: MS (LC-MS): m/z(%) [tr=0.88 min.]: 175(100, MH+), 349(30).    
 
(1-(3-Azidophenyl)-1H-1,2,3-triazol-4-yl)methanaminium 2,2,2-trifluoroacetate (19) 
The compound was prepared according to general procedure D. A yellow oil was obtained. 
1H NMR (300 MHz, D2O): 4.27 (s, 2H), 7.00 – 7.10 (m, 1H), 7.20 – 7.26 (m, 1H), 7.30 – 
7.45 (m, 2H), 8.38 (s, 1H). 13C NMR (75 MHz, D2O): 33.8, 110.5, 116.1, 118.9, 122.9, 130.8, 
136.8, 140.4, 141.1. C9H9N7: MS (LC-MS): m/z(%) [tr=2.93 min.]: 216(100, MH+), 431 
(100).   
 
N-Methyl-1-(1-phenyl-1H-1,2,3-triazol-4-yl)methanaminium chloride (20) 
The compound was prepared according to general procedure D. A white solid was obtained, 
m.p. 228 °C. 1H NMR (300 MHz, D2O): 2.73 (s, 3H), 4.38 (s, 2H), 7.40 – 7.58 (m, 3H), 7.60 
101 
– 7.70 (m, 2H), 8.50 (s, 1H). 13C NMR (75 MHz, D2O): 32.1, 42.6, 121.1, 124.8, 129.8, 
130.0, 136.0, 138.5. C10H12N4: MS (LC-MS): m/z(%) [tr=1.04 min.]: 189(100, MH+), 
377(35). 
 
tert-Butyl methylthio(3-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)ureido)-methylene-
carbamate (21) 
The compound was prepared according to general procedure A. Column chromatography 
(PE/EA 3:1 -> 2:3, Rf=0.3(PE/EA 3:2)). A white solid was obtained (308 mg, 79%), m.p. 157 
°C. 1H NMR (300 MHz, CDCl3): 1.48 (s, 9H), 2.30 (s, 3H), 4.55 – 4.65 (d, J=6.15, 2H), 6.24 
(s, 1H), 7.35 – 7.60 (m, 3H), 7.60 – 7.80 (m, 2H), 7.80 (s, 1H), 12.21 (bs, 1H). 13C NMR (75 
MHz, CDCl3): 14.4, 28.0, 35.6, 82.8, 120.4, 120.6, 128.8, 129.8, 137.0, 145.6, 160.0, 161.8, 
168.3. C17H22N6O3S: MS (LC-MS): m/z(%) [tr=7.51 min.]: 391(100, MH+), 781(60). 
 
tert-Butyl (3-((1-(3-azidophenyl)-1H-1,2,3-triazol-4-yl)methyl)ureido)(methylthio)-
methylenecarbamate (22) 
The compound was prepared according to general procedure A. Column chromatography 
(PE/EA 3:1 -> 2:3, Rf=0.3(PE/EA 3:2)). A white solid was obtained (164 mg, 38%), m.p. 128 
°C. 1H NMR (300 MHz, CDCl3): 1.48 (s, 9H), 2.30 (s, 3H), 4.55 – 4.65 (d, J=6.15, 2H), 6.24 
(s, 1H), 7.00 – 7.10 (m, 1H), 7.20 – 7.26 (m, 1H), 7.30 – 7.45 (m, 2H), 7.70 (s, 1H), 12.18 (bs, 
1H). C17H22N6O3S: MS (LC-MS): m/z(%) [tr=7.88 min.]: 432(100), 863(60). 
 
tert-Butyl (3-methyl-3-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)ureido)(methyl-
thio)methylenecarbamate (23) 
The compound was prepared according to general procedure A. Column chromatography 
(PE/EA 3:1 -> 2:3, Rf=0.3(PE/EA 3:2)). A white solid was obtained (144 mg, 25%), m.p. 145 
°C. 1H NMR (300 MHz, CDCl3): 1.49 (s, 9H), 2.33 (d, J=4.75, 3H), 3.00 – 3.30 (m, 3H), 4.65 
– 5.30 (m, 2H), 7.35 – 7.60 (m, 3H), 7.65 – 7.75 (m, 2H), 7.75 – 8.05 (m, 1H), 12.30 – 12.55 
(m, 1H). C18H24N6O3S: MS (LC-MS): m/z(%) [tr=7.95 min.]: 405 (100, MH+), 809(20). 
 
10-(4-Hydroxybenzylcarbamoyl)-3,12-dioxo-13,13-diphenyl-1-(1-phenyl-1H-1,2,3-
triazol-4-yl)-2,4,6,11-tetraazatridecan-5-iminium 2,2,2-trifluoroacetate (1d) 
The compound was prepared according to general procedure B. The product is a white solid 
(158 mg, 57%), m.p. > 190 °C (decomp). 1H NMR (300 MHz, DMSO-d6): 1.30 – 1.80 (m, 
4H), 3.15 – 3.30 (m, 2H), 4.05 – 4.25 (m, 2H), 4.25 – 4.40 (m, 1H), 4.40 – 4.55 (d, J=5.31, 
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2H), 5.12 (s, 1H), 6.68 (d, J=8.44, 2H), 7.00 (d, J=8.44, 2H), 7.15 – 7.35 (m, 10H), 7.45 – 
7.55 (m, 1H), 7.55 – 7.65 (m, 2H), 7.85 – 7.95 (m, 2H), 8.11 (m, 1H), 8.30 – 8.65 (m, 4H), 
8.70 (s, 1H), 8.96 (bs, 1H), 9.30 (bs, 1H), 10.08 (s, 1H). C37H39N9O4: MS (LC-MS): m/z(%) 
[tr=5.63 min.]: 337(10), 674(100, MH+). UV (MeCN): λ(ε) 248 (9⋅103). 
 
1-(1-(3-Azidophenyl)-1H-1,2,3-triazol-4-yl)-10-(4-hydroxybenzylcarbamoyl)-3,12-dioxo-
13,13-diphenyl-2,4,6,11-tetraazatridecan-5-iminium 2,2,2-trifluoroacetate (1b) 
The compound was prepared according to general procedure B. The product is a white solid 
(166 mg, 21%), m.p. > 190 °C (decomp). 1H NMR (300 MHz, DMSO-d6):  1.30 – 1.80 (m, 
4H), 3.15 – 3.30 (m, 2H), 4.05 – 4.25 (m, 2H), 4.25 – 4.40 (m, 1H), 4.40 – 4.55 (d, J=5.31, 
2H), 5.12 (s, 1H), 6.68 (d, J=8.45, 2H), 7.00 (d, J=8.45, 2H), 7.15 – 7.35 (m, 11H), 7.58 – 
7.68 (m, 2H), 7.68 – 7.78 (m, 1H), 8.12 (bs, 1H), 8.30 – 8.55 (m, 4H), 8.79 (s, 1H), 8.91 (bs, 
1H), 9.30 (s, 1H), 9.91 (s, 1H). C37H38N12O4: MS (LC-MS): m/z(%) [tr=5.78 min.]: 715(100, 
MH+). UV (MeCN): λ(ε) 244 (19⋅103). 
 
10-(4-Hydroxybenzylcarbamoyl)-2-methyl-3,12-dioxo-13,13-diphenyl-1-(1-phenyl-1H-
1,2,3-triazol-4-yl)-2,4,6,11-tetraazatridecan-5-iminium 2,2,2-trifluoroacetate (1e) 
The compound was prepared according to general procedure B. The product is a white solid 
(160 mg, 72%), m.p. > 190 °C (decomp). 1H NMR (300 MHz, DMSO-d6): 1.30 – 1.80 (m, 
4H), 3.06 (s, 3H), 3.20 – 3.30 (m, 2H), 4.05 – 4.25 (m, 2H), 4.25 – 4.40 (m, 1H), 4.70 (s, 2H), 
5.13 (s, 1H), 6.67 (d, J=8.42, 2H), 7.00 (d, J=8.42, 2H), 7.15 – 7.35 (m, 10H), 7.45 – 7.55 (m, 
1H), 7.55 – 7.65 (m, 2H), 7.85 – 7.95 (m, 2H), 8.33 – 8.43 (m, 1H), 8.45 – 8.65 (m, 3H), 8.77 
(s, 1H), 8.90 – 9.05 (bs, 1H), 9.31 (bs, 1H), 9.79 (bs, 1H). C38H41N9O4: MS (LC-MS): 
m/z(%) [tr=5.70 min.]: 688(100, MH+). UV (MeCN): λ(ε) 248 (12⋅103). 
 
tert-Butyl (1-methyl-1H-1,2,3-triazol-4-yl)methylcarbamate (24) 
NaN3 (714 mg, 11.0 mmol) was dissolved in 2 mL H2O in a 10 mL flask and 4 mL Et2O were 
added. Then the phase-transfer catalyst tetrabutylammonium tetrafluoroborate (90 mg, 0.27 
mmol) was added and then MeI (780 mg, 5.49 mmol) was added. The mixture was stirred 
vigorously for two days at room temperature. Then the organic layer was separated and the 
aqueous phase was washed with Et2O (2 x 2 mL). Then the organic fractions were mixed and 
a solution of the Boc-protected propargylamine (510 mg, 3.29 mmol) in 3 mL of MeOH was 
added. Then ascorbic acid (95 mg, 0.54 mmol, dissolved in 0.8 mL H2O) and CuSO4 ⋅ 5 H2O 
(68 mg, 0.27 mmol, dissolved in 0.8 mL H2O) were added. The mixture was stirred 
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vigorously at room temperature overnight. The next day the solvent was evaporated 
completely and the residue was dissolved in 1 mL of (CHCl3/EtOH 19:1). The crude material 
was purified with column chromatography (CHCl3/EtOH 19:1 -> 9:1, Rf=0.3 [CHCl3/EtOH 
9:1]). A white solid was obtained (500 mg, 72%). The compound was deprotected without 
further characterisation. 
 
(1-Methyl-1H-1,2,3-triazol-4-yl)methanaminium chloride (25) 
The compound was deprotected according to general procedure D. A light yellow solid was 
obtained (351 mg, quantitative), m.p. 172 °C. 1H NMR (300 MHz, D2O): 4.10 (s, 3H), 4.30 
(s, 2H), 8.02 (s, 1H). 13C NMR (75 MHz, D2O): 34.0, 36.7, 126.2. C4H8N4: MS (LC-MS): 
m/z(%) [tr=0.32 min.]: 113(60, MH+), 225(100). 
 
tert-Butyl (3-((1-methyl-1H-1,2,3-triazol-4-yl)methyl)ureido)(methylthio)-
methylenecarbamate (26) 
The compound was prepared according to general procedure A. Column chromatography 
(EA, Rf=0.26). A white solid was obtained (735 mg, 78%), m.p. 138 °C. 1H NMR (300 MHz, 
CDCl3): 1.49 (s, 9H), 2.33 (s, 3H), 4.08 (s, 3H), 4.40 – 4.80 (m, 2H), 6.40 (bs, 1H), 7.58 (bs, 
1H), 12.28 (bs, 1H). 13C NMR (75 MHz, CDCl3): 14.3, 28.0, 35.5, 36.7, 82.7, 123.0, 145.1, 
151.0, 161.8, 168.0. C12H20N6O3S: MS (LC-MS): m/z(%) [tr=6.27 min.]: 328(75, MH+), 
657(100). 
 
10-(4-Hydroxybenzylcarbamoyl)-1-(1-methyl-1H-1,2,3-triazol-4-yl)-3,12-dioxo-13,13-
diphenyl-2,4,6,11-tetraazatridecan-5-iminium 2,2,2-trifluoroacetate (1f) 
The compound was prepared according to general procedure B. A white solid was obtained 
(80 mg, 55%), m.p. > 190 °C (decomp.). 1H NMR (300 MHz, DMSO-d6): 1.30 – 1.80 (m, 
4H), 3.10 – 3.30 (m, 2H), 4.01 (s, 3H), 4.05 – 4.25 (m, 2H), 4.25 – 4.40 (m, 3H), 5.13 (s, 1H), 
6.67 (d, J=8.42, 2H), 7.00 (d, J=8.42, 2H), 7.15 – 7.35 (m, 11H), 7.93 (s, 1H), 7.95 – 8.05 (m, 
1H), 8.30 – 8.60 (m, 4H), 8.98 (s, 1H), 10.17 (s, 1H). C32H37N9O4: MS (LC-MS): m/z(%) 
[tr=5.15 min.]: 612(100, MH+), 1223(5).  
 
(R)-1-(3-Azidophenyl)-15-(4-hydroxybenzylcarbamoyl)-1,8,17-trioxo-18,18-diphenyl-
2,7,9,11,16-pentaazaoctadecan-10-iminium 2,2,2-trifluoroacetate (1h) 
Compound 27 (3.9 mg, 23.7 µmol) was dissolved in 1.5 mL of DMF. DIPEA (28 mg, 215 
µmol) and TBTU (8.3 mg, 25.8 µmol) dissolved in 500 µL of MeCN was added. After 10 
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minutes compound 28 (20.0 mg, 21.5 µmol) was added and the mixture was stirred overnight. 
Next day DMF was removed completely and the crude material was redissolved in 1 mL of 
MeCN/H2O (1:9) containing 0.1% TFA. It was purified with HPLC. A white solid was 
obtained (11.1 mg, 61%), m.p. 158 °C (decomp.). 1H NMR (600 MHz, DMSO-d6): 1.30 – 
1.70 (m, 8H), 3.05 – 3.35 (m, 6H), 4.05 – 4.20 (m, 2H), 4.33 (m, 1H), 5.12 (s, 1H), 6.67 (d, 
J=8.46, 2H), 7.00 (d, J=8.46, 2H), 7.15 – 7.30 (m, 11H), 7.35 – 7.80 (m, 5H), 8.20 – 8.50 (bs, 
1H), 8.35 (t, J=5.78, 1H), 8.47 (d, J=8.09, 1H), 8.58 (t, J=5.57, 1H), 8.87 (bs, 1H), 9.27 (bs, 
1H), 9.60 (bs, 1H). 13C NMR (HSQC, HMBC) (151 MHz, DMSO-d6): 24.53, 26.43, 26.50, 
29.40, 40.04, 40.31, 41.58, 52.21, 55.88, 114.97, 117.60, 121.70, 123.87, 130.01, 126.55, 
128.14, 128.17, 128.39, 128.47, 128.48, 129.10, 136.25, 139.63, 140.24, 140.43, 156.23, 
165.06, 170.92, 170.98. C39H44N10O5: MS (LC-MS): m/z(%) [tr=5.83 min.]: 733(100, MH+). 
UV (MeCN): λ(ε) 249 (16⋅103). UV (MeCN): λ(ε) 248 (16⋅103). IR (ν [cm-1]): 3303, 2114 
(N3), 1638, 1538, 1515, 1450. 
 
5.4.3 Radioligand competition binding assay 
 
Radioligand competition experiments at SK-N-MC neuroblastoma cells using the radioligand 
[3H]UR-MK114 (1.5 nM) were performed as described elsewhere.14  
 
5.4.4 Fura-2 assay on HEL cells 
 
The Fura assay was performed with HEL cells as previously described using a Perkin-Elmer 
LS50 B spectrofluorimeter (Perkin Elmer, Überlingen, Germany).32  
 
5.4.5 Cell culture and confocal microscopy 
 
MCF-7 cells were cultivated at 37 °C for two days in 8 well µ-slides (Ibidi GmbH, Munich) 
with EMEM medium (Sigma, Deisenhofen, Germany) containing 5% FCS (Biochrom AG, 
Berlin, Germany). Estradiol (1 nM) was added to the cultivation medium to stimulate Y1R 
expression.33 After two days, shortly before the experiment the medium was replaced by 
Leibovitz L15 medium (LM). All microscopy experiments were performed in LM. Stock 
solutions of the ligands were prepared in DMSO at a concentration that is at least hundredfold 
higher as the concentration in the experiment. The corresponding dilutions in LM were 
prepared shortly before the experiment, the DMSO concentration in the cell experiment was 
equal or below 1%.  
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Confocal microscopy was performed with a Zeiss Axiovert 200M microscope, equipped with 
a LSM 510 laser scanner. The fluorescent dye 29 was excited with a HeNe-laser at 633 nm 
and fluorescence was detected with a 650 nm long-pass filter. The objective was a Plan-
Neofluar 40x/1.3 or a  Plan-Apochromat 63x/1.4 with oil immersion. 
 
5.4.6 Data processing 
 
Data from radioligand competition experiments were analyzed by 4 parameter sigmoidal fits 
(SigmaPlot 9.0, Systat Software). IC50 values from radioligand competition studies were 
converted to Ki values according to the Cheng-Prusoff equation34 using the respective KD 
value of the radioligand.  
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Appendix 
 
A.1 Abbreviations 
 
aq.  Aqueous 
Bmax  maximum number of binding sites 
Bn  benzyl 
Boc  tert-butoxycarbonyl 
Boc2O  di-tert-butyl dicarbonate 
BRET  bioluminescence resonance energy transfer 
BSA  bovine serum albumin 
c  concentration 
Cbz  benzyloxycarbonyl 
Cy5  red fluorescent cyanine dye 
DAD  diode array detector 
DAPI  4′,6-Diamidin-2-phenylindol 
DCC  N,N´-dicyclohexylcarbodiimide 
DCM  dichloromethane 
DIPEA  N,N-diisopropyl-ethylamine 
DMAEA  2-(Dimethylamino)ethylamine 
DMAP  4-(dimethylamino)-pyridine 
DMF  N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
EA  ethylacetate 
EC50  agonist concentration that elicits 50 % of the max. response 
EDC  3-(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine 
EtOH  ethanol 
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ELSD  evaporative light scattering detection 
Excimer  excited dimer 
FACS  fluorescence activated cell sorting 
FCS  fetal calf serum 
FRET  fluorescence resonance energy transfer 
GPCR  G protein-coupled receptor 
HEL cells  human erythroleukemia cells 
HEPES  2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethansulfonsäure 
HMBC  heteronuclear multiple bond coherence 
HOBt   1-hydroxybenzotriazole 
HPLC   high performance liquid chromatography 
HSQC  heteronuclear single quantum coherence 
IC50 antagonist concentration that suppresses 50 % of an agonist 
induced effect or displaces 50 % of a labeled ligand from the 
binding site 
IR infrared spectroscopy 
Kd dissociation constant derived from a saturation experiment 
Ki dissociation constant derived from a competition binding assay 
Kob observed association rate constant 
Koff dissociation rate constant 
Kon association rate constant 
logD logarithm of the pH dependent n-octanol/water partition 
coefficient 
logP logarithm of the n-octanol/water partition coefficient 
MCF-7 cells human breast adenocarcinoma cells 
MeCN acetonitrile 
MeOH methanol 
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mp melting point 
MS mass spectroscopy 
NEt3 triethylamine 
NG guanidine nitrogen 
NHS N-hydroxysuccinimide 
NMR nuclear magnetic resonance 
NPY neuropeptide Y 
PBS phosphate buffered saline 
Pd-C palladium on activated charcoal (5 – 10 % w) 
PE petrol ether 
PEG polyethylene glycol 
pNPY porcine neuropeptide Y 
Rf retention factor 
RT room temperature 
SEM standard error of the mean 
SK-N-MC cells human neuroblastoma cell line 
TBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
tetrafluoroborate 
tBu tert-butyl 
TFA trifluoroacetic acid 
THF tetrahydrofurane 
TLC thin layer chromatography 
UV ultraviolet 
VIS visible  
Y1R neuropeptide Y1 receptor subtype    
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A.4 Summary in German and English 
 
Summary in German 
In dieser Arbeit wurden Antagonisten für den Neuropeptid Y1 Rezeptor synthetisiert. 
Das Ziel dabei war einen bekannten Antagonisten (BIBP 3226) mit unterschiedlichen 
Substituenten zu versehen, deren spezielle Eigenschaften einen Einblick in die 
Struktur und Funktionalität des Rezeptors gewähren sollen.  
Dazu wurde im ersten Kapitel die Stabilität und Affinität verschiedener substituierter 
BIBP 3226 Derivate untersucht, die eine große Diversität in Polarität und Struktur 
aufwiesen. Das Ergebnis war, dass der Y1 Rezeptor eine große Vielfalt an 
verschieden substituierten BIBP 3226 Derivaten mit relativ hoher Affinität binden 
kann und dass polare Acylguanidine zum Teil eine starke Tendenz zur Hydrolyse 
aufweisen. 
Im zweiten Kapitel wurde Pyren als fluoreszierende Sonde über verschieden lange 
Spacer an das BIBP 3226 Grundgerüst angebaut, um eine eventuelle Ausbildung 
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von Rezeptordimeren beobachten zu können. Pyren bildet bei hohen lokalen 
Konzentrationen Excimere, die Licht mit einer längeren Wellenlänge emittieren als 
das Pyren Monomer. Es wurden Moleküle mit nanomolaren Affinitäten erhalten, die 
aber leider im eingesetzten Konzentrationsbereich zu schwach fluoreszierten um 
eine Detektion von Rezeptordimeren zu ermöglichen.  
Im dritten Kapitel wurden lipophile BIBP 3226 Derivate hergestellt und zusammen mit 
lipophilen Carboxyfluorescein Derivaten in Vesikel eingebaut um Y1 Rezeptor 
spezifische Vesikel zu erhalten. Als weiterer Bestandteil wurde PEG verschiedener 
Kettenlänge in die Vesikel mit eingebaut. Die Spezifität der Vesikel konnte zwar nicht 
erreicht werden, jedoch konnte die starke Bindung der PEG freien Vesikel an die 
Zellmembran mit geringen PEG-Konzentrationen stark reduziert werden. 
Im vierten Teil wurde der Acylierungskatalysator DMAP an BIBP 3226 angebaut. Die 
so erhaltenen Derivate sollten den Y1 Rezeptor spezifisch in Gegenwart eines 
fluoreszierenden Aktivesters färben. Dazu wurden Testreaktionen durchgeführt um 
den besten Aktivester zu ermitteln und die Reaktion wurde dann an lebenden Zellen 
getestet.  
Das fünfte Kapitel behandelt (pseudo)-irreversible Antagonisten für den Y1 Rezeptor. 
Es wurde eine Serie von Substanzen gefunden, welche den Rezeptor nach Bindung 
irreversibel gegenüber NPY und einem fluoreszierenden Y1 Antagonisten blockieren 
können.       
 
 
 
 
Summary in English 
In this thesis antagonists for the neuropeptide Y1 receptor were synthesized. The 
goal was to modify the known Y1 receptor antagonist BIBP 3266 with different 
substituents to obtain an insight in structure and functionality of the receptor.  
Therefore the stability and the affinity of the diverse substituted BIBP 3226 
derivatives was investigated in the first chapter. The result was that the Y1 receptor 
has a relative high affinity to a broad variety of different substituted BIBP 3226 
derivatives and that some polar acylguanidines exhibit a strong tendency for 
hydrolysis. 
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In the second chapter the fluorescent probe pyrene was attached to the BIBP 3226 
scaffold with spacers of different length to investigate a possible formation of receptor 
dimers. Pyrene forms excimers at a high local concentration that emit light at a longer 
wavelength as the pyrene monomer. Molecules with nanomolar affinity were 
obtained, but their fluorescence intensity was too weak to use them for the detection 
of receptordimers. 
In the third chapter lipophilic BIBP 3226 derivatives were synthesized and embeded 
in vesicles together with lipophilic carboxyfluorescein derivatives to obtain Y1 receptor 
specific vesicles. PEG of different chain length was added as a further component. 
The specifity of the vesicles was not achieved, but the strong binding of the PEG free 
vesicles to the cell membrane could be reduced significantly with small amounts of 
PEG. 
In the fourth part the acyl-transfer catalyst DMAP was attached to the BIBP 3226 
scaffold. The resulting derivatives should specifically stain the Y1 receptor in 
presence of a fluorescent active ester. Therefore test reactions were performed to 
identify the best active ester and then the reaction was performed on living cells. 
The fifth chapter deals with (pseudo)-irreversible antagonists for the Y1 receptor. A 
series of compounds was investigated that block the receptor irreversible against 
NPY and a fluorescent Y1 receptor antagonist.  
 
